
<html lang="en"     class="pb-page"  data-request-id="33feee31-121d-4042-b399-6c254c637e81"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2013.56.issue-5;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/jm301762v"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases" /></meta><meta name="dc.Creator" content="Matt  Addie" /></meta><meta name="dc.Creator" content="Peter  Ballard" /></meta><meta name="dc.Creator" content="David  Buttar" /></meta><meta name="dc.Creator" content="Claire  Crafter" /></meta><meta name="dc.Creator" content="Gordon  Currie" /></meta><meta name="dc.Creator" content="Barry R.  Davies" /></meta><meta name="dc.Creator" content="Judit  Debreczeni" /></meta><meta name="dc.Creator" content="Hannah  Dry" /></meta><meta name="dc.Creator" content="Philippa  Dudley" /></meta><meta name="dc.Creator" content="Ryan  Greenwood" /></meta><meta name="dc.Creator" content="Paul D.  Johnson" /></meta><meta name="dc.Creator" content="Jason G.  Kettle" /></meta><meta name="dc.Creator" content="Clare  Lane" /></meta><meta name="dc.Creator" content="Gillian  Lamont" /></meta><meta name="dc.Creator" content="Andrew  Leach" /></meta><meta name="dc.Creator" content="Richard W. A.  Luke" /></meta><meta name="dc.Creator" content="Jeff  Morris" /></meta><meta name="dc.Creator" content="Donald  Ogilvie" /></meta><meta name="dc.Creator" content="Ken  Page" /></meta><meta name="dc.Creator" content="Martin  Pass" /></meta><meta name="dc.Creator" content="Stuart  Pearson" /></meta><meta name="dc.Creator" content="Linette  Ruston" /></meta><meta name="dc.Description" content="Wide-ranging exploration of analogues of an ATP-competitive pyrrolopyrimidine inhibitor of Akt led to the discovery of clinical candidate AZD5363, which showed increased potency, reduced hERG affin..." /></meta><meta name="Description" content="Wide-ranging exploration of analogues of an ATP-competitive pyrrolopyrimidine inhibitor of Akt led to the discovery of clinical candidate AZD5363, which showed increased potency, reduced hERG affin..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 26, 2013" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm301762v" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm301762v" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm301762v" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm301762v" /></link>
        
    
    

<title>Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm301762v" /></meta><meta property="og:title" content="Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0017.jpeg" /></meta><meta property="og:description" content="Wide-ranging exploration of analogues of an ATP-competitive pyrrolopyrimidine inhibitor of Akt led to the discovery of clinical candidate AZD5363, which showed increased potency, reduced hERG affinity, and higher selectivity against the closely related AGC kinase ROCK. This compound demonstrated good preclinical drug metabolism and pharmacokinetics (DMPK) properties and, after oral dosing, showed pharmacodynamic knockdown of phosphorylation of Akt and downstream biomarkers in vivo, and inhibition of tumor growth in a breast cancer xenograft model." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm301762v"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm301762v">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm301762v&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm301762v&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm301762v&amp;href=/doi/10.1021/jm301762v" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2013</span><span class="cit-fg-volume">, 56</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2059-2073</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/56/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm3017464" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm301780s" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 4-Amino-<i>N</i>-[(1<i>S</i>)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matt++Addie">Matt Addie</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Ballard">Peter Ballard</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++Buttar">David Buttar</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Claire++Crafter">Claire Crafter</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gordon++Currie">Gordon Currie</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Barry+R.++Davies">Barry R. Davies</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Judit++Debreczeni">Judit Debreczeni</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hannah++Dry">Hannah Dry</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Philippa++Dudley">Philippa Dudley</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ryan++Greenwood">Ryan Greenwood</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul+D.++Johnson">Paul D. Johnson</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jason+G.++Kettle">Jason G. Kettle</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Clare++Lane">Clare Lane</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gillian++Lamont">Gillian Lamont</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew++Leach">Andrew Leach</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard+W.+A.++Luke">Richard W. A. Luke</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeff++Morris">Jeff Morris</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Donald++Ogilvie">Donald Ogilvie</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ken++Page">Ken Page</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin++Pass">Martin Pass</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stuart++Pearson">Stuart Pearson</a></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Linette++Ruston">Linette Ruston</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Oncology iMed, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, United Kingdom</span></div><div class="corresp-info"><strong>*</strong>Telephone +441625 517920; e-mail <a href="/cdn-cgi/l/email-protection#7f151e0c101151141a0b0b131a3f1e0c0b0d1e051a111a1c1e511c1012"><span class="__cf_email__" data-cfemail="036962706c6d2d686677776f6643627077716279666d6660622d606c6e">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm301762v&amp;href=/doi/10.1021%2Fjm301762v" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2013</span></span><span class="cit-volume">, 56</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2059â2073</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 11, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>29 November 2012</li><li><span class="item_label"><b>Published</b> online</span>26 February 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 March 2013</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm301762v" title="DOI URL">https://doi.org/10.1021/jm301762v</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2059%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMatt%2BAddie%252C%2BPeter%2BBallard%252C%2BDavid%2BButtar%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D56%26issueNum%3D5%26contentID%3Djm301762v%26title%3DDiscovery%2Bof%2B4-Amino-N-%255B%25281S%2529-1-%25284-chlorophenyl%2529-3-hydroxypropyl%255D-1-%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529piperidine-4-carboxamide%2B%2528AZD5363%2529%252C%2Ban%2BOrally%2BBioavailable%252C%2BPotent%2BInhibitor%2Bof%2BAkt%2BKinases%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2073%26publicationDate%3DMarch%2B2013">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm301762v"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4627</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">73</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm301762v" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Matt&quot;,&quot;last_name&quot;:&quot;Addie&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Ballard&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Buttar&quot;},{&quot;first_name&quot;:&quot;Claire&quot;,&quot;last_name&quot;:&quot;Crafter&quot;},{&quot;first_name&quot;:&quot;Gordon&quot;,&quot;last_name&quot;:&quot;Currie&quot;},{&quot;first_name&quot;:&quot;Barry&quot;,&quot;last_name&quot;:&quot;R. Davies&quot;},{&quot;first_name&quot;:&quot;Judit&quot;,&quot;last_name&quot;:&quot;Debreczeni&quot;},{&quot;first_name&quot;:&quot;Hannah&quot;,&quot;last_name&quot;:&quot;Dry&quot;},{&quot;first_name&quot;:&quot;Philippa&quot;,&quot;last_name&quot;:&quot;Dudley&quot;},{&quot;first_name&quot;:&quot;Ryan&quot;,&quot;last_name&quot;:&quot;Greenwood&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;D. Johnson&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;G. Kettle&quot;},{&quot;first_name&quot;:&quot;Clare&quot;,&quot;last_name&quot;:&quot;Lane&quot;},{&quot;first_name&quot;:&quot;Gillian&quot;,&quot;last_name&quot;:&quot;Lamont&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;Leach&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;W. A. Luke&quot;},{&quot;first_name&quot;:&quot;Jeff&quot;,&quot;last_name&quot;:&quot;Morris&quot;},{&quot;first_name&quot;:&quot;Donald&quot;,&quot;last_name&quot;:&quot;Ogilvie&quot;},{&quot;first_name&quot;:&quot;Ken&quot;,&quot;last_name&quot;:&quot;Page&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;Pass&quot;},{&quot;first_name&quot;:&quot;Stuart&quot;,&quot;last_name&quot;:&quot;Pearson&quot;},{&quot;first_name&quot;:&quot;Linette&quot;,&quot;last_name&quot;:&quot;Ruston&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;26&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;56&quot;,&quot;pages&quot;:&quot;2059-2073&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm301762v&quot;},&quot;abstract&quot;:&quot;Wide-ranging exploration of analogues of an ATP-competitive pyrrolopyrimidine inhibitor of Akt led to the discovery of clinical candidate AZD5363, which showed increased potency, reduced hERG affinity, and higher selectivity against the closely related AGC kinase ROCK. This compound demonstrated good preclinical drug metabolism and pharmacokinetics (DMPK) properties and, after oral dosing, showed pharmacodynamic knockdown of phosphorylation of Akt and downstream biomarkers in vivo, and inhibition of tumor growth in a breast cancer xenograft model.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301762v&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301762v" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301762v&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301762v" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301762v&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301762v" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm301762v&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301762v&amp;href=/doi/10.1021/jm301762v" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm301762v" /></input><a href="/doi/pdf/10.1021/jm301762v" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm301762v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm301762v%26sid%3Dliteratum%253Aachs%26pmid%3D23394218%26genre%3Darticle%26aulast%3DAddie%26date%3D2013%26atitle%3DDiscovery%2Bof%2B4-Amino-N-%255B%25281S%2529-1-%25284-chlorophenyl%2529-3-hydroxypropyl%255D-1-%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529piperidine-4-carboxamide%2B%2528AZD5363%2529%252C%2Ban%2BOrally%2BBioavailable%252C%2BPotent%2BInhibitor%2Bof%2BAkt%2BKinases%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D56%26issue%3D5%26spage%3D2059%26epage%3D2073%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/56/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jmcmar.2013.56.issue-5/production/jmcmar.2013.56.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301762v&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Wide-ranging exploration of analogues of an ATP-competitive pyrrolopyrimidine inhibitor of Akt led to the discovery of clinical candidate AZD5363, which showed increased potency, reduced hERG affinity, and higher selectivity against the closely related AGC kinase ROCK. This compound demonstrated good preclinical drug metabolism and pharmacokinetics (DMPK) properties and, after oral dosing, showed pharmacodynamic knockdown of phosphorylation of Akt and downstream biomarkers in vivo, and inhibition of tumor growth in a breast cancer xenograft model.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43614" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43614" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Akt (also known as protein kinase B or PKB) is a serine threonine kinase that acts as a key node in the phosphoinositide 3-kinase (PI3K)âAkt signaling pathway. This axis is one of the most frequently deregulated signaling pathways in human cancers and has been shown to mediate resistance to a range of cytotoxic, antihormonal, and targeted therapies. The pathway plays a critical role in cell growth, proliferation, motility, and survival<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> through modulation of a large number of downstream substrates<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and is activated by several mechanisms in different cancer types, including somatic mutation, deletion, and amplification of genes encoding key components. Co-localization of Akt with 3-phosphoinositide-dependent protein kinase 1 (PDK1) at the plasma membrane allows the phosphorylation of threonine 308 (Thr308), located in the Akt activation loop. This phosphorylation event is necessary and sufficient for Akt activation.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Further phosphorylation of Akt on serine 473 (Ser473), located in the C-terminal hydrophobic motif by the mammalian target of rapamycin (mTOR) complex 2,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> allows for maximal activation of Akt enzymes. There are three mammalian isoforms of Akt (Akt1, Akt2, and Akt3) that are broadly expressed in most normal tissues and are also expressed in most tumor types to varying degrees. The three enzymes have a similar organizational structure: an N-terminal pleckstrin homology (PH) domain, a central serine/threonine catalytic domain, and a short regulatory region at the C-terminus, also called the hydrophobic motif.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> A unique feature of the Akt isoforms is the C-terminal extension, which folds back over the ATP site to position two aromatic residues into a hydrophobic groove present in the N-lobe. This results in the occlusion of the solvent channel present in the hinge region of most other kinases.</div><div class="NLM_p">Due to the strong rationale for targeting Akt in cancer, much effort has been made to identify Akt inhibitors with acceptable pharmaceutical properties, particularly for oral dosing. The most common approaches described to date have been through the development of compounds that are either ATP-competitive or that prevent the formation of the active enzyme.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Despite the significant efforts invested in the generation of inhibitors of components of this pathway, it remains unclear whether ATP-competitive or noncompetitive inhibitors will be most beneficial for the treatment of cancer. A number of Akt inhibitors are currently being tested in clinical trials, including allosteric inhibitors of inactive Akt, such as <b>1</b> (MK-2206),<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and ATP-competitive inhibitors of active enzyme, such as <b>2</b> (GDC-0068)<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) and GSK-2141795.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Here we describe some aspects of the work leading to the discovery of an ATP-competitive Akt inhibitor, 4-amino-<i>N</i>-[(1<i>S</i>)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), <b>64</b>.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Allosteric inhibitor of inactive Akt, MK-2206 (<b>1</b>), and an example of an inhibitor of active Akt, GDC-0068 (<b>2</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301762v&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37457" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37457" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Benzylamide <b>3</b> has previously been reported as an orally bioavailable inhibitor of Akt. This compound was originally identified as a suitable starting point for further optimization as a result of our prior collaboration with Astex Therapeutics Ltd. and their collaboration with the Institute of Cancer Research.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a>This lead arose from a fragment-based screening campaign from which several alternative hinge binding groups were found, which were then elaborated into potent Akt inhibitors; a selection of the chemotypes explored are highlighted in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Common features of these inhibitors include a small hinge-binding heteroaromatic ring presenting a donorâacceptor motif to Glu228 and Ala230, a phenyl or piperidine spacing group, a primary or secondary amino functionality that can form a H-bonding interaction with the acid hole formed by Glu234 and Glu278, and a lipophilic aromatic group that is positioned in a hydrophobic pocket under the P-loop of the ATP-binding site. This pharmacophore for ATP-competitive inhibition of Akt matches has subsequently been reported by a number of other groups.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Following thorough evaluation of the various lead series, we elected to work on the benzylamide series as exemplified by compound <b>3</b>, as its efficacy and tolerability were favorable. Key data for <b>3</b> are listed in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. Compound <b>3</b> is a reasonably potent enzyme inhibitor of all three Akt isoforms and is a moderately potent inhibitor of phosphorylation of glycogen synthase kinase 3Î² (GSK3Î²) by Akt in human MDAMB468 cells. Following oral dosing, <b>3</b> had also demonstrated pharmacodynamic inhibition of Akt pathway signaling and demonstrated growth inhibition in a relevant xenograft model.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> However, enzyme selectivity over closely related ROCK2 was judged to be insufficient at just 5-fold based on enzyme activity. ROCK2 is another member of the AGC kinases and is involved in regulation of vascular tone and thus control of blood pressure. There is high homology within the AGC kinase family, with Akt1 and ROCK2 sharing 40% sequence identify (53% similarity) in the kinase domain; this increases to 86% sequence identity (100% similarity) when the 15 residues within 3 Ã of ATP are considered. A selective ROCK inhibitor has been shown to significantly decrease blood pressure and cause increased heart rate and cardiac contractility in a canine in vivo cardiovascular model.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Our extensive structureâactivity relationship (SAR) studies exploring the series had revealed that achieving selectivity over ROCK while retaining Akt potency was challenging. At the same time, we aspired to resolve the issue of activity at the hERG ion channel, given that compound <b>3</b>, with an IC<sub>50</sub> of 5 Î¼M for inhibition, may present issues further in development. Activity against the hERG ion channel is implicated in the development of Torsades de Pointes and sudden cardiac death. Despite these issues, <b>3</b> demonstrated good pharmacokinetics across three species, showing reasonable absorption and low to moderate clearance. In vitro hepatic clearance values were also low, including importantly in human cells. It is noteworthy that this good drug metabolism and pharmacokinetics (DMPK) profile is observed in the presence of the required primary amino pharmacophore. We speculate that the combination of close proximity to the electron-withdrawing amido group, coupled with high steric hindrance at this tertiary center, mitigates against the clearance and absorption issues one might otherwise anticipate.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Inhibitors of Akt arising from collaboration with Astex Therapeutics Ltd. and the Institute of Cancer Research.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301762v&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Profiling of Early Lead Akt Inhibitor <b>3</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">value</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">enzyme potency IC<sub>50</sub> (nM)  [Akt1, Akt2, Akt3]</td><td class="colsep0 rowsep0" align="left">13, 66, 57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cell IC<sub>50</sub><a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a> (nM)</td><td class="colsep0 rowsep0" align="left">328</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ROCK2 IC<sub>50</sub> (nM), <i>n</i>-fold-selectivity</td><td class="colsep0 rowsep0" align="left">66, 5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log <i>D</i>, pH 7.4</td><td class="colsep0 rowsep0" align="left">2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma protein binding, % free [mouse, rat, dog, human]</td><td class="colsep0 rowsep0" align="left">14, 14, 11, 22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solubility, pH 7.4 (Î¼M)</td><td class="colsep0 rowsep0" align="left">150</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">5235</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hepatocyte Cl<sub>int</sub> (Î¼LÂ·min<sup>â1</sup>Â·(10<sup>6</sup> cells)<sup>â1</sup>) [mouse, rat, dog, human]</td><td class="colsep0 rowsep0" align="left">10, 19, 6, 15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (mLÂ·min<sup>â1</sup>Â·kg<sup>â1</sup>) [mouse, rat, dog]</td><td class="colsep0 rowsep0" align="left">42, 48, 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vd<sub>ss</sub> [mouse, rat, dog]</td><td class="colsep0 rowsep0" align="left">2.8, 3.1, 0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h) [mouse, rat, dog]</td><td class="colsep0 rowsep0" align="left">0.8, 2.3, 3.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%) [mouse, rat, dog]</td><td class="colsep0 rowsep0" align="left">88, 56, 70</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup>a</sup><p class="last">Inhibition of pGSK3Î² by Akt.</p></div></div></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">Inhibitors of Akt described in this work were generally assembled in a short sequence from readily available starting materials (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). Piperidine <b>5</b> and chloroheterocycle <b>4</b> were condensed to give the key carboxylic acid building block <b>6</b>, which was subsequently coupled with a variety of primary amines to give the requisite amide group. Acid-promoted deprotection of the primary amine functionality revealed Akt inhibitors <b>7</b>. The amines used in this coupling were often commercially available; however, representative examples of the synthesis of more complex coupling partners is outlined in Schemes <a class="ref internalNav" href="#sch2" aria-label="2">2</a> and <a class="ref internalNav" href="#sch3" aria-label="3">3</a>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis of Akt Inhibitors <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301762v&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) NaHCO<sub>3</sub>, CH<sub>3</sub>CN/H<sub>2</sub>O, reflux 24 h; (ii) <i>N</i>-(3-dimethylaminopropyl)-3-ethylcarbodiimide, HBT, DMF, 16 h; (iii) 4 M HCl in dioxane, RT, 16 h.</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0008.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Representative Substituted Benzylamines Used in the Elaboration of Akt Inhibitors <b>45</b>, <b>61</b>, and <b>63</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301762v&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) BH<sub>3</sub>.THF, RT, 5 h; (ii) di-<i>tert</i>-butyl dicarbonate, DCM, RT, 2 h; (iii) MsCl, Et<sub>3</sub>N, DCM, RT, 2 h; (iv) Me<sub>2</sub>NH, TBAI, THF, 150 Â°C, 0.5 h; (v) 4 M HCl, dioxane, DCM, methanol, RT, 4 h; (vi) NaH, MeI, THF, RT, 4 h.</p></p></figure><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0009.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Representative Substituted Benzylamines Used in the Elaboration of Akt Inhibitors <b>55</b>, <b>56</b>, <b>58</b>, and <b>59</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301762v&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) NaBH<sub>4</sub>, I<sub>2</sub>, THF, reflux, 12 h, and then di-<i>tert</i>-butyl dicarbonate, Et<sub>3</sub>N, RT, 2 h; (ii) MsCl, DIPEA, DCM, RT, 2â18 h; (iii) KSAc, DMF, 50 Â°C, 1 h; (iv) NCS, 2 M HCl, CH<sub>3</sub>CN, 10 Â°C, 0.3 h; (v) NH<sub>3</sub>, CH<sub>3</sub>CN, RT, 16 h; (vi) TFA, RT, 0.3 h; (vii) NaN<sub>3</sub>, DMF, 80 Â°C, 1 h, and then H<sub>2</sub>, 10% Pd/C, ethanol, RT, 1 h; (viii) Ac<sub>2</sub>O, DIPEA, THF, RT, 2 h; (ix) MsCl, DIPEA, THF, RT, 2 h; (x) NaCN, DMF, 80 Â°C, 3 h; (xi) LiAlH<sub>4</sub>, THF, RT, 2 h.</p></p></figure><div class="NLM_p last">Amino acid <b>8</b> was reduced to amino alcohol <b>9</b>, which was coupled to building block <b>6</b> to give, after deprotection, inhibitor <b>61</b>. Amino alcohol <b>9</b> also served as a useful precursor to bis-amine <b>13</b> and ether <b>14</b>, used in the synthesis of Akt inhibitors <b>45</b> and <b>63</b>, respectively. The alcohol was converted to mesylate <b>11</b>, which in turn gave bis-amine <b>13</b> by displacement with dimethylamine and subsequent deprotection of the benzylamine moiety. Alternatively, simple alkylation of <b>10</b> with methyl iodide gave ether <b>15</b> after removal of the protecting group. Similarly, amino acid <b>16</b> was used as a starting material for a range of differently substituted benzylamines. Reduction of the acid and in situ protection of the amino group gave alcohol <b>17</b>, with subsequent mesylate ester <b>18</b> proving a versatile intermediate for introduction of a range of polar substituents. Thioester formation and <i>N</i>-chlorosuccinimide-promoted oxidation give sulfonyl chloride <b>20</b>. Quenching with ammonia and amine deprotection yielded Î²-aminosulfonamide <b>22</b>, used in the synthesis of inhibitor <b>56</b>. Primary amine <b>23</b> was also synthesized from mesylate <b>18</b> through azide displacement and reduction. This amine was capped with an acyl group to give <b>25</b> or with a mesyl group to give <b>27</b>, and these ultimately yielded Akt inhibitors <b>55</b> and <b>58</b>, respectively. Mesylate <b>18</b> was also used to access higher alkyl homologues such as <b>31</b>, used to deliver inhibitor <b>59</b>. Displacement with cyanide gave nitrile <b>28</b>, which was reduced to primary amine <b>29</b>. As before, capping with a mesyl group and deprotection yielded amine <b>31</b>. Further details of all the routes used to make the compounds described herein can be found in the <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Î±-Substitution with Alkyl Groups</h3><div class="NLM_p">A crystal structure of <b>3</b> bound to Akt2 was available to AstraZeneca from our collaboration<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2X39">2X39</a>), which showed that the pyrrolopyrimidine of <b>3</b> formed hydrogen bonds to the hinge domain, the amino group interacted with an acidic hole, and the <i>p</i>-chlorophenyl group entered a pocket under the P-loop. SAR around this lead has been reported, although no further improvements in potency were found in the analogues tested.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Indeed, our own extensive medicinal chemistry exploration of this lead also indicated many different modifications ultimately proved unproductive in achieving the desired combination of properties, including changes to the hinge binding group, amide functionality, and any changes to the nature and position of the primary amine. We were intrigued, however, by the potential to substitute on the Î±-carbon of the benzyl group, since inspection of the available crystal structure suggested space to accommodate such a change. No obvious interactions would result from this, however, so it was unclear what effect this would have on potency or other key properties. Initially the racemic Î±-methylated compound <b>32</b> was synthesized, and despite showing broadly similar enzyme potency to <b>3</b>, a modest improvement in cell activity was observed, in addition to slightly better selectivity. To understand whether one isomer was more responsible than the other for this profile, both individual enantiomers were synthesized. The <i>S</i>-enantiomer <b>34</b> proved significantly more active than the <i>R</i>-enantiomer <b>33</b>, and despite absolute ROCK activity also being greater in <b>33</b>, the improvements in Akt enzyme potency meant the selectivity ratio was also improved (Table <a class="ref showTableEvent internalNav" data-ID="tbl1a" href="#tbl1a">2</a>). No significant movement in hERG inhibition was observed for this small change, however. It was hypothesized that the introduction of the Î±-methyl chiral center introduced a ligand conformational preference with respect to the P-loop aryl group and consequently that the selectivity differences observed could potentially arise from differences in the nature of the P-loop hydrophobic pocket between Akt1 and ROCK2. If this hypothesis was correct, different selectivity profiles might be achievable, enhancing Akt1 potency and reducing ROCK2 potency through the development of ligands that might exploit this proposed difference.</div><div class="NLM_table-wrap" id="tbl1a"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Akt Enzyme and Cell Potency, Selectivity, and hERG Activity for Î±-Alkyl-Substituted Benzylamide Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0010.gif" alt="" id="t1aheader" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="[" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="6" align="center" char=".">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">Â </th><th class="colsep0 rowsep0" align="center" char=".">Â </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char=".">Akt1<a class="ref internalNav" href="#t1afn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">Akt2<a class="ref internalNav" href="#t1afn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">Akt3<a class="ref internalNav" href="#t1afn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">cell<a class="ref internalNav" href="#t1afn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="[">ROCK2<a class="ref internalNav" href="#t1afn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">hERG<a class="ref internalNav" href="#t1afn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">log <i>D</i></th><th class="colsep0 rowsep0" align="center" char=".">solubility<a class="ref internalNav" href="#t1afn5" aria-label="e">e</a> (Î¼M)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">66</td><td class="colsep0 rowsep0" align="char" char=".">57</td><td class="colsep0 rowsep0" align="char" char=".">328</td><td class="colsep0 rowsep0" align="char" char="[">66 [5]</td><td class="colsep0 rowsep0" align="char" char=".">5235</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char=".">150</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">40</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">197</td><td class="colsep0 rowsep0" align="char" char="[">101 [13]</td><td class="colsep0 rowsep0" align="char" char=".">7200</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="char" char=".">180</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left"><i>R</i>-Me</td><td class="colsep0 rowsep0" align="char" char=".">276</td><td class="colsep0 rowsep0" align="char" char=".">836</td><td class="colsep0 rowsep0" align="char" char=".">523</td><td class="colsep0 rowsep0" align="char" char=".">4594</td><td class="colsep0 rowsep0" align="char" char="[">1396 [5]</td><td class="colsep0 rowsep0" align="char" char=".">9092</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td><td class="colsep0 rowsep0" align="char" char=".">77</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left"><i>S</i>-Me</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">134</td><td class="colsep0 rowsep0" align="char" char="[">55 [15]</td><td class="colsep0 rowsep0" align="char" char=".">6747</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="char" char=".">110</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">144</td><td class="colsep0 rowsep0" align="char" char="[">126 [19]</td><td class="colsep0 rowsep0" align="char" char=".">6495</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="char" char=".">13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">c-Pr</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">24</td><td class="colsep0 rowsep0" align="char" char=".">208</td><td class="colsep0 rowsep0" align="char" char="[">261 [52]</td><td class="colsep0 rowsep0" align="char" char=".">2600</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="char" char=".">41</td><td class="colsep0 rowsep0" align="char" char=".">210</td><td class="colsep0 rowsep0" align="char" char=".">270</td><td class="colsep0 rowsep0" align="char" char=".">1620</td><td class="colsep0 rowsep0" align="char" char="[">576 [14]</td><td class="colsep0 rowsep0" align="char" char=".">1600</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td><td class="colsep0 rowsep0" align="char" char="."><1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="left">Bn</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">190</td><td class="colsep0 rowsep0" align="char" char=".">150</td><td class="colsep0 rowsep0" align="char" char=".">1650</td><td class="colsep0 rowsep0" align="char" char="[">586 [19]</td><td class="colsep0 rowsep0" align="char" char=".">3500</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td><td class="colsep0 rowsep0" align="char" char="."><1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1afn1"><div class="footnote" id="t1afn1"><sup>a</sup><p class="last">All IC<sub>50</sub> data are the mean of at least <i>n</i> = 2 independent measurements. Each has a standard error of measurement (SEM) Â±0.2 log unit.</p></div><div class="footnote" id="t1afn2"><sup>b</sup><p class="last">Inhibition of phosphorylation of GSK3Î² mediated by Akt in MDAMB468 cells.</p></div><div class="footnote" id="t1afn3"><sup>c</sup><p class="last">Value in brackets indicates enzyme selectivity ratio to Akt1.</p></div><div class="footnote" id="t1afn4"><sup>d</sup><p class="last">CHO cells, IonWorks assay.</p></div><div class="footnote" id="t1afn5"><sup>e</sup><p class="last">Thermodynamic solubility in 0.1 M phosphate buffer at pH 7.4 (25 Â°C).</p></div></div></div><div class="NLM_p last">Additional Î±-alkyl analogues were synthesized to explore the effect of further substitution, and for synthetic convenience the initial follow-up studies were performed with racemic samples. Small lipophilic substituents such as ethyl <b>35</b> and cyclopropyl <b>36</b> showed similar potency to methyl, and hERG activity was also unchanged, although ROCK selectivity was improved, particularly for the latter (Table <a class="ref showTableEvent internalNav" data-ID="tbl1a" href="#tbl1a">2</a>). Larger Î±-substituents were generally less potent in both enzyme and cell assays. The compound with an Î±-phenyl group, <b>37</b>, led to a significant reduction in cellular potency, as did other compounds with large aromatic substituents such as the benzylic analogue <b>38</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1a" href="#tbl1a">2</a>). Alkyl substituents larger than methyl generally came with an expected increase in lipophilicity and concomitant reduction in solubility, and this issue was particularly acute for Î± side chains that contained aromatic rings. For these larger groups, hERG inhibition also appeared to increase in line with log <i>D</i>.</div></div><div id="sec2_2a" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Aromatic Ring Substitution</h3><div class="NLM_p">Previous studies had demonstrated that while a range of other pendant phenyl substituents could be tolerated, in the limited compounds studied, a <i>p</i>-chloro group offered the best overall balance, particularly with respect to potency.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> As methyl appeared to be the optimal Î±-substituent in this initial limited expansion, this group was fixed and variation of the aromatic ring in the benzyl group was revisited in an attempt to explore in particular the effect on hERG potency. Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">3</a> shows a selection of the aromatic substitutions examined, all in a racemic Î±-methyl series to aid synthetic tractability. Removal of the chloro group to give unsubstituted compound <b>39</b> resulted in a reduction in potency, at both the enzyme and cellular level, consistent with earlier observations. Introduction of a <i>p</i>-fluoro group as in compound <b>40</b> recovered some of this potency, but not to the level seen with chloro analogue <b>32</b>. In both these examples however, absolute hERG affinity was lowered, broadly consistent with lowered lipophilicity, but this did not result in improvements to solubility. Heterocycles in this region were also poorly tolerated, with both 2- and 3-pyridyl analogues <b>41</b> and <b>42</b> showing no cellular activity at the top concentration tested. Despite significant improvements in both hERG activity and solubility for this change, selectivity at the enzyme level versus ROCK was also severely compromised. A range of other simple substitutions were explored as typified by sulfone <b>43</b> and dimethoxy analogue <b>44</b>. The picture relative to chloro lead <b>32</b> was again consistent, with compounds often showing improved hERG margin, but generally weaker Akt cell activity and compromised selectivity profile.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Akt Enzyme and Cell Potency, Selectivity, and hERG Activity for Selected Aryl-Substituted Benzylamide Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0011.gif" alt="" id="t2header" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0012.gif" alt="" id="t2body" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">All IC<sub>50</sub> data are the mean of at least <i>n</i> = 2 independent measurements. Each has a SEM Â±0.2 log unit. <sup><i>b</i></sup>Inhibition of phosphorylation of GSK3Î² mediated by Akt in MDAMB468 cells. <sup><i>c</i></sup>Values in brackets indicate enzyme selectivity ratio to Akt1. <sup><i>d</i></sup>CHO cells, IonWorks assay. <sup><i>e</i></sup>Thermodynamic solubility in 0.1 M phosphate buffer at pH 7.4 (25 Â°C).</p></div></div><div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Î±-Substitution Carrying a Basic Side Chain</h3><div class="NLM_p">Following initial exploration of the vector provided by the benzyl methylene group that led to <i>S</i>-Me analogue <b>34</b>, this region was revisited with a broader range of functionalities. The impact of appending basic groups in this region was explored with a focused set of targets, since although the modest solubility of lead <b>3</b> does not compromise its pharmacokinetic profile, further improvements might be beneficial. Initial exploration targeted a dimethylamino side chain as in homologues <b>45</b> and <b>46</b>. Both analogues showed potent enzyme and cellular inhibition, with a three-carbon side chain seemingly offering modest advantage over a two-carbon side chain with respect to ROCK selectivity. In both molecules hERG activity is dramatically reduced. Further exploration of the SAR around the basic group with analogues such as pyrrolidine (<b>47</b>), morpholine (<b>48</b>), and piperidine (<b>49</b>) led to compounds with a very similar overall profile: improved potency and selectivity and lowered hERG affinity (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">4</a>). A number of chirally pure <i>S</i>-enantiomers were also synthesized. Compound <b>50</b> is the <i>S</i>-enantiomer of racemate <b>45</b>, and in this case the profile is largely identical with <b>50</b>, showing potent cell activity, high solubility, and good hERG margin, albeit with a lower selectivity over ROCK. Varying the base further, such as with pyrrolidine <b>51</b> or piperidine <b>52</b>, again led to compounds with a good balance of properties but with lower than ideal ROCK selectivity (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">4</a>). Single <i>S</i>-isomers <b>50</b>â<b>52</b> were all tested in a rat DMPK study and all showed clearance at a rate significantly in excess of liver blood flow, and consequently no oral bioavailability (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">4</a>). A contribution to this from limited absorption cannot be ruled out, however.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Akt Enzyme and Cell Potency, Selectivity, and hERG Activity for Î±-Substituted Benzylamide Analogues Carrying a Basic Side Chain</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0013.gif" alt="" id="t3header" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0014.gif" alt="" id="t3body" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">All IC<sub>50</sub> data are the mean of at least <i>n</i> = 2 independent measurements. Each has a SEM Â±0.2 log unit. <sup><i>b</i></sup>Inhibition of phosphorylation of GSK3Î² mediated by Akt in MDAMB468 cells. <sup><i>c</i></sup>Values in bracketss indicate enzyme selectivity ratio to Akt1. <sup><i>d</i></sup>CHO cells, IonWorks assay. <sup><i>e</i></sup>Thermodynamic solubility in 0.1 M phosphate buffer at pH 7.4 (25 Â°C).</p></div></div><div></div></div></div><div id="sec2_3a" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Î±-Substitution Carrying a Neutral Side Chain</h3><div class="NLM_p">Since side chains carrying a basic group had led to high clearance and low oral bioavailability, the exploration of nonbasic polar substituents was initiated. Amides <b>53</b> and <b>54</b> and reversed amide <b>55</b> showed much reduced hERG activity, but cell potency and overall ROCK selectivity was compromised (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">5</a>). A similar profile was observed with sulfonamides <b>56</b> and <b>57</b>, one of compromised cell activity and selectivity. Two-carbon side-chain analogue <b>56</b> showed slightly greater activity than the three-carbon analogue <b>57</b> but worse absolute selectivity, and solubility was poor despite comparable log <i>D</i> to other examples (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">5</a>). This pattern was reinforced when the sulfonamide was reversed, as in <b>58</b> and <b>59</b>, where again a two-carbon spacer in compound <b>59</b> gave better cell activity, and here improved selectivity, over the shorter one-carbon linker in <b>58</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">5</a>). Both compounds had an acceptable hERG margin, but again, sulfonamides consistently demonstrated only modest solubility. The impact of spacing a hydroxyl substituent at varying distances from the methylene group was explored with homologues <b>60</b>â<b>62</b>. As before, a clear preference for a two-carbon spacer emerged, with <b>61</b> showing the greatest cell potency, ROCK selectivity and hERG margin (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">5</a>). One-carbon spacing as in <b>60</b> also had much reduced hERG potency but with compromised cell potency, and three-carbon spacing in <b>62</b>, while more potent than <b>60</b>, showed measurable hERG inhibition. Methylating <b>61</b> to give ether <b>63</b> led to an increase in lipophilicity, much increased hERG inhibition, and also compromised cellular potency. Finally, isolation of the more active <i>S</i>-enantiomer of <b>61</b> gave <b>64</b>, subsequently designated AZD5363. This compound showed potent pan-Akt enzyme inhibition (3â8 nM) and cell activity (89 nM), high hERG margin (>100â000),h excellent solubility, and 18-fold selectivity for Akt1 enzyme over ROCK2 (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">5</a>). The corresponding <i>R</i>-enantiomer was synthesized and exhibited markedly lower enzyme and cell potency of 90 nM and 3300 nM respectively, confirming a chiral preference for binding.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Akt Enzyme and Cell Potency, Selectivity, and hERG Activity for Î±-Substituted Benzylamide Analogues Carrying a Neutral Side Chain</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0015.gif" alt="" id="t4header" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0016.gif" alt="" id="t4body" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">All IC<sub>50</sub> data are the mean of at least <i>n</i> = 2 independent measurements. Each has a SEM Â±0.2 log unit. <sup><i>b</i></sup>Inhibition of phosphorylation of GSK3Î² mediated by Akt in MDAMB468 cells. <sup><i>c</i></sup>Values in brackets indicate enzyme selectivity ratio to Akt1. <sup><i>d</i></sup>CHO cells, IonWorks assay. <sup><i>e</i></sup>Thermodynamic solubility in 0.1 M phosphate buffer at pH 7.4 (25 Â°C).</p></div></div><div></div></div></div><div id="sec2_3b" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> X-ray Crystallographic Studies</h3><div class="NLM_p">A crystal structure of <b>64</b> bound to Akt1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GV1">4GV1</a>) was obtained (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). This revealed key interactions and features that may contribute to the high Akt affinity of this compound. The protein is in the active form with the C-terminal tail folding back over the N-terminal lobe to position Phe469 and Phe472 in the hydrophobic pocket essential for regulatory control of Akt1. The pyrrolopyrimidine ring forms two hydrogen bonds to the kinase hinge through residues Ala230 and Glu228. Interestingly, the central piperidine ring adopts an axial conformation with respect to both the pyrrolopyrimidine hinge group and the P-loop aryl group. This axial over equatorial preference is influenced by the ortho-sp<sup>2</sup> nitrogen in the pyrrolopyrimidine core, and adoption of this conformation positions the basic amino group in the acidic hole formed by Glu234 and Glu278, and the <i>p</i>-chlorophenyl group in a hydrophobic pocket under the P-loop formed by the side chains of Lys179, Leu181, and Val164 and backbone atoms of Lys158 and Gly162. The conformation of the central piperidine observed in the Akt1 crystal structure is consistent with the conformation observed previously for the initial lead <b>3</b>.<a onclick="showRef(event, 'cit10a'); return false;" href="javascript:void(0);" class="ref cit10a">(10a)</a> Although the axial positioning of the substituents is likely to be energetically less favorable than the corresponding equatorially substituted analogue, this conformation is believed to be adopted to position the central ring substituents optimally with respect to the Akt1 binding site. It is also of note that the basic amino group forms a close contact with the sulfur of Met281<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and hydrogen bonds with the side chain of Glu234, the backbone carbonyl of Glu278, and an associated water molecule. The p<i>K</i><sub>a</sub> of the amino group of <b>64</b> was experimentally determined and was found to have a relatively low value of 6.1. The amide NH does not form any direct contacts with the protein, although it could form a water-mediated interaction to Asp292 and Asn279. The hydroxyethyl side chain also does not appear to form any direct interactions with the protein but occupies a solvent-filled region and possibly forms a water-mediated interaction to Glu278. This residue Glu278 corresponds to Asp218 in ROCK2; consequently the presence of the hydoxyethyl group may result in a different interaction profile between the two proteins in this region. However, from the available information it is not possible to definitively explain how this group contributes to the increased potency and selectivity of this compound.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Ligand binding mode of compound <b>64</b> in Akt1 determined by X-ray crystallography at 1.49 Ã resolution. The 2<i>F</i><sub>o</sub> â <i>F</i><sub>c</sub> electron density map is displayed in orange and contoured at 1Ï around the inhibitor. Nearby water molecules are represented as red spheres. (b) Molecular surface representation of the Akt1 binding pocket, looking toward the kinase hinge region. (c) Hydrogen-bond network formed by <b>64</b> and Akt1 residues within 3 Ã of the inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301762v&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3c" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Pharmacokinetic Profiling</h3><div class="NLM_p">The DMPK profile of <b>64</b> is highlighted in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">6</a>. Protein binding remained low across all species, consistent with initial lead <b>3</b>. Compound <b>64</b> is extensively distributed outside of blood, with volumes of distribution ranging from 2 to 4 L/kg in preclinical species. Oral bioavailability in mouse remains high despite higher clearance, which may indicate a saturation of first-pass metabolism with the oral dose or extrahepatic metabolism. The profile in rat is somewhat worse, however: whole blood clearance is relatively high, and consequently bioavailability remains a modest 13%. Optimization of the critical parameters of cell potency, ROCK selectivity, and absolute hERG margin of <b>3</b> has been achieved, but here at the expense of some of the favorable pharmacokinetic properties the early lead demonstrated. The profile in dog appears more balanced, with moderate clearance and moderate bioavailability. As with the initial lead, in vitro intrinsic hepatic clearance (Cl<sub>int</sub>) measured in hepatocytes is generally low, with turnover in human cells only measurable by an assay with a 2 h incubation.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Selected DMPK Properties of Compound <b>64</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center" char=".">mouse<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">rat<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">dog<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">human</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein binding (free drug %)</td><td class="colsep0 rowsep0" align="char" char=".">14.3â16.7</td><td class="colsep0 rowsep0" align="char" char=".">23.5â25.1</td><td class="colsep0 rowsep0" align="char" char=".">19.2â22.9</td><td class="colsep0 rowsep0" align="char" char=".">22.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">oral bioavailability (%)</td><td class="colsep0 rowsep0" align="char" char=".">86</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">37</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">blood Cl (mLÂ·min<sup>â1</sup>Â·kg<sup>â1</sup>)</td><td class="colsep0 rowsep0" align="char" char=".">207</td><td class="colsep0 rowsep0" align="char" char=".">95</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vd<sub>ss</sub>(L/kg)</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">half-life (i.v., h)</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hepatocyte Cl<sub>int</sub> (Î¼LÂ·min<sup>â1</sup>Â·(10<sup>6</sup> cells)<sup>â1</sup>)</td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Alderley Park mouse.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Han Wistar rat.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Alderley Park beagle.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Biological Activity</h3><div class="NLM_p">In order to understand the compoundÊ¼s selectivity profile, <b>64</b> was assayed against a larger enzyme panel of 75 kinases, of which 35 were also AGC family kinases. Significant activity, defined herein as >75% inhibition at a fixed concentration of 1 Î¼M, was seen for just 15 kinases, of which 14 were unsurprisingly from the AGC family. In addition to Akt1â3, these were ROCK2, MKK1, MSK1, MSK2, PKCÎ³, PKGÎ±, PKGÎ², PRKX, RSK2, RSK3, P70S6K, and PKA. Only the latter two kinases, P70S6K and PKA, were inhibited with enzyme IC<sub>50</sub> values comparable to Akt1â3 inhibition, at 6 and 7 nM, respectively. However, in cellular end points of these two kinases, activity was relatively reduced compared to the primary Akt pharmacology. The cellular IC<sub>50</sub> against P70S6K was approximately 5 Î¼M, as measured by inhibition of S6 phosphorylation in TSC1 null RT4 bladder cancer cells, while activity against PKA was around 1 Î¼M, as determined by inhibition of VASP phosphorylation in A431 cells. Activity against related ROCK1 isoform was much reduced relative to ROCK2, with an IC<sub>50</sub> of 470 nM. Compound <b>64</b> was also very effective at inhibiting the phosphorylation of downstream Akt substrates in a variety of cell lines (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">7</a>). Potent inhibition was seen against pGSK3Î² and pPRAS40 as direct markers of Akt cell activity. The growth inhibitory effect of <b>64</b> was also examined across a much larger in-house cellular panel of 182 tumor cell lines in standard proliferation assay format. Sensitive cell lines were defined as those inhibited with an IC<sub>50</sub> of 3 Î¼M or less. A majority of breast cell lines proved to be sensitive (64%), with gastric, endometrial, prostate, and hematologic lines showing intermediate sensitivity (24â33% responsive). Lines that showed a poor response to <b>64</b> were derived from lung (12% sensitive), colorectal (7%), and bladder (0%) cells. The degree of sensitivity of a line could be correlated with a variety of oncogenic markers. Specifically, activating mutations in PIK3CA, loss or inactivation of tumor suppressor PTEN, or HER2 amplification all were significantly predictive of responsiveness to therapy. Additionally, correlation was also seen between the RAS mutation status of cell lines and resistance to <b>64</b>.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Effect of <b>64</b> on Akt-Driven Cellular End Points in Various Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">IC<sub>50</sub> (Î¼M)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">marker</th><th class="colsep0 rowsep0" align="center" char=".">BT474c<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">LNCaP<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">MDA-MB-468<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pGSK3Î²</td><td class="colsep0 rowsep0" align="char" char=".">0.76</td><td class="colsep0 rowsep0" align="char" char=".">0.06</td><td class="colsep0 rowsep0" align="char" char=".">0.38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pPRAS40</td><td class="colsep0 rowsep0" align="char" char=".">0.31</td><td class="colsep0 rowsep0" align="char" char=".">0.22</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">HER2+, PIK3CA mutant, breast line.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">PTEN null, prostate line.</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">PTEN null, breast line.</p></div></div></div><div class="NLM_p">The effect of <b>64</b> in vivo was characterized first by measuring pharmacodynamic activity in a BT474c breast adenocarcinoma xenograft model. Following single oral doses of 100 and 300 mg/kg, <b>64</b> potently inhibited the phosphorylation of Akt downstream substrates pGSK3Î² and pPRAS40 as well as pS6 in a manner that was directly linked to plasma exposure (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Potent inhibition of pPRAS40 and pGSK3Î² was seen out to 4 h, which started to recover at 8 h, and was back to basal levels by 24 h as compound was eliminated. The more distal cellular marker pS6 showed a similar exposure response despite overall less marked inhibition. The impact on tumor growth of continuous oral dosing of <b>64</b> was also assessed in the same model over 14 days. When dosed at 200 mg/kg once per day, <b>64</b> was less effective than dosing at 100 mg/kg twice per day (39% inhibition versus 80%). Greatest inhibition of growth was observed with a dose of 200 mg/kg twice per day, which led to 104% inhibition, and this proved to be the maximum well-tolerated continuous twice-daily dose (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Pharmacodynamic activity of <b>64</b> in a BT474c xenograft model in nude mice. Concentration response was established by dosing groups at either 100 or 300 mg/kg and assaying for compound and effect at 1, 2, 4, 8, 16, and 24 h time points. Each point represents the mean of four animals.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301762v&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Activity of <b>64</b> in a BT474c tumor-bearing nude mouse disease model. Each error bar represents one standard error from the mean.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301762v&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Conclusions</h3><div class="NLM_p last">Compound <b>3</b> served as a lead Akt inhibitor with an acceptable DMPK profile in preclinical species and in vivo antitumor efficacy with modulation of biomarkers following oral dosing. Nevertheless, it had an unfavorably low ROCK selectivity, only modest cell activity, and unwanted activity at the hERG ion channel. A crystal structure of this compound bound to Akt1 suggested a possible vector for further substitution, and this position was ultimately explored with a range of diverse substituents and chain lengths, leading ultimately to compound <b>64</b>, AZD5363. This agent inhibits all Akt isoforms with a potency of <10 nM in vitro and is a potent inhibitor of phosphorylation of the Akt substrates GSK3Î², PRAS40, and S6 in a range of cell lines. It has good selectivity over both the hERG ion channel and closely related AGC kinase ROCK, and it shows pharmacodynamic and xenograft activity in vivo. It has potential in cancer therapy and is currently in phase 1 clinical trials.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54537" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54537" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Chemistry</h3><div class="NLM_p last">All reactions were performed under inert conditions (nitrogen) unless otherwise stated. Temperatures are given in degrees Celsius (Â°C); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18â25 Â°C. All solvents and reagents were purchased from commercial sources and used without further purification. For coupling reactions, all solvents were dried and degassed prior to reaction. Reactions performed under microwave irradiation utilized either a Biotage Initiator or CEM Discover microwave. Upon workup, organic solvents were typically dried prior to concentration with anhydrous MgSO<sub>4</sub> or Na<sub>2</sub>SO<sub>4</sub>. Flash silica chromatography was typically performed on an Isco Companion, using Silicycle silica gel, 230â400 mesh 40â63 Î¼m cartridges, Grace Resolv silica cartridges, or Isolute Flash Si or Si II cartridges. Reverse-phase chromatography was performed on a Waters XBridge Prep C18 optimum bed density (OBD) column (5 Î¼m silica, 19 mm diameter, 100 mm length), with decreasingly polar mixtures of either water (containing 1% NH<sub>3</sub>) and acetonitrile, or water (containing 0.1% formic acid) and acetonitrile, as eluents. Analytical liquid chromatographyâmass spectrometry (LC-MS) was performed on a Waters 2790 LC with a 996 photodiode array (PDA) detector and 2000 amu ZQ single-quadrupole mass spectrometer using a Phenomenex Gemini 50 Ã 2.1 mm 5 Î¼m C18 column, or ultra-performance liquid chromatography (UPLC) was performed on an Waters Acquity binary solvent manager with Acquity PDA and an SQD mass spectrometer using a 50 Ã 2.1 mm 1.7 Î¼m bridged ethyl hybrid (BEH) column from Waters, and purities were measured by UV absorption at 254 nm or by total ion chromatogram (TIC) and are â¥95% unless otherwise stated. NMR spectra were recorded on a Bruker Av400 or Bruker DRX400 spectrometer at 400 MHz in deuterated dimethyl sulfoxide (DMSO-<i>d</i><sub>6</sub>) at 303 K unless otherwise indicated. <sup>1</sup>H NMR spectra are reported as chemical shifts in parts per million (ppm) relative to an internal solvent reference. Yields are given for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 4-(<i>tert</i>-Butoxycarbonylamino)-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxylic Acid (<b>6</b>)</h3><div class="NLM_p last">To a mixture of 4-[(2-methylpropan-2-yl)oxycarbonylamino]piperidine-4-carboxylic acid <b>5</b> (115.6 g, 473 mmol) in acetonitrile (1.5 L) and water (4.5 L) was added sodium bicarbonate (181 g, 2.2 mol), followed by 4-chloro-7<i>H</i>-pyrrole[2,3-<i>d</i>]pyrimidine <b>4</b> (72.7 g, 473 mmol). The mixture was heated at reflux under nitrogen for 24 h and then extracted with ethyl acetate (4 Ã 1 L). The aqueous layer was concentrated and methanol (1.5 L) was added. The mixture was shaken for 30 min at 45 Â°C and filtered. The filtrate was concentrated again and dissolved in water (300 mL). HCl (6 N) was added until the pH reached 4.5 (ca. 80 mL). The mixture was filtered and the solid was dried under vacuum to afford the crude product, which was further purified by silica gel chromatography [elution with methanol/dichloromethane (DCM) 1:3] to yield the title compound <b>6</b> as a pale gray solid (105 g, 63%). <sup>1</sup>H NMR Î´ 1.40 (9H, s), 1.88â1.95 (2H, m), 2.02â2.06 (2H, m), 3.44â3.51 (2H, m), 4.30 (2H, d), 6.60â6.61 (1H, m), 7.16â7.18 (1H, m), 7.29 (1H, s), 8.14 (1H, s), 11.68 (1H, s); MS <i>m</i>/<i>z</i> MH<sup>+</sup> = 362.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 4-Amino-<i>N</i>-[1-(4-chlorophenyl)ethyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>32</b>)</h3><div class="NLM_p last">Compound <b>6</b>(362 mg, 1 mmol), 1-(4-chlorophenyl)ethanamine (172 mg, 1.1 mmol), <i>N</i>-(3-dimethylaminopropyl)-3-ethylcarbodiimide (231 mg, 1.5 mmol), and 1-hydroxybenzotriazole (163 mg, 1.1 mmol) were stirred together in <i>N</i>,<i>N</i>-dimethylformamide (DMF; 2 mL) under nitrogen for 16 h. The reaction mixture was partitioned between ethyl acetate (20 mL) and brine (4 Ã 20 mL). The organics were combined, dried, and evaporated in vacuo. The resultant white solid was dissolved in 1,4-dioxane (5 mL), and a 4 M solution of HCl in 1,4-dioxane (5 mL) was added. The resulting mixture was stirred for 16 h and then diluted with diethyl ether (50 mL). The crude product was isolated by filtration as the HCl salt, which was purified by ion-exchange chromatography on an SCX column. The desired product was eluted from the column with 7 M ammonia/methanol, and pure fractions were evaporated to dryness. This material was purified by preparative LC-MS. Fractions containing the desired compound were evaporated to dryness to afford <b>32</b> as a white solid (168 mg, 42%). <sup>1</sup>H NMR Î´ 1.33â1.49 (m, 5H), 1.84â2.04 (m, 2H), 2.12â2.22 (br s, 2H), 3.54 (t, 2H), 4.39 (t, 2H), 4.81â4.92 (m, 1H), 6.55â6.59 (m, 1H), 7.13â7.18 (m, 1H), 7.31â7.39 (m, 4H), 8.12 (s, 1H), 8.30 (d, 1H), 11.62 (s, 1H); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 399.16934 (theor 399.16946).</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (<i>R</i>)-4-Amino-<i>N</i>-[1-(4-chlorophenyl)ethyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>33</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of (<i>R</i>)-1-(4-chlorophenyl)ethanamine, <b>33</b> was obtained as a white solid (53%). <sup>1</sup>H NMR Î´ 1.37 (3H, d), 1.39â1.48 (2H, m), 1.86â2.02 (2H, m), 2.19 (2H, s), 3.49â3.58 (2H, m), 4.34â4.43 (2H, m), 4.83â4.91 (1H, m), 6.56â6.59 (1H, m), 7.14â7.16 (1H, m), 7.32â7.38 (4H, m), 8.12 (1H, s), 8.30 (1H, d), 11.62 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 399.16943 (theor 399.16946).</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (<i>S</i>)-4-Amino-<i>N</i>-[1-(4-chlorophenyl)ethyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>34</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of (<i>S</i>)-1-(4-chlorophenyl)ethanamine, <b>34</b> was obtained as a white solid (70%). <sup>1</sup>H NMR Î´ 1.37 (3H, d), 1.42â1.45 (2H, m), 1.88â2.01 (2H, m), 2.27 (2H, s), 3.49â3.59 (2H, m), 4.34â4.44 (2H, m), 4.83â4.90 (1H, m), 6.57â6.58 (1H, m), 7.14â7.16 (1H, m), 7.32â7.38 (4H, m), 8.12 (1H, s), 8.30 (1H, d), 11.62 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 399.16946 (theor 399.16946).</div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 4-Amino-<i>N</i>-[1-(4-chlorophenyl)propyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>35</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of 1-(4-chlorophenyl)propan-1-amine, <b>35</b> was obtained as a white solid (67%). <sup>1</sup>H NMR Î´ 0.87 (3H, t), 1.42â1.55 (2H, m), 1.72â1.79 (2H, m), 1.91â2.05 (2H, m), 2.21 (2H, s), 3.54 â 3.62 (2H, m), 4.38â4.45 (2H, m), 4.65â4.70 (1H, m), 6.61 (1H, dd), 7.18 (1H, dd), 7.32â7.37 (4H, m), 8.31 (1H, d), 8.12 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 413.18515 (theor 413.18511).</div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 4-Amino-<i>N</i>-[(4-chlorophenyl)(cyclopropyl)methyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>36</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of 1-(4-chlorophenyl)cyclopropylmethanamine (<b>65,</b><a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>), <b>36</b> was obtained as a white solid (79%). <sup>1</sup>H NMR Î´ 0.27â0.37 (2H, m), 0.48â0.52 (2H, m), 1.18â1.24 (1H, m), 1.40â1.48 (2H, m), 1.88â2.02 (2H, m), 2.20 (2H, s), 3.50â3.59 (2H, m), 4.15 (1H, t), 4.36â4.42 (2H, m), 6.57â6.58 (1H, m), 7.14â7.16 (1H, m), 7.35â7.40 (4H, m), 8.12 (1H, s), 8.47 (1H, d), 11.62 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 425.18509 (theor 425.18511).</div></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 4-Amino-<i>N</i>-[(4-chlorophenyl)(phenyl)methyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>37</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of (4-chlorophenyl)-phenylmethanamine, <b>37</b> was obtained as a colorless solid (45%). <sup>1</sup>H NMR Î´ 11.65 (1H, s), 8.76 (1H, s), 8.13 (1H, s), 7.42â7.25 (9H, m), 7.17â7.15 (1H, m), 6.60â6.58 (1H, m), 6.07 (1H, s), 4.45â4.39 (2H, m), 3.59â3.51 (2H, m), 2.34â2.27 (2H, m), 2.02â1.93 (2H, m), 1.52â1.46 (2H, m); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 461.18533 (theor 461.18511).</div></div><div id="sec3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 4-Amino-<i>N</i>-[1-(4-chlorophenyl)-2-phenylethyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>38</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of 1-(4-chlorophenyl)-2-phenylethanamine, <b>38</b> was obtained as a white solid (90%). <sup>1</sup>H NMR Î´ 1.21â1.42 (2H, m), 1.72â1.94 (2H, m), 2.98â3.10 (2H, m), 3.44â3.62 (2H, m), 4.13â4.23 (1H, m), 4.24â4.35 (1H, m), 4.98â5.12 (1H, m), 6.54 (1H, d), 7.12â7.29 (6H, m), 7.32â7.44 (4H, m), 8.12 (1H, s), 8.44 (1H, d), 11.63 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 475.20389 (theor 475.20365).</div></div><div id="sec3_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 4-Amino-<i>N</i>-(1-phenylethyl)-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>39</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of 1-phenylethanamine, <b>39</b> was obtained as a white solid (63%). <sup>1</sup>H NMR Î´ 1.38 (3H, d), 1.89â2.03 (2H, m), 2.17 (2H, s), 3.50â3.57 (2H, m), 4.37â4.43 (2H, m), 4.84â4.92 (1H, m), 6.57â6.58 (1H, m), 7.15 (1H, dd), 7.19â7.26 (1H, m), 7.31â7.32 (4H, m), 8.12 (1H, s), 8.28 (1H, d), 11.62 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 365.20847 (theor 365.20844).</div></div><div id="sec3_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 4-Amino-<i>N</i>-[1-(4-fluorophenyl)ethyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>40</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of 1-(4-fluorophenyl)ethanamine, <b>40</b> was obtained as a white solid (58%). <sup>1</sup>H NMR Î´ 1.38 (3H, d), 1.40â1.46 (2H, m), 1.87â1.91 (1H, m), 1.96â2.01 (1H, m), 2.16 (2H, s), 3.50â3.58 (2H, m), 4.35â4.43 (2H, m), 4.84â4.92 (1H, m), 6.57â6.58 (1H, m), 7.10â7.15 (3H, m), 7.34â7.37 (2H, m), 8.12 (1H, s), 8.28 (1H, d), 11.62 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 383.19894 (theor 383.19901).</div></div><div id="sec3_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 4-Amino-<i>N</i>-(1-pyridin-3-ylethyl)-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>41</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of 1-(3-pyridyl)ethanamine, <b>41</b> was obtained as a white solid (64%). <sup>1</sup>H NMR Î´ 1.42 (3H, d), 1.44â1.48 (2H, m), 1.85â2.02 (2H, m), 2.20 (2H, s), 3.50â3.59 (2H, m), 4.35â4.42 (2H, m), 4.88â4.96 (1H, m), 6.57â6.58 (1H, m), 7.14â7.16 (1H, m), 7.32â7.35 (1H, m), 7.71â7.74 (1H, m), 8.12 (1H, s), 8.36 (1H, d), 8.42â8.44 (1H, m), 8.54 (1H, d), 11.62 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 366.20367 (theor 366.20368).</div></div><div id="sec3_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 4-Amino-<i>N</i>-(1-pyridin-2-ylethyl)-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>42</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of 1-(2-pyridyl)ethanamine, <b>42</b> was obtained as a white solid (38%). <sup>1</sup>H NMR (700 MHz) Î´ 1.36 (3H, d), 1.39â1.43 (1H, m), 1.44â1.47 (1H, m), 1.93â1.97 (1H, m), 1.98â2.03 (1H, m), 2.22 (2H, br s), 3.48â3.55 (2H, m), 4.38â4.44 (2H, m), 4.91 (1H, p), 6.56 (1H, d), 7.14 (1H, d), 7.25 (1H, ddd), 7.35 (1H, d), 7.74 (1H, td), 8.12 (1H, s), 8.52 (1H, ddd), 8.63 (1H, d), 11.62 (1H, br s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 366.20365 (theor 366.20368).</div></div><div id="sec3_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 4-Amino-<i>N</i>-{1-[4-(methylsulfonyl)phenyl]ethyl}-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>43</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of 1-(4-methylsulfonylphenyl)ethanamine, <b>43</b> was obtained as a white solid (32%). <sup>1</sup>H NMR Î´ 1.42 (3H, d), 1.43â1.48 (2H, m), 1.86â2.03 (2H, m), 2.19 (2H, s), 3.19 (3H, s), 3.52â3.59 (2H, m), 4.36â4.42 (2H, m), 4.91â4.99 (1H, m), 6.57â6.58 (1H, m), 7.14â7.16 (1H, m), 7.58 (2H, d), 7.87 (2H, d), 8.12 (1H, s), 8.40 (1H, d), 11.62 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 443.18582 (theor 443.18599).</div></div><div id="sec3_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 4-Amino-<i>N</i>-[1-(3,4-dimethoxyphenyl)ethyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>44</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of 1-(3,4-dimethoxyphenyl)ethanamine, <b>44</b> was obtained as a white solid (32%). <sup>1</sup>H NMR (700 MHz) Î´ 1.36 (3H, d), 1.39â1.45 (2H, m), 1.9â1.95 (1H, m), 1.97â2.02 (1H, m), 2.19 (2H, br s), 3.5â3.56 (2H, m), 3.71 (3H, s), 3.73 (3H, s), 4.36â4.41 (2H, m), 4.82 (1H, p), 6.56 (1H, d), 6.81 (1H, dd), 6.86 (1H, d), 6.90 (1H, d), 7.14 (1H, dd), 8.12 (1H, s), 8.20 (1H, d), 11.61 (1H, br s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 425.22937 (theor 425.22957).</div></div><div id="sec3_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 4-Amino-<i>N</i>-[1-(4-chlorophenyl)-3-(dimethylamino)propyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>45</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of 1-(4-chlorophenyl)-<i>N</i><sup><i>3</i></sup><i>,N</i><sup><i>3</i></sup>-dimethylpropane-1,3-diamine <b>13</b>, <b>45</b> was obtained as a colorless gum (70%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 1.57 (2H, m), 1.66 (2H, br s), 1.81 (1H, m), 2.02 (1H, m), 2.18 (6H, s), 2.18â2.36 (4H, m), 3.67 (3H, m), 4.50 (2H, m), 5.00 (1H, dt), 6.52 (1H, d), 7.05 (1H, d), 7.18 (2H, d), 7.29 (2H, d), 8.33 (1H, s), 9.07 (1H, d), 9.61 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 456.22714 (theor 456.22731).</div></div><div id="sec3_16a" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> </h3><div class="NLM_p">Amine <b>13</b> used above was obtained as described below:</div><div id="sec3_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 3-Amino-3-(4-chlorophenyl)propan-1-ol (<b>9</b>)</h4><div class="NLM_p last">Boraneâtetrahydrofuran (THF) complex (94.0 mL, 93.9 mmol) was added dropwise to a stirred suspension of 3-amino-3-(4-chlorophenyl)propionic acid <b>8</b> (2.50 g, 12.5 mmol) in THF (75 mL) at 0 Â°C over a period of 20 min under nitrogen. The resulting suspension was stirred at 0 Â°C for 30 min and then at 22 Â°C for 5 h. The reaction mixture was added portionwise to methanol (500 mL). The mixture was concentrated, redissolved in methanol (250 mL), and reconcentrated (this process was repeated three times). The residue was dissolved in DCM (200 mL) and washed with 1 N NaOH (150 mL). The aqueous layer was extracted with DCM (5 Ã 100 mL) and the extracts were combined with the organic layer. The combined organics were washed with saturated brine (2 Ã 150 mL), dried, and concentrated to afford a white semisolid. The crude product was purified by flash silica chromatography, elution gradient 5â7% (10:1 methanol/concentrated aqueous ammonia) in DCM. Pure fractions were evaporated to dryness to afford <b>9</b> as a white solid (1.32 g, 57%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 1.87 (2H, m), 2.34 (2H, br s), 3.79 (2H, m), 4.13 (1H, t), 7.24 (2H, d), 7.32 (2H, d); MS <i>m</i>/<i>z</i> M â H<sup>+</sup> = 184.25.</div></div><div id="sec3_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>tert</i>-Butyl 1-(4-Chlorophenyl)-3-hydroxypropylcarbamate (<b>10</b>)</h4><div class="NLM_p last">Di-<i>tert</i>-butyl dicarbonate (0.705 g, 3.23 mmol) was added to <b>9</b> (0.5 g, 2.69 mmol) in DCM (30 mL) at 22 Â°C. The resulting solution was stirred at 22 Â°C for 2 h. The mixture was concentrated and the residue was purified by flash silica chromatography, elution gradient 0â4% (10:1 methanol/concentrated aqueous ammonia) in DCM. Pure fractions were evaporated to dryness to afford <b>10</b> as a white solid (0.759 g, 99%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 1.43 (9H, s), 1.81 (1H, m), 2.04 (1H, m), 2.74 (1H, br s), 3.69 (2H, m), 4.88 (1H, br s), 5.04 (1H, d), 7.23 (2H, d), 7.32 (2H, d); MS <i>m</i>/<i>z</i> M<sup>+</sup> = 286.</div></div><div id="sec3_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 3-(<i>tert</i>-Butoxycarbonylamino)-3-(4-chlorophenyl)propyl Methanesulfonate (<b>11</b>)</h4><div class="NLM_p last">Methanesulfonyl chloride (0.097 mL, 1.25 mmol) was added dropwise to <b>10</b> (0.326 g, 1.14 mmol) and triethylamine (0.191 mL, 1.37 mmol) in DCM (15 mL) at 22 Â°C. The resulting solution was stirred at 22 Â°C for 2 h. The mixture was concentrated and the residue was purified by flash silica chromatography, elution gradient 20â40% ethyl acetate in isohexane. Pure fractions were evaporated to dryness to afford <b>11</b> as a white solid (0.366 g, 88%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 1.42 (9H, s), 2.19 (2H, m), 3.01 (3H, s), 4.24 (2H, m), 4.82 (2H, m), 7.22 (2H, d), 7.33 (2H, d); MS <i>m</i>/<i>z</i> M<sup>+</sup> = 364.</div></div><div id="sec3_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>tert</i>-Butyl 1-(4-Chlorophenyl)-3-(dimethylamino)propylcarbamate (<b>12</b>)</h4><div class="NLM_p last">Compound <b>11</b> (0.075 g, 0.21 mmol) and tetra-<i>n</i>-butylammonium iodide (0.015 g, 0.04 mmol) were dissolved in a solution of dimethylamine in THF (2M, 5.15 mL, 10.3 mmol) and sealed into a microwave tube. The reaction was heated to 150 Â°C for 30 min in the microwave reactor and cooled to ambient temperature. The reaction mixture was concentrated, diluted with DCM (25 mL), and washed with water (25 mL). The organic layer was filtered through a phase-separating filter paper and evaporated. The crude product was purified by flash silica chromatography, elution gradient 4â8% (10:1 methanol/concentrated aqueous ammonia) in DCM. Pure fractions were evaporated to dryness to afford <b>12</b> as a colorless oil (0.054 mg, 84%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 1.40 (9H, s), 1.80 (1H, br s), 1.94 (1H, m), 2.23 (6H, s), 2.26 (2H, m), 4.71 (1H, br s), 6.16 (1H, br s), 7.21 (2H, d), 7.29 (2H, d); MS <i>m</i>/<i>z</i> MH<sup>+</sup> = 313.</div></div><div id="sec3_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 1-(4-Chlorophenyl)-<i>N</i><sup>3</sup><i>,N</i><sup>3</sup>-dimethylpropane-1,3-diamine (<b>13</b>)</h4><div class="NLM_p last">Hydrogen chloride (4 M in 1,4-dioxane, 1.13 mL, 32.6 mmol) was added to <b>12</b> (0.051 g, 0.16 mmol) in a mixture of DCM (5 mL) and methanol (2 mL) at 22 Â°C. The resulting solution was stirred at 22 Â°C for 4 h. The mixture was concentrated and the residue was purified by ion-exchange chromatography on an SCX column. The desired product was eluted from the column with 2 M ammonia/methanol, and pure fractions were evaporated to dryness to afford <b>13</b> as a colorless oil (0.032 g, 92%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 1.72â1.85 (2H, m), 2.19â2.32 (2H, m), 2.21 (6H, s), 3.99 (1H, t), 7.25â7.31 (4H, m); MS <i>m</i>/<i>z</i>MH<sup>+</sup> = 213.</div></div></div><div id="sec3_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 4-Amino-<i>N</i>-[1-(4-chlorophenyl)-4-(dimethylamino)butyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>46</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of 1-(4-chlorophenyl)-<i>N</i><sup>4</sup><i>,N</i><sup>4</sup>-dimethylbutane-1,4-diamine (<b>71</b>, <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>), <b>46</b> was obtained as a white solid (36%). <sup>1</sup>H NMR Î´ 1.26â1.33 (2H, m), 1.38â1.47 (2H, m), 1.65â1.75 (2H, m), 1.87â2.01 (2H, m), 2.08 (6H, s), 2.18 (2H, t), 3.50â3.58 (2H, m), 4.35â4.41 (2H, m), 4.73 (1H, m), 6.57 (1H, d), 7.14â7.16 (1H, m), 7.32â7.37 (4H, m), 8.12 (1H, s), 8.31 (1H, d), 11.62 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 470.24261 (theor 470.24296).</div></div><div id="sec3_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 4-Amino-<i>N</i>-[1-(4-chlorophenyl)-4-pyrrolidin-1-ylbutyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>47</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of 1-(4-chlorophenyl)-4-(pyrrolidin-1-yl)butan-1-amine (<b>74</b>, <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>), <b>47</b> was obtained as a white solid (12%). <sup>1</sup>H NMR Î´ 1.31â1.49 (4H, m), 1.65 (4H, s), 1.69â1.77 (2H, m), 1.88â1.98 (2H, m), 2.15 (2H, s), 2.34 (4H, s), 2.36 (2H, s), 3.53â3.58 (2H, m), 4.34â4.41 (2H, m), 4.73 (1H, m), 6.57 (1H, d), 7.14â7.15 (1H, d), 7.32â7.37 (4H, m), 8.12 (1H, s), 8.30 (1H, d), 11.62 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 496.25839 (theor 496.25861).</div></div><div id="sec3_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 4-Amino-<i>N</i>-[1-(4-chlorophenyl)-4-morpholin-4-ylbutyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>48</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of 1-(4-chlorophenyl)-4-morpholinobutan-1-amine (<b>72</b>, <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>), <b>48</b> was obtained as a white solid (3%). <sup>1</sup>H NMR Î´ 1.32â1.37 (1H, m), 1.44â1.51 (1H, m), 1.57â1.76 (4H, m), 2.10â2.17 (2H, m), 2.26â2.35 (6H, m), 3.47â3.56 (6H, m), 4.51 (2H, d), 4.79 (1H, m), 6.62â6.64 (1H, m), 7.19 (1H, t), 7.32â7.34 (2H, d), 7.37â7.39 (2H, d), 8.16 (1H, s), 8.49 (1H, s), 11.68 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 512.25324 (theor 512.25353).</div></div><div id="sec3_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 4-Amino-<i>N</i>-[1-(4-chlorophenyl)-4-piperidin-1-ylbutyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>49</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of 1-(4-chlorophenyl)-4-(piperidin-1-yl)butan-1-amine (<b>73</b>, <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>), <b>49</b> was obtained as a white solid (17%). <sup>1</sup>H NMR Î´ 1.31â1.37 (3H, m), 1.41â1.47 (6H, m), 1.66â1.73 (2H, m), 1.86â2.00 (2H, m), 2.16â2.24 (7H, m), 3.50â3.58 (2H, m), 4.34â4.40 (2H, m), 4.73 (1H, m), 6.57 (1H, d), 7.15 (1H, d), 7.31â7.37 (4H, m), 8.12 (1H, s), 8.29 (1H, d), 11.62 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 510.27451 (theor 510.27426).</div></div><div id="sec3_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> (<i>S</i>)-4-Amino-<i>N</i>-[1-(4-chlorophenyl)-3-(dimethylamino)propyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>50</b>)</h3><div class="NLM_p last">Racemic <b>45</b> was chirally separated on a Chiralpak AD-H supercritical fluid chromatography (SFC; 250 mm Ã 20 mm) column, using SFC, elution solvent 7:3 CO<sub>2</sub>/(ethanol + 0.1% diethylamine, DEA). The appropriate fractions for the first eluted isomer were evaporated and the residue was triturated with diethyl ether to give <b>50</b> as a white solid (25%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 1.57 (2H, m), 1.66 (2H, br s), 1.81 (1H, m), 2.02 (1H, m), 2.18 (6H, s), 2.18â2.36 (4H, m), 3.67 (3H, m), 4.50 (2H, m), 5.00 (1H, dt), 6.52 (1H, d), 7.05 (1H, d), 7.18 (2H, d), 7.29 (2H, d), 8.33 (1H, s), 9.07 (1H, d), 9.61 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 456.22723 (theor 456.22731).</div></div><div id="sec3_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 4-Amino-<i>N</i>-[(1<i>S</i>)-1-(4-chlorophenyl)-3-pyrrolidin-1-ylpropyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>51</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of 1-(4-chlorophenyl)-4-(pyrrolidin-1-yl)butan-1-amine (<b>85</b>, <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>), <b>51</b> was obtained as a white solid (10%). <sup>1</sup>H NMR Î´ 1.42â1.58 (2H, m), 1.71 (5H, s), 1.84â2.02 (5H, m), 2.33 (2H, m), 2.55 (2H, m), 3.51â3.59 (2H, m), 4.36â4.43 (2H, m), 4.86 (1H, t), 6.58 (1H, d), 7.16 (1H, d), 7.30â7.38 (5H, m), 8.12 (1H, s), 11.63 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 482.24289 (theor 482.24296).</div></div><div id="sec3_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 4-Amino-<i>N</i>-[(1<i>S</i>)-1-(4-chlorophenyl)-3-piperidin-1-ylpropyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>52</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of 1-(4-chlorophenyl)-4-(piperidin-1-yl)butan-1-amine (<b>84</b>, <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>), <b>52</b> was obtained as a white solid (17%). <sup>1</sup>H NMR Î´ 1.33â1.50 (8H, m), 1.82â1.90 (4H, m), 2.15 (2H, t), 2.25â2.34 (4H, m), 3.53â3.57 (2H, m), 4.39 (2H, m), 4.82 (1H, m), 6.57 (1H, d), 7.14â7.16 (1H, d), 7.30â7.37 (4H, m), 8.12 (1H, s), 8.64â8.66 (1H, d), 11.62 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 496.25900 (theor 496.25861).</div></div><div id="sec3_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 4-Amino-<i>N</i>-[2-amino-1-(4-chlorophenyl)-2-oxoethyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>53</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of 2-amino-2-(4-chlorophenyl)acetamide, <b>53</b> was obtained as a white solid (92%). <sup>1</sup>H NMR Î´ 11.65 (1H, s), 8.92 (1H, s), 8.13 (1H, s), 7.80 (1H, s), 7.45â7.39 (4H, m), 7.29 (1H, s), 7.17â7.15 (1H, m), 6.58â6.57 (1H, m), 5.30 (1H, s), 4.48â4.38 (2H, m), 3.55â3.46 (2H, m), 2.43 (2H, s), 2.03â1.94 (1H, m), 1.90â1.82 (1H, m), 1.49â1.39 (2H, m); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 428.15979 (theor 428.15963).</div></div><div id="sec3_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> <i>N</i>-[2-Acetamido-1-(4-chlorophenyl)ethyl]-4-amino-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>55</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of <i>N</i>-[2-amino-2-(4-chlorophenyl)ethyl]acetamide <b>25</b>, <b>55</b> was obtained as a cream film (81%). <sup>1</sup>H NMR Î´ 1.43 (2H, t), 1.79 (3H, s), 1.83â2.04 (2H, m), 2.20 (2H, br s), 3.32â3.38 (2H, m), 3.58 (2H, q), 4.32â4.42 (2H, m), 4.82â4.88 (1H, m), 6.56â6.60 (1H, m), 7.14â7.18 (1H, m), 7.33 (2H, d), 7.38 (2H, d), 7.94 (1H, t), 8.13 (1H, s), 8.42â8.50 (1H, m), 11.63 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 456.19113 (theor 456.19093).</div></div><div id="sec3_30a" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> </h3><div class="NLM_p">The amine <b>25</b> used above was synthesized as described below:</div><div id="sec3_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>tert</i>-Butyl 2-Acetamido-1-(4-chlorophenyl)ethylcarbamate (<b>24</b>)</h4><div class="NLM_p last">A solution of <b>23</b> (0.208 g, 0.77 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA; 0.266 mL, 1.54 mmol) in THF (5 mL) was treated with acetic anhydride (0.102 mL, 1.08 mmol). The resulting solution was stirred at ambient temperature for 2 h. The mixture was partitioned between DCM and sodium bicarbonate solution. The organic layer was concentrated and the residue was purified by flash column chromatography on silica with gradient elution (10â40% ethyl acetate/DCM) to afford <b>24</b> as a colorless solid (0.15 g, 63%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 1.41 (9H, s), 1.98 (3H, s), 3.46â3.67 (2H, m), 4.74 (1H, br s), 4.97â5.56 (1H, m), 5.89 (1H, br s), 7.22 (2H, d), 7.32 (2H, d); MS <i>m</i>/<i>z</i>MH<sup>+</sup> = 313.</div></div><div id="sec3_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>N</i>-[2-Amino-2-(4-chlorophenyl)ethyl]acetamide (<b>25</b>)</h4><div class="NLM_p last">Compound <b>24</b> (148 mg, 0.47 mmol) was treated with TFA (2 mL). The solution was stirred for 1 h at room temperature. The mixture was concentrated under reduced pressure. The crude product was purified by ion-exchange chromatography on an SCX column. The residue was loaded onto the column in methanol and washed with methanol. The desired product was eluted from the column with 2 M ammonia in methanol, and pure fractions were evaporated to dryness to afford <b>25</b> as a pale yellow crystalline solid (98 mg, 97%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 1.61 (2H, br s), 1.97 (3H, s), 3.28â3.37 (1H, m), 3.44â3.52 (1H, m), 4.05â4.11 (1H, m), 5.78 (1H, br s), 7.28â7.36 (4H, m); MS <i>m</i>/<i>z</i> MH<sup>+</sup> = 213.</div></div></div><div id="sec3_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 4-Amino-<i>N</i>-[1-(4-chlorophenyl)-2-sulfamoylethyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>56</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of 2-amino-2-(4-chlorophenyl)ethanesulfonamide <b>22</b>, <b>56</b> was obtained as a colorless solid (84%). <sup>1</sup>H NMR Î´ 1.35â1.53 (2H, m), 1.86â2.04 (2H, m), 3.35â3.40 (1H, m), 3.52â3.62 (2H, m), 3.68 (1H, dd), 4.33â4.41 (2H, m), 5.24â5.29 (1H, m), 6.56â6.60 (1H, m), 6.88 (2H, s), 7.13â7.17 (1H, m), 7.39 (4H, s), 8.13 (1H, s), 8.68 (1H, br s), 11.63 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 478.14221 (theor 478.14226).</div></div><div id="sec3_33a" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> </h3><div class="NLM_p">The amine <b>22</b> used above was synthesized as described below:</div><div id="sec3_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 2-(<i>tert</i>-Butoxycarbonylamino)-2-(4-chlorophenyl)ethyl Ethanethioate (<b>19</b>)</h4><div class="NLM_p last">A solution of <b>18</b> (600 mg, 1.72 mmol) in DMF (10 mL) was treated with potassium thioacetate (392 mg, 3.43 mmol), and the mixture was heated at 50 Â°C for 1 h. The mixture was cooled and partitioned between ethyl acetate and water. The organic layer was washed twice with water and then dried and concentrated to dryness. The residue was purified by flash column chromatography on silica with gradient elution (10â20% ethyl acetate/isohexane) to give <b>19</b> as a cream crystalline solid (509 mg, 90%). <sup>1</sup>H NMR (CDCl3) Î´ 1.40 (9H, s), 2.35 (3H, s), 3.15â3.28 (2H, m), 4.78 (1H, br s), 5.07 (1H, br s), 7.24 (2H, d), 7.31 (2H, d); MS <i>m</i>/<i>z</i> [M â H â CH<sub>3</sub>CO]<sup>â</sup> = 286.</div></div><div id="sec3_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> <i>tert</i>-Butyl 1-(4-Chlorophenyl)-2-(chlorosulfonyl)ethylcarbamate (<b>20</b>)</h4><div class="NLM_p last"><i>N</i>-Chlorosuccinimide (819 mg, 6.14 mmol) was added to a solution of 2 M hydrochloric acid (0.8 mL) in acetonitrile (10 mL). The reaction flask was cooled with an ice bath to 10 Â°C, and <b>19</b>(506 mg, 1.53 mmol) was added portionwise. The mixture warmed during the addition and was stirred for 10 min at room temperature. The mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried, and concentrated to dryness to afford <b>20</b> as a colorless solid (602 mg, 100%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 1.44 (9H, s), 2.77 (1H, s), 4.06 (1H, dd), 4.36 (1H, br s), 5.15â5.23 (1H, m), 5.29â5.37 (1H, m), 7.29 (2H, d), 7.38 (2H, d).</div></div><div id="sec3_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> <i>tert</i>-Butyl 1-(4-Chlorophenyl)-2-sulfamoylethylcarbamate (<b>21</b>)</h4><div class="NLM_p last">Ammonia (1.5 mL, 31.50 mmol) was added to a suspension of <b>20</b> (0.542 g, 1.53 mmol) in acetonitrile (10 mL). The mixture was stirred for 16 h at room temperature. The mixture was partitioned between ethyl acetate and water and the organic layer was washed with brine. The organic solution was dried and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica with gradient elution (10â30% ethyl acetate/DCM) to afford <b>21</b> as a colorless solid (0.35 g, 69%). <sup>1</sup>H NMR Î´ 1.36 (9H, s), 3.21â3.28 (1H, m), 3.47â3.56 (1H, m), 5.02 (1H, br s), 6.88 (2H, s), 7.35 (2H, d), 7.41 (2H, d), 7.49â7.60 (1H, m); MS <i>m</i>/<i>z</i> [M â H]<sup>â</sup> = 333.</div></div><div id="sec3_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 2-Amino-2-(4-chlorophenyl)ethanesulfonamide (<b>22</b>)</h4><div class="NLM_p last">Compound <b>21</b> (325 mg, 0.97 mmol) was treated with trifluoroacetic acid (TFA; 8 mL). The resulting solution was stirred for 15 min at room temperature. The mixture was concentrated under reduced pressure and the residue was purified by ion-exchange chromatography on an SCX column. The column was washed with methanol, the desired product was eluted with ammonia in methanol (2 M), and pure fractions were evaporated to dryness to afford <b>22</b> as a colorless solid (221 mg, 97%). <sup>1</sup>H NMR Î´ 3.13â3.25 (2H, m), 4.39 (1H, dd), 7.35â7.48 (4H, m); MS <i>m</i>/<i>z</i> [M â H]<sup>â</sup> = 233.</div></div></div><div id="sec3_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 4-Amino-<i>N</i>-[1-(4-chlorophenyl)-3-sulfamoylpropyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>57</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of 3-amino-3-(4-chlorophenyl)propane-1-sulfonamide (<b>81</b>, <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>), <b>57</b> was obtained as a colorless gum (32%). <sup>1</sup>H NMR Î´ 1.48 (2H, m), 1.90â2.06 (2H, m), 2.09â2.24 (2H, m), 2.87 (1H, ddd), 3.02 (1H, ddd), 3.56 (2H, m), 3.56 (2H, d), 4.41 (2H, m), 4.91 (1H, br s), 6.59 (1H, dd), 6.80 (2H, s), 7.16 (1H, dd), 7.38â7.43 (4H, m), 8.13 (1H, s), 8.46 (1H, s), 11.64 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 492.15775 (theor 492.15791).</div></div><div id="sec3_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 4-Amino-<i>N</i>-[1-(4-chlorophenyl)-2-sulfamoylethyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>58</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of <i>N</i>-[2-amino-2-(4-chlorophenyl)ethyl]methanesulfonamide <b>27</b>, <b>58</b> was obtained as a colorless solid (75%). <sup>1</sup>H NMR Î´ 1.38â1.53 (2H, m), 1.85â2.07 (2H, m), 2.20 (2H, br s), 2.85 (3H, s), 3.57 (2H, m), 4.34â4.46 (2H, m), 4.87â4.94 (1H, m), 6.57â6.60 (1H, m), 7.12â7.19 (2H, m), 7.35â7.43 (4H, m), 8.13 (1H, s), 8.46 (1H, br s), 11.64 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 492.15784 (theor 492.15791).</div></div><div id="sec3_39a" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> </h3><div class="NLM_p">Amine <b>27</b> used above was synthesized as described below:</div><div id="sec3_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> <i>tert</i>-Butyl 1-(4-Chlorophenyl)-2-hydroxyethylcarbamate (<b>17</b>)</h4><div class="NLM_p last">2-Amino-2-(4-chlorophenyl)acetic acid (12 g, 64.65 mmol) was stirred in THF (200 mL), and sodium borohydride (5.82 g, 153.87 mmol) was added in portions to the stirred mixture under nitrogen. A solution of iodine (16.41 g, 64.65 mmol) in THF (20 mL) was added dropwise while the temperature was maintained below 15 Â°C by use of an ice bath. The resulting mixture was warmed to room temperature and stirred at reflux overnight. The reaction was quenched by the addition of methanol (40 mL) and then treated with triethylamine (18.02 mL, 129 mmol) and di-<i>tert</i>-butyl dicarbonate (14.11 g, 65 mmol). The mixture was stirred for 2 h at room temperature before being partitioned between ethyl acetate and water. The organic layer was dried and concentrated under reduced pressure. The residue was purified by flash silica chromatography with gradient elution (10â50% ethyl acetate/DCM) to afford <b>17</b> as a colorless solid (10.32 g, 59%). <sup>1</sup>H NMR Î´ 1.37 (9H, s), 3.41â3.52 (2H, m), 4.42â4.58 (1H, m), 4.79 (1H, t), 7.23 (1H, d), 7.31 (2H, d), 7.37 (2H, d).</div></div><div id="sec3_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 2-(<i>tert</i>-Butoxycarbonylamino)-2-(4-chlorophenyl)ethyl Methanesulfonate (<b>18</b>)</h4><div class="NLM_p last">Methanesulfonyl chloride (1.45 mL, 19 mmol) was added to <b>17</b> (4.63 g, 17 mmol) and DIPEA (6.23 mL, 35.78 mmol) in DCM (40 mL) cooled to 0 Â°C over a period of 5 min under nitrogen. The resulting solution was stirred at 20 Â°C for 2 h. The reaction mixture was diluted with DCM (100 mL) and washed sequentially with water (100 mL). The organic layer was dried and evaporated to afford crude product, which was purified by flash silica chromatography, elution gradient 0â10% ethyl acetate in DCM. Pure fractions were evaporated to dryness to afford <b>18</b> as a white solid (3.12 g, 52%). <sup>1</sup>H NMR Î´ 1.39 (9H, s), 3.17 (3H, s), 4.22â4.28 (2H, m), 4.90 (1H, d), 7.40â7.46 (4H, m), 7.68 (1H, d). <i>m</i>/<i>z</i> (ESI+) [M â H]<sup>â</sup> = 348.</div></div><div id="sec3_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> <i>tert</i>-Butyl 2-amino-1-(4-chlorophenyl)ethylcarbamate (<b>23</b>)</h4><div class="NLM_p last">A solution of <b>18</b> (535 mg, 1.53 mmol) in DMF (8 mL) was treated with sodium azide (199 mg, 3.06 mmol), and the mixture was heated at 80 Â°C for 1 h. The mixture was cooled and allowed to stir at room temperature overnight. The solution was partitioned between ethyl acetate and water. The organic layer was washed twice with water and then dried and concentrated until the final volume was approximately 5 mL. Ethanol (20 mL) and 10% palladium on carbon (75 mg, 0.07 mmol) were added. The resulting suspension was stirred under an atmosphere of hydrogen at ambient pressure and temperature for 1 h. The mixture was filtered and the filtrate was concentrated under reduced pressure to give <b>23</b> as a gum (410 mg, 99%), which was used without further purification. MS <i>m</i>/<i>z</i> MH<sup>+</sup> = 271.</div></div><div id="sec3_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> <i>tert</i>-Butyl 1-(4-Chlorophenyl)-2-(methylsulfonamido)ethylcarbamate (<b>26</b>)</h4><div class="NLM_p last">A solution of <b>23</b> (220 mg, 0.81 mmol) and DIPEA (0.28 mL, 1.63 mmol) in THF (5 mL) was treated with methanesulfonyl chloride (0.075 mL, 0.98 mmol). The resulting solution was stirred at ambient temperature for 2 h. The mixture was partitioned between DCM and sodium bicarbonate solution. The organic layer was concentrated and the residue was purified by flash column chromatography on silica with gradient elution (10â30% ethyl acetate/DCM) to afford <b>26</b> as a colorless solid (154 mg, 54%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 1.43 (9H, s), 2.92 (3H, s), 3.38â3.52 (2H, m), 4.68â4.84 (2H, m), 5.20â5.28 (1H, m), 7.23 (2H, d), 7.35 (2H, d); MS <i>m</i>/<i>z</i> [M â H]<sup>â</sup> = 347.</div></div><div id="sec3_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> <i>N</i>-[2-Amino-2-(4-chlorophenyl)ethyl]methanesulfonamide (<b>27</b>)</h4><div class="NLM_p last">Compound <b>26</b> (151 mg, 0.43 mmol) was treated with TFA (2 mL). The solution was stirred for 1 h at room temperature and then concentrated under reduced pressure. The crude product was purified by ion-exchange chromatography on an SCX column. The residue was loaded onto the column in methanol and washed with methanol. The desired product was eluted from the column with 2 M ammonia in methanol, and pure fractions were evaporated to dryness to afford <b>27</b> as a colorless crystalline solid (93 mg, 86%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 2.89 (3H, s), 3.17 (1H, dd), 3.33 (1H, dd), 4.12 (1H, dd), 4.74 (1H, br s), 7.29 (2H, d), 7.34 (2H, d); MS <i>m</i>/<i>z</i> [M â H]<sup>â</sup> = 247.</div></div></div><div id="sec3_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 4-Amino-<i>N</i>-[1-(4-chlorophenyl)-3-(methylsulfonamido)propyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>59</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of <i>N</i>-[3-amino-3-(4-chlorophenyl)propyl]methanesulfonamide <b>31</b>, <b>59</b> was obtained as a white solid (65%). <sup>1</sup>H NMR Î´ 1.40â1.48 (2H, m), 1.86â1.90 (2H, m), 1.93â1.97 (2H, m), 2.17 (2H, s), 2.88 (3H, s), 2.93â2.97 (2H, m), 3.53â3.60 (2H, m), 4.37 (2H, t), 4.87 (1H, d), 6.57â6.59 (1H, m), 7.00 (1H, t), 7.15â7.16 (1H, m), 7.35â7.40 (4H, m), 8.13 (1H, s), 8.38 (1H, d), 11.63 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 506.17361 (theor 506.17356).</div></div><div id="sec3_45a" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> </h3><div class="NLM_p">The amine <b>31</b> used above was synthesized as described below:</div><div id="sec3_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> <i>tert</i>-Butyl 1-(4-Chlorophenyl)-2-cyanoethylcarbamate (<b>28</b>)</h4><div class="NLM_p last">Sodium cyanide (105 mg, 2.14 mmol) was added to <b>18</b> (300 mg, 0.86 mmol) in DMF (5 mL) at 20 Â°C. The resulting suspension was stirred at 80 Â°C for 3 h. The reaction mixture was evaporated to dryness and redissolved in water (10 mL) and then washed sequentially with DCM (3 Ã 10 mL). The organic layer was dried and evaporated to afford crude product, which was purified by flash silica chromatography, elution gradient 0â25% ethyl acetate in isohexane, to afford <b>28</b> as a white solid (209 mg, 87%). <sup>1</sup>H NMR Î´ 1.38â1.42 (9H, s), 2.82â2.89 (2H, m), 4.89 (1H, d), 7.38â7.45 (4H, m), 7.76 (1H, d); <i>m</i>/<i>z</i> (ESI+) [M â H]<sup>â</sup> = 279.</div></div><div id="sec3_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> <i>tert</i>-Butyl 3-Amino-1-(4-chlorophenyl)propylcarbamate (<b>29</b>)</h4><div class="NLM_p last">Lithium aluminum hydride (1 M in THF, 0.71 mL, 0.71 mmol) was added dropwise to <b>28</b> (200 mg, 0.71 mmol) in THF (4 mL) at 20 Â°C under nitrogen. The resulting solution was stirred at 20 Â°C for 2 h. The reaction mixture was quenched with aqueous NaOH (1 M, 1 mL) and the solution was filtered. The solution was diluted with ethyl acetate (20 mL), and washed with water (2 Ã 10 mL). The organic layer was dried and evaporated to afford <b>29</b> as a gum (203 mg, 100%), which was used without further purification. <i>m</i>/<i>z</i> (ESI+) [M + H]<sup>+</sup> = 285.</div></div><div id="sec3_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> <i>tert</i>-Butyl 1-(4-Chlorophenyl)-3-(methylsulfonamido)propylcarbamate (<b>30</b>)</h4><div class="NLM_p last">Methanesulfonyl chloride (0.082 mL, 1.05 mmol) was added dropwise to <b>29</b> (300 mg, 1.05 mmol) and DIPEA (0.367 mL, 2.11 mmol) in DCM (4 mL) at 20 Â°C. The resulting solution was stirred at 20 Â°C for 18 h. The reaction mixture was concentrated and diluted with diethyl ether (25 mL) and washed with water (25 mL). The organic layer was dried and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0â20% ethyl acetate in DCM. Pure fractions were evaporated to dryness to afford <b>30</b> as a white solid (275 mg, 72%). <sup>1</sup>H NMR Î´ 1.37 (9H, s), 1.76 (1H, m), 1.82â1.88 (1H, m), 2.87 (3H, s), 2.89â2.91 (2H, m), 4.58 (1H, d), 7.00 (1H, t), 7.32 (2H, d), 7.39 (2H, d), 7.48 (1H, d); <i>m</i>/<i>z</i> (ESI+) [M + H]<sup>+</sup> = 361.</div></div><div id="sec3_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> <i>N</i>-[3-Amino-3-(4-chlorophenyl)propyl]methanesulfonamide (<b>31</b>)</h4><div class="NLM_p last">TFA (4 mL) was added to <b>30</b> (275 mg, 0.76 mmol) and the mixture was stirred at 20 Â°C for 2 h. The reaction was concentrated and the residue was purified by ion-exchange chromatograph on an SCX column. The desired product was eluted from the column with 7 N ammonia in methanol to afford <b>31</b> as a colorless gum (113 mg, 57%). <sup>1</sup>H NMR Î´ 1.69â1.72 (2H, m), 2.87 (3H, s), 2.94â2.98 (2H, m), 3.18â3.19 (1H, m), 3.87 (1H, t), 7.35â7.40 (4H, m); <i>m</i>/<i>z</i> (ESI+) [M + H]<sup>+</sup> = 262.</div></div></div><div id="sec3_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> 4-Amino-<i>N</i>-[1-(4-chlorophenyl)-2-hydroxyethyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>60</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of 2-amino-2-(4-chlorophenyl)ethanol (see US2006/0004045 for preparation), <b>32</b> was obtained as a colorless crystalline solid (80%). <sup>1</sup>H NMR Î´ 1.40â1.49 (2H, m), 1.85â2.09 (2H, m), 3.48â3.69 (4H, m), 4.35â4.48 (2H, m), 4.72â4.81 (1H, m), 4.90â4.96 (1H, m), 6.58 (1H, br s), 7.12â7.18 (1H, m), 7.30â7.40 (4H, m), 8.13 (1H, s), 8.45â8.53 (1H, m), 11.64 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 415.16461 (theor 415.16438).</div></div><div id="sec3_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> 4-Amino-<i>N</i>-[1-(4-chlorophenyl)-4-hydroxybutyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>62</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of 4-amino-4-(4-chlorophenyl)butan-1-ol (<b>68</b>, <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>), <b>62</b> was obtained as a colorless solid (34%). <sup>1</sup>H NMR Î´ 1.28â1.51 (4H, m), 1.69â1.80 (2H, m), 1.90â2.03 (2H, m), 3.37â3.41 (2H, m), 3.50â3.58 (2H, m), 4.37â4.43 (3H, m), 4.71â4.76 (1H, m), 6.59 (1H, m), 7.16 (1H, m), 7.36 (4H, m), 8.13 (1H, s), 8.33 (1H, d), 11.64 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 443.19553 (theor 443.19568).</div></div><div id="sec3_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> 4-Amino-<i>N</i>-[1-(4-chlorophenyl)-3-methoxypropyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide (<b>63</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of 1-(4-chlorophenyl)-3-methoxypropan-1-amine <b>15</b>, <b>63</b> was obtained as a white solid (66%). <sup>1</sup>H NMR Î´ 1.44 (2H, m), 1.88â2.02 (5H, m), 2.46 (2H, s), 3.21 (3H, s), 3.28 (2H, t), 3.55 (2H, m), 4.39 (2H, m), 4.87 (1H, dt), 6.59 (1H, dd), 7.16 (1H, dd), 7.33 (2H, d), 7.37 (2H, d), 8.13 (1H, s), 8.45 (1H, d), 11.63 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 443.19592 (theor 443.19568).</div></div><div id="sec3_52a" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> </h3><div class="NLM_p">The amine <b>15</b> used above was synthesized as described below:</div><div id="sec3_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> <i>tert</i>-Butyl 1-(4-Chlorophenyl)-3-methoxypropylcarbamate (<b>14</b>)</h4><div class="NLM_p last">Sodium hydride (35 mg, 0.87 mmol) was added to <b>10</b> (200 mg, 0.70 mmol) in THF (10 mL) at 0 Â°C under nitrogen. The mixture was stirred at 0 Â°C for 15 min. Methyl iodide (0.044 mL, 0.70 mmol) was added dropwise, and the resulting suspension was stirred at 22 Â°C for 4 h. The reaction was quenched with potassium bisulfate solution (1M, 0.5 mL) and water (15 mL). The mixture was extracted with diethyl ether (3 Ã 20 mL), and the combined extracts were washed with saturated brine (20 mL), dried, and evaporated to give crude product. The crude product was purified by flash silica chromatography, elution gradient 20â60% ethyl acetate in isohexane, to afford <b>14</b> as a white solid (80 mg, 38%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 1.40 (9H, s), 1.91 (1H, s), 2.01 (1H, s), 3.30 (3H, s), 3.32 (2H, m), 4.79 (1H, br s), 5.45 (1H, br s), 7.20 (2H, d), 7.29 (2H, d); <i>m</i>/<i>z</i> (ESI+) [M + H]<sup>+</sup> = 300.</div></div><div id="sec3_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 1-(4-Chlorophenyl)-3-methoxypropan-1-amine (<b>15</b>)</h4><div class="NLM_p last">Hydrogen chloride (4 M in 1,4-dioxane, 0.667 mL, 2.67 mmol) was added to <b>14</b> (80 mg, 0.27 mmol) in a mixture of DCM (5 mL) and methanol (2 mL) at 22 Â°C. The resulting solution was stirred at 22 Â°C for 5 h. The mixture was concentrated and the residue was purified by ion-exchange chromatography on an SCX column. The desired product was eluted from the column with 2 M ammonia in methanol, and pure fractions were evaporated to dryness to afford <b>15</b> as a colorless oil (47 mg, 88%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 1.80â1.96 (2H, m), 3.31 (3H, s), 3.32 (1H, m), 3.43 (1H, m), 4.09 (1H, t), 7.27â7.31 (4H, m); <i>m</i>/<i>z</i> (ESI+) [M + H]<sup>+</sup> = 200.</div></div></div><div id="sec3_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> (<i>S</i>)-4-Amino-<i>N</i>-[1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamide, AZD5363 (<b>64</b>)</h3><div class="NLM_p last">In a similar manner to that described for <b>32</b>, by use of (<i>S</i>)-3-amino-3-(4-chlorophenyl)propan-1-ol (<b>75</b>, <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>), <b>64</b> was obtained as a white solid (25%). <sup>1</sup>H NMR Î´ 1.45 (2H, d), 1.86 (1H, d), 1.90â1.93 (1H, m), 2.19 (2H, s), 3.38 (2H, q), 3.51â3.58 (2H, m), 4.35â4.38 (2H, m), 4.53 (1H, t), 4.88 (1H, d), 6.58 (1H, t), 7.16 (1H, t), 7.32â7.38 (4H, m), 8.12 (1H, s), 8.43 (1H, d), 11.63 (1H, s); HRMS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 429.17978 (theor 429.18003). The chiral purity of <b>64</b> was assessed by use of a 5 Î¼m Chiralpak IA (250 mm Ã 4.6 mm) GB012 column with isohexane/ethanol/triethylamine (50/50/0.1) as eluent, and it was determined to contain <0.1% of the other enantiomer.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i84"><a href="/doi/suppl/10.1021/jm301762v">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56015" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56015" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Additional text with details of the full synthesis and spectroscopic characterization of all additional compounds and intermediate, together with all protocols for in vitro and in vivo experiments, and one table listing crystallographic information. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm301762v/suppl_file/jm301762v_si_001.pdf">jm301762v_si_001.pdf (244.03 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm301762v" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37166" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37166" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason G. Kettle</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, AstraZeneca, Alderley Park, Macclesfield
SK10 4TG, United Kingdom</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#650f04160a0b4b0e00111109002504161117041f000b0006044b060a08"><span class="__cf_email__" data-cfemail="aec4cfddc1c080c5cbdadac2cbeecfdddadccfd4cbc0cbcdcf80cdc1c3">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matt Addie</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, AstraZeneca, Alderley Park, Macclesfield
SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Ballard</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, AstraZeneca, Alderley Park, Macclesfield
SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Buttar</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, AstraZeneca, Alderley Park, Macclesfield
SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claire Crafter</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, AstraZeneca, Alderley Park, Macclesfield
SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gordon Currie</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, AstraZeneca, Alderley Park, Macclesfield
SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Barry R. Davies</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, AstraZeneca, Alderley Park, Macclesfield
SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Judit Debreczeni</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, AstraZeneca, Alderley Park, Macclesfield
SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hannah Dry</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, AstraZeneca, Alderley Park, Macclesfield
SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philippa Dudley</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, AstraZeneca, Alderley Park, Macclesfield
SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ryan Greenwood</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, AstraZeneca, Alderley Park, Macclesfield
SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul D. Johnson</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, AstraZeneca, Alderley Park, Macclesfield
SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Clare Lane</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, AstraZeneca, Alderley Park, Macclesfield
SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gillian Lamont</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, AstraZeneca, Alderley Park, Macclesfield
SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew Leach</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, AstraZeneca, Alderley Park, Macclesfield
SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard W. A. Luke</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, AstraZeneca, Alderley Park, Macclesfield
SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeff Morris</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, AstraZeneca, Alderley Park, Macclesfield
SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Donald Ogilvie</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, AstraZeneca, Alderley Park, Macclesfield
SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ken Page</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, AstraZeneca, Alderley Park, Macclesfield
SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin Pass</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, AstraZeneca, Alderley Park, Macclesfield
SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stuart Pearson</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, AstraZeneca, Alderley Park, Macclesfield
SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Linette Ruston</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, AstraZeneca, Alderley Park, Macclesfield
SK10 4TG, United Kingdom</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e3898-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i86">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87136" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87136" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank our former colleagues at AstraZeneca for their contributions to this work: Keith Johnson, Glen Hatter, Geoff Bird, Bish Matusiak and Ciorsdaidh Watts. We thank Anja Jestel, Stefan Steinbacher and Holger Steuber of Proteros for crystallography determination. We also acknowledge our former collaborators at Astex Therapeutics and the Institute of Cancer Research for the discovery of the various lead series that provided the starting points for this work.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i87" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i87"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i88" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i88"> Abbreviations Used</h2><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">GSK3Î²</td><td class="NLM_def"><p class="first last">glycogen synthase kinase 3Î²</p></td></tr><tr><td class="NLM_term">PDK1</td><td class="NLM_def"><p class="first last">3-phosphoinositide-dependent protein kinase 1</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">PH</td><td class="NLM_def"><p class="first last">pleckstrin homology</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structureâactivity relationship</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i89">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17526" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17526" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 14 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J. J.</span><span> </span><span class="NLM_article-title">Targeting the phosphoinositide 3-kinase pathway in cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">627</span><span class="NLM_x">â</span> <span class="NLM_lpage">644</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm301762v&amp;key=10.1038%2Fnrd2926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm301762v&amp;key=19644473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=627-644&author=P.+Liuauthor=H.+Chengauthor=T.+M.+Robertsauthor=J.+J.+Zhao&title=Targeting+the+phosphoinositide+3-kinase+pathway+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the phosphoinositide 3-kinase pathway in cancer</span></div><div class="casAuthors">Liu, Pixu; Cheng, Hailing; Roberts, Thomas M.; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">627-644</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K) pathway is a key signal transduction system that links oncogenes and multiple receptor classes to many essential cellular functions, and is perhaps the most commonly activated signalling pathway in human cancer.  This pathway therefore presents both an opportunity and a challenge for cancer therapy.  Even as inhibitors that target PI3K isoforms and other major nodes in the pathway, including AKT and mammalian target of rapamycin (mTOR), reach clin. trials, major issues remain.  Here, we highlight recent progress that has been made in our understanding of the PI3K pathway and discuss the potential of and challenges for the development of therapeutic agents that target this pathway in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUk9T-ZoNDtLVg90H21EOLACvtfcHk0lhT_K3zqi_Wdg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D&md5=fdc94abd15178a9dbe7c56dafbfb7787</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd2926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2926%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DTargeting%2520the%2520phosphoinositide%25203-kinase%2520pathway%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D627%26epage%3D644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Manning, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span> </span><span class="NLM_article-title">Navigating downstream of AKT</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">1261</span><span class="NLM_x">â</span> <span class="NLM_lpage">1274</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2007&pages=1261-1274&author=B.+D.+Manningauthor=L.+C.+Cantley&title=Navigating+downstream+of+AKT"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DB.%2BD.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DNavigating%2520downstream%2520of%2520AKT%26jtitle%3DCell%26date%3D2007%26volume%3D129%26spage%3D1261%26epage%3D1274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Bozulic, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemmings, B. A.</span><span> </span><span class="NLM_article-title">PIKKing on PKB: Regulation of PKB activity by phosphorylation</span> <span class="citation_source-journal">Curr. Opin. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">256</span><span class="NLM_x">â</span> <span class="NLM_lpage">261</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm301762v&amp;key=10.1016%2Fj.ceb.2009.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm301762v&amp;key=19303758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVClu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=256-261&author=L.+Bozulicauthor=B.+A.+Hemmings&title=PIKKing+on+PKB%3A+Regulation+of+PKB+activity+by+phosphorylation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">PIKKing on PKB: regulation of PKB activity by phosphorylation</span></div><div class="casAuthors">Bozulic, Lana; Hemmings, Brian A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">256-261</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Protein kinase B (PKB)/Akt kinase is a key regulator of a wide range of cellular processes including growth, proliferation and survival.  PKB is clearly a crucial signaling mol. and extensive research efforts aim to understand its regulation and action.  Recent studies of the regulation of PKB activity by hydrophobic motif phosphorylation have yielded several exciting findings about members of the phosphatidylinositol 3-kinase (PI3K)-like family of kinases (PIKKs) acting as PKB regulators.  Mammalian target of rapamycin complex 2 (mTORC2) and DNA-dependent protein kinase (DNA-PK) can both phosphorylate Ser-473 and activate PKB.  This review concerns PKB regulation by mTORC2 and DNA-PK in a stimulus-dependent and context-dependent manner and the possible implications of this for PKB activity, substrate specificity, and therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgDTdYbqJWtLVg90H21EOLACvtfcHk0lhT_K3zqi_Wdg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVClu7Y%253D&md5=0b7a3e6ea561f8479701a01133b5d30c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2009.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2009.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DBozulic%26aufirst%3DL.%26aulast%3DHemmings%26aufirst%3DB.%2BA.%26atitle%3DPIKKing%2520on%2520PKB%253A%2520Regulation%2520of%2520PKB%2520activity%2520by%2520phosphorylation%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2009%26volume%3D21%26spage%3D256%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Sarbassov, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guertin, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatini, D. M.</span><span> </span><span class="NLM_article-title">Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">307</span><span class="NLM_x">, </span> <span class="NLM_fpage">1098</span><span class="NLM_x">â</span> <span class="NLM_lpage">1101</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm301762v&amp;key=10.1126%2Fscience.1106148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm301762v&amp;key=15718470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=1098-1101&author=D.+D.+Sarbassovauthor=D.+A.+Guertinauthor=S.+M.+Aliauthor=D.+M.+Sabatini&title=Phosphorylation+and+regulation+of+Akt%2FPKB+by+the+rictor-mTOR+complex"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex</span></div><div class="casAuthors">Sarbassov, Dos D.; Guertin, David A.; Ali, Siraj M.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5712</span>),
    <span class="NLM_cas:pages">1098-1101</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Deregulation of Akt/protein kinase B (PKB) is implicated in the pathogenesis of cancer and diabetes.  Akt/PKB activation requires the phosphorylation of Thr308 in the activation loop by the phosphoinositide-dependent kinase 1 (PDK1) and Ser473 within the carboxyl-terminal hydrophobic motif by an unknown kinase.  We show that in Drosophila and human cells the target of rapamycin (TOR) kinase and its assocd. protein rictor are necessary for Ser473 phosphorylation and that a redn. in rictor or mammalian TOR (mTOR) expression inhibited an Akt/PKB effector.  The rictor-mTOR complex directly phosphorylated Akt/PKB on Ser473 in vitro and facilitated Thr308 phosphorylation by PDK1.  Rictor-mTOR may serve as a drug target in tumors that have lost the expression of PTEN, a tumor suppressor that opposes Akt/PKB activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfO1KyVE3glrVg90H21EOLACvtfcHk0lhJTKQslpHm9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D&md5=de758fd8128561e34301e67a42ae13a6</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.1106148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1106148%26sid%3Dliteratum%253Aachs%26aulast%3DSarbassov%26aufirst%3DD.%2BD.%26aulast%3DGuertin%26aufirst%3DD.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DPhosphorylation%2520and%2520regulation%2520of%2520Akt%252FPKB%2520by%2520the%2520rictor-mTOR%2520complex%26jtitle%3DScience%26date%3D2005%26volume%3D307%26spage%3D1098%26epage%3D1101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Pearce, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komander, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alessi, D. R.</span><span> </span><span class="NLM_article-title">The nuts and bolts of ABC protein kinases</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">â</span> <span class="NLM_lpage">22</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm301762v&amp;key=10.1038%2Fnrm2822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm301762v&amp;key=20027184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFymt7bI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=9-22&author=L.+R.+Pearceauthor=D.+Komanderauthor=D.+R.+Alessi&title=The+nuts+and+bolts+of+ABC+protein+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The nuts and bolts of AGC protein kinases</span></div><div class="casAuthors">Pearce, Laura R.; Komander, David; Alessi, Dario R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-22</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The AGC kinase subfamily of protein kinases contains 60 members, including protein kinase A (PKA), protein kinase G (PKG), and protein kinase C (PKC).  The family comprises some intensely examd. protein kinases (such as Akt, S6K, RSK, MSK, PDK1 and GRK) as well as many less well-studied enzymes (such as SGK, NDR, LATS, CRIK, SGK494, PRKX, PRKY, and MAST).  Research has shed new light onto the architecture and regulatory mechanisms of these kinases.  In addn., AGC kinases mediate diverse and important cellular functions, and their mutation and/or dysregulation contributes to the pathogenesis of many human diseases, including cancer and diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDlqo5AR3FN7Vg90H21EOLACvtfcHk0lhJTKQslpHm9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFymt7bI&md5=9752bf2068b10ab67b97e257f1f127d5</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrm2822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2822%26sid%3Dliteratum%253Aachs%26aulast%3DPearce%26aufirst%3DL.%2BR.%26aulast%3DKomander%26aufirst%3DD.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26atitle%3DThe%2520nuts%2520and%2520bolts%2520of%2520ABC%2520protein%2520kinases%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2010%26volume%3D11%26spage%3D9%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Mattmann, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoops, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span> </span><span class="NLM_article-title">Inhibition of Akt with small molecules and biologics: Historical perspective and current status of the patent landscape</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1309</span><span class="NLM_x">â</span> <span class="NLM_lpage">1338</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm301762v&amp;key=10.1517%2F13543776.2011.587959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm301762v&amp;key=21635152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVWnurfM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1309-1338&issue=9&author=M.+E.+Mattmannauthor=S.+L.+Stoopsauthor=C.+W.+Lindsley&title=Inhibition+of+Akt+with+small+molecules+and+biologics%3A+Historical+perspective+and+current+status+of+the+patent+landscape"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape</span></div><div class="casAuthors">Mattmann, Margrith E.; Stoops, Sydney L.; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1309-1338</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Akt plays a pivotal role in cell survival and proliferation through a no. of downstream effectors; unregulated activation of the PI3K/PTEN/Akt pathway is a prominent feature of many human cancers.  Akt is considered an attractive target for cancer therapy by the inhibition of Akt alone or in combination with std. cancer chemotherapeutics.  Both preclin. animal studies and clin. trials in humans have validated Akt as an important target of cancer drug discovery.Area covered: A historical perspective of Akt inhibitors, including PI analogs, ATP-competitive and allosteric Akt inhibitors, along with other inhibitory mechanisms are reviewed in this paper with a focus on issued patents, patent applications and a summary of clin. trial updates since the last review in 2007.Expert opinion: A vast diversity of inhibitors of Akt, both small mol. and biol., have been developed in the past 5 years, with over a dozen in various phases of clin. development, and several displaying efficacy in humans.  While it is not yet clear which mechanism of Akt inhibition will be optimal in humans, or which Akt isoforms to inhibit, or whether a small mol. or biol. agent will be best, data to all of these points will be available in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoByLgyoYrIULVg90H21EOLACvtfcHk0lhJTKQslpHm9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVWnurfM&md5=292eeb3e83a0a8aaa3fea0cb8df7d83d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1517%2F13543776.2011.587959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2011.587959%26sid%3Dliteratum%253Aachs%26aulast%3DMattmann%26aufirst%3DM.%2BE.%26aulast%3DStoops%26aufirst%3DS.%2BL.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DInhibition%2520of%2520Akt%2520with%2520small%2520molecules%2520and%2520biologics%253A%2520Historical%2520perspective%2520and%2520current%2520status%2520of%2520the%2520patent%2520landscape%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2011%26volume%3D21%26issue%3D9%26spage%3D1309%26epage%3D1338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Hirai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sootome, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakatsuru, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taguchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuijioka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majumder, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, B.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotani, H.</span><span> </span><span class="NLM_article-title">MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1956</span><span class="NLM_x">â</span> <span class="NLM_lpage">1967</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm301762v&amp;key=10.1158%2F1535-7163.MCT-09-1012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm301762v&amp;key=20571069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFertbnL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1956-1967&issue=7&author=H.+Hiraiauthor=H.+Sootomeauthor=Y.+Nakatsuruauthor=K.+Miyamaauthor=S.+Taguchiauthor=K.+Tsuijiokaauthor=Y.+Uenoauthor=H.+Hatchauthor=P.+K.+Majumderauthor=B.-S.+Panauthor=H.+Kotani&title=MK-2206%2C+an+allosteric+Akt+inhibitor%2C+enhances+antitumor+efficacy+by+standard+chemotherapeutic+agents+or+molecular+targeted+drugs+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo</span></div><div class="casAuthors">Hirai, Hiroshi; Sootome, Hiroshi; Nakatsuru, Yoko; Miyama, Katsuyoshi; Taguchi, Shunsuke; Tsujioka, Kyoko; Ueno, Yoko; Hatch, Harold; Majumder, Pradip K.; Pan, Bo-Sheng; Kotani, Hidehito</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1956-1967</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The serine/threonine kinase Akt lies at a crit. signaling node downstream of phosphatidylinositol-3-kinase and is important in promoting cell survival and inhibiting apoptosis.  An Akt inhibitor may be particularly useful for cancers in which increased Akt signaling is assocd. with reduced sensitivity to cytotoxic agents or receptor tyrosine kinase inhibitors.  We evaluated the effect of a novel allosteric Akt inhibitor, MK-2206, in combination with several anticancer agents.  In vitro, MK-2206 synergistically inhibited cell proliferation of human cancer cell lines in combination with mol. targeted agents such as erlotinib (an epidermal growth factor receptor inhibitor) or lapatinib (a dual epidermal growth factor receptor/human epidermal growth factor receptor 2 inhibitor).  Complementary inhibition of erlotinib-insensitive Akt phosphorylation by MK-2206 was one mechanism of synergism, and a synergistic effect was found even in erlotinib-insensitive cell lines.  MK-2206 also showed synergistic responses in combination with cytotoxic agents such as topoisomerase inhibitors (doxorubicin, camptothecin), antimetabolites (gemcitabine, 5-fluorouracil), anti-microtubule agents (docetaxel), and DNA cross-linkers (carboplatin) in lung NCI-H460 or ovarian A2780 tumor cells.  The synergy with docetaxel depended on the treatment sequence; a schedule of MK-2206 dosed before docetaxel was not effective.  MK-2206 suppressed the Akt phosphorylation that is induced by carboplatin and gemcitabine.  In vivo, MK-2206 in combination with these agents exerted significantly more potent tumor inhibitory activities than each agent in the monotherapy setting.  These findings suggest that Akt inhibition may augment the efficacy of existing cancer therapeutics; thus, MK-2206 is a promising agent to treat cancer patients who receive these cytotoxic and/or mol. targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPgnWgk1SeALVg90H21EOLACvtfcHk0ljku3Ypb-Pxyw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFertbnL&md5=f2d97ab64963cc82d97b35697e49b172</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-1012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-1012%26sid%3Dliteratum%253Aachs%26aulast%3DHirai%26aufirst%3DH.%26aulast%3DSootome%26aufirst%3DH.%26aulast%3DNakatsuru%26aufirst%3DY.%26aulast%3DMiyama%26aufirst%3DK.%26aulast%3DTaguchi%26aufirst%3DS.%26aulast%3DTsuijioka%26aufirst%3DK.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DHatch%26aufirst%3DH.%26aulast%3DMajumder%26aufirst%3DP.%2BK.%26aulast%3DPan%26aufirst%3DB.-S.%26aulast%3DKotani%26aufirst%3DH.%26atitle%3DMK-2206%252C%2520an%2520allosteric%2520Akt%2520inhibitor%252C%2520enhances%2520antitumor%2520efficacy%2520by%2520standard%2520chemotherapeutic%2520agents%2520or%2520molecular%2520targeted%2520drugs%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26issue%3D7%26spage%3D1956%26epage%3D1967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Blake, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bencsik, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlachter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banka, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woessner, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G. P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safina, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oeh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liederer, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N. J.</span><span> </span><span class="NLM_article-title">Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8110</span><span class="NLM_x">â</span> <span class="NLM_lpage">8127</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301024w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yrtr7K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8110-8127&author=J.+F.+Blakeauthor=R.+Xuauthor=J.+R.+Bencsikauthor=D.+Xiaoauthor=N.+C.+Kallanauthor=S.+Schlachterauthor=I.+S.+Mitchellauthor=K.+L.+Spencerauthor=A.+L.+Bankaauthor=E.+M.+Wallaceauthor=S.+L.+Gloorauthor=M.+Martinsonauthor=R.+D.+Woessnerauthor=G.+P.+A.+Vigersauthor=B.+J.+Brandhuberauthor=J.+Liangauthor=B.+S.+Safinaauthor=J.+Liauthor=B.+Zhangauthor=C.+Chabotauthor=S.+Doauthor=L.+Leeauthor=J.+Oehauthor=D.+Sampathauthor=B.+B.+Leeauthor=K.+Linauthor=B.+M.+Liedererauthor=N.+J.+Skelton&title=Discovery+and+preclinical+pharmacology+of+a+selective+ATP-competitive+Akt+inhibitor+%28GDC-0068%29+for+the+treatment+of+human+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors</span></div><div class="casAuthors">Blake, James F.; Xu, Rui; Bencsik, Josef R.; Xiao, Dengming; Kallan, Nicholas C.; Schlachter, Stephen; Mitchell, Ian S.; Spencer, Keith L.; Banka, Anna L.; Wallace, Eli M.; Gloor, Susan L.; Martinson, Matthew; Woessner, Richard D.; Vigers, Guy P. A.; Brandhuber, Barbara J.; Liang, Jun; Safina, Brian S.; Li, Jun; Zhang, Birong; Chabot, Christine; Do, Steven; Lee, Leslie; Oeh, Jason; Sampath, Deepak; Lee, Brian B.; Lin, Kui; Liederer, Bianca M.; Skelton, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8110-8127</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery and optimization of a series of 6,7-dihydro-5H-cyclopenta[d]pyrimidine compds. that are ATP-competitive, selective inhibitors of protein kinase B/Akt is reported.  The initial design and optimization was guided by the use of X-ray structures of inhibitors in complex with Akt1 and the closely related protein kinase A.  The resulting compds. demonstrate potent inhibition of all three Akt isoforms in biochem. assays and poor inhibition of other members of the cAMP-dependent protein kinase/protein kinase G/protein kinase C extended family and block the phosphorylation of multiple downstream targets of Akt in human cancer cell lines.  Biol. studies with one such compd., 28 (GDC-0068), demonstrate good oral exposure resulting in dose-dependent pharmacodynamic effects on downstream biomarkers and a robust antitumor response in xenograft models in which the phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin pathway is activated. 28 is currently being evaluated in human clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowH24ZkuGlNLVg90H21EOLACvtfcHk0lgFcTVgxL8YIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yrtr7K&md5=1fa690cda22a2548eb2795305e1c7253</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm301024w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301024w%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DBencsik%26aufirst%3DJ.%2BR.%26aulast%3DXiao%26aufirst%3DD.%26aulast%3DKallan%26aufirst%3DN.%2BC.%26aulast%3DSchlachter%26aufirst%3DS.%26aulast%3DMitchell%26aufirst%3DI.%2BS.%26aulast%3DSpencer%26aufirst%3DK.%2BL.%26aulast%3DBanka%26aufirst%3DA.%2BL.%26aulast%3DWallace%26aufirst%3DE.%2BM.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DWoessner%26aufirst%3DR.%2BD.%26aulast%3DVigers%26aufirst%3DG.%2BP.%2BA.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DSafina%26aufirst%3DB.%2BS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DChabot%26aufirst%3DC.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DB.%2BB.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520and%2520preclinical%2520pharmacology%2520of%2520a%2520selective%2520ATP-competitive%2520Akt%2520inhibitor%2520%2528GDC-0068%2529%2520for%2520the%2520treatment%2520of%2520human%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8110%26epage%3D8127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Pal, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reckamp, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figlin, R. A.</span><span> </span><span class="NLM_article-title">Akt inhibitors in clinical development for the treatment of cancer</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1355</span><span class="NLM_x">â</span> <span class="NLM_lpage">1366</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=1355-1366&issue=11&author=S.+K.+Palauthor=K.+Reckampauthor=H.+Yuauthor=R.+A.+Figlin&title=Akt+inhibitors+in+clinical+development+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPal%26aufirst%3DS.%2BK.%26aulast%3DReckamp%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DFiglin%26aufirst%3DR.%2BA.%26atitle%3DAkt%2520inhibitors%2520in%2520clinical%2520development%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2010%26volume%3D19%26issue%3D11%26spage%3D1355%26epage%3D1366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McHardy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldwell, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlands, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruddle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Haven Brandon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seavers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Discovery of 4-amino-1-(7<i>H</i>-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2239</span><span class="NLM_x">â</span> <span class="NLM_lpage">2249</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901788j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2239-2249&author=T.+McHardyauthor=J.+J.+Caldwellauthor=K.-M.+Cheungauthor=L.+J.+Hunterauthor=K.+Taylorauthor=M.+Rowlandsauthor=R.+Ruddleauthor=A.+Henleyauthor=A.+de+Haven+Brandonauthor=M.+Valentiauthor=T.+G.+Daviesauthor=L.+Fazalauthor=L.+Seaversauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=G.+W.+Aherneauthor=M.+D.+Garrettauthor=I.+Collins&title=Discovery+of+4-amino-1-%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29piperidine-4-carboxamides+as+selective%2C+orally+active+inhibitors+of+protein+kinase+B+%28Akt%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1021%2Fjm901788j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901788j%26sid%3Dliteratum%253Aachs%26aulast%3DMcHardy%26aufirst%3DT.%26aulast%3DCaldwell%26aufirst%3DJ.%2BJ.%26aulast%3DCheung%26aufirst%3DK.-M.%26aulast%3DHunter%26aufirst%3DL.%2BJ.%26aulast%3DTaylor%26aufirst%3DK.%26aulast%3DRowlands%26aufirst%3DM.%26aulast%3DRuddle%26aufirst%3DR.%26aulast%3DHenley%26aufirst%3DA.%26aulast%3Dde%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DT.%2BG.%26aulast%3DFazal%26aufirst%3DL.%26aulast%3DSeavers%26aufirst%3DL.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DDiscovery%2520of%25204-amino-1-%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529piperidine-4-carboxamides%2520as%2520selective%252C%2520orally%2520active%2520inhibitors%2520of%2520protein%2520kinase%2520B%2520%2528Akt%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2239%26epage%3D2249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Caldwell, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donald, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHardy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlands, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruddle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdonk, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Identification of 4-(4-aminopiperidin-1-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2147</span><span class="NLM_x">â</span> <span class="NLM_lpage">2157</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701437d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2147-2157&author=J.+J.+Caldwellauthor=T.+G.+Daviesauthor=A.+Donaldauthor=T.+McHardyauthor=M.+G.+Rowlandsauthor=G.+W.+Aherneauthor=L.+K.+Hunterauthor=K.+Taylorauthor=R.+Ruddleauthor=F.+I.+Raynaudauthor=M.+Verdonkauthor=P.+Workmanauthor=M.+D.+Garrettauthor=I.+Collins&title=Identification+of+4-%284-aminopiperidin-1-yl%29-7H-pyrrolo%5B2%2C3-d%5Dpyrimidines+as+selective+inhibitors+of+protein+kinase+B+through+fragment+elaboration"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1021%2Fjm701437d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701437d%26sid%3Dliteratum%253Aachs%26aulast%3DCaldwell%26aufirst%3DJ.%2BJ.%26aulast%3DDavies%26aufirst%3DT.%2BG.%26aulast%3DDonald%26aufirst%3DA.%26aulast%3DMcHardy%26aufirst%3DT.%26aulast%3DRowlands%26aufirst%3DM.%2BG.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DHunter%26aufirst%3DL.%2BK.%26aulast%3DTaylor%26aufirst%3DK.%26aulast%3DRuddle%26aufirst%3DR.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DVerdonk%26aufirst%3DM.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DIdentification%2520of%25204-%25284-aminopiperidin-1-yl%2529-7H-pyrrolo%255B2%252C3-d%255Dpyrimidines%2520as%2520selective%2520inhibitors%2520of%2520protein%2520kinase%2520B%2520through%2520fragment%2520elaboration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2147%26epage%3D2157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Saxty, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodhead, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdonk, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyatt, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downham, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, R. A.</span><span> </span><span class="NLM_article-title">Identification of inhibitors of protein kinase B using fragment-based lead discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2293</span><span class="NLM_x">â</span> <span class="NLM_lpage">2296</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm070091b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksVKjur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2293-2296&author=G.+Saxtyauthor=S.+J.+Woodheadauthor=V.+Berdiniauthor=T.+G.+Daviesauthor=M.+L.+Verdonkauthor=P.+G.+Wyattauthor=R.+G.+Boyleauthor=D.+Barfordauthor=R.+Downhamauthor=M.+D.+Garrettauthor=R.+A.+Carr&title=Identification+of+inhibitors+of+protein+kinase+B+using+fragment-based+lead+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Inhibitors of Protein Kinase B Using Fragment-Based Lead Discovery</span></div><div class="casAuthors">Saxty, Gordon; Woodhead, Steven J.; Berdini, Valerio; Davies, Thomas G.; Verdonk, Marcel L.; Wyatt, Paul G.; Boyle, Robert G.; Barford, David; Downham, Robert; Garrett, Michelle D.; Carr, Robin A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2293-2296</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Using fragment-based screening techniques, 5-methyl-4-phenyl-1H-pyrazole (IC50 80 Î¼M) was identified as a novel, low mol. wt. inhibitor of protein kinase B (PKB).  Herein we describe the rapid elaboration of highly potent and ligand efficient analogs using a fragment growing approach.  Iterative structure-based design was supported by protein-ligand structure detns. using a PKA-PKB "chimera" and a final protein-ligand structure of a lead compd. in PKBÎ² itself.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlCYaIT8Xn87Vg90H21EOLACvtfcHk0lgT2EwFn1rjYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksVKjur8%253D&md5=2a09e4bbaca1493be8e215927e7e72e1</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1021%2Fjm070091b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070091b%26sid%3Dliteratum%253Aachs%26aulast%3DSaxty%26aufirst%3DG.%26aulast%3DWoodhead%26aufirst%3DS.%2BJ.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DDavies%26aufirst%3DT.%2BG.%26aulast%3DVerdonk%26aufirst%3DM.%2BL.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DBoyle%26aufirst%3DR.%2BG.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DDownham%26aufirst%3DR.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DCarr%26aufirst%3DR.%2BA.%26atitle%3DIdentification%2520of%2520inhibitors%2520of%2520protein%2520kinase%2520B%2520using%2520fragment-based%2520lead%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2293%26epage%3D2296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Donald, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHardy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlands, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, L. J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2289</span><span class="NLM_x">â</span> <span class="NLM_lpage">2292</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0700924" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2289-2292&author=A.+Donaldauthor=T.+McHardyauthor=M.+G.+Rowlandsauthor=L.+J.+K.+Hunterauthor=T.+G.+Daviesauthor=V.+Berdiniauthor=R.+G.+Boyleauthor=G.+W.+Aherneauthor=M.+D.+Garrettauthor=I.+Collins&title=Rapid+evolution+of+6-phenylpurine+inhibitors+of+protein+kinase+B+through+structure-based+design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1021%2Fjm0700924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0700924%26sid%3Dliteratum%253Aachs%26aulast%3DDonald%26aufirst%3DA.%26aulast%3DMcHardy%26aufirst%3DT.%26aulast%3DRowlands%26aufirst%3DM.%2BG.%26aulast%3DHunter%26aufirst%3DL.%2BJ.%2BK.%26aulast%3DDavies%26aufirst%3DT.%2BG.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBoyle%26aufirst%3DR.%2BG.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DRapid%2520evolution%2520of%25206-phenylpurine%2520inhibitors%2520of%2520protein%2520kinase%2520B%2520through%2520structure-based%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2289%26epage%3D2292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ashton, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Jean, D. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poon, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lofgren, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fotsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hungate, R.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel amide AKT1 inhibitors with selectivity over CDK2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">5191</span><span class="NLM_x">â</span> <span class="NLM_lpage">5196</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=5191-5196&author=K.+S.+Ashtonauthor=D.+J.+St.+Jeanauthor=S.+F.+Poonauthor=M.+R.+Leeauthor=J.+G.+Allenauthor=S.+Zhangauthor=J.+A.+Lofgrenauthor=X.+Zhangauthor=C.+Fotschauthor=R.+Hungate&title=Design+and+synthesis+of+novel+amide+AKT1+inhibitors+with+selectivity+over+CDK2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAshton%26aufirst%3DK.%2BS.%26aulast%3DSt.%2BJean%26aufirst%3DD.%2BJ.%26aulast%3DPoon%26aufirst%3DS.%2BF.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DAllen%26aufirst%3DJ.%2BG.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLofgren%26aufirst%3DJ.%2BA.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DHungate%26aufirst%3DR.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520amide%2520AKT1%2520inhibitors%2520with%2520selectivity%2520over%2520CDK2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D5191%26epage%3D5196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bencsik, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woessner, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dizon, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G. P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L. J.</span><span> </span><span class="NLM_article-title">Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">7037</span><span class="NLM_x">â</span> <span class="NLM_lpage">7041</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Fjm301762v&amp;key=10.1016%2Fj.bmcl.2010.09.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Fjm301762v&amp;key=20971641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2gtLnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7037-7041&author=J.+R.+Bencsikauthor=D.+Xiaoauthor=J.+F.+Blakeauthor=N.+C.+Kallanauthor=I.+S.+Mitchellauthor=K.+L.+Spencerauthor=R.+Xuauthor=S.+L.+Gloorauthor=M.+Martinsonauthor=T.+Risomauthor=R.+D.+Woessnerauthor=F.+Dizonauthor=W.-I.+Wuauthor=G.+P.+A.+Vigersauthor=B.+J.+Brandhuberauthor=N.+J.+Skeltonauthor=W.+W.+Priorauthor=L.+J.+Murray&title=Discovery+of+dihydrothieno-+and+dihydrofuropyrimidines+as+potent+pan+Akt+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors</span></div><div class="casAuthors">Bencsik, Josef R.; Xiao, Dengming; Blake, James F.; Kallan, Nicholas C.; Mitchell, Ian S.; Spencer, Keith L.; Xu, Rui; Gloor, Susan L.; Martinson, Matthew; Risom, Tyler; Woessner, Richard D.; Dizon, Faith; Wu, Wen-I.; Vigers, Guy P. A.; Brandhuber, Barbara J.; Skelton, Nicholas J.; Prior, Wei Wei; Murray, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7037-7041</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis of a novel series of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors is reported.  Inhibitors displaying increased PKA and general kinase selectivity with improved tolerability compared to the progenitor pyrrolopyrimidine were developed using previous SAR and anal. of the amino acid sequences in the binding site.  Dihydrothieno compd. I was advanced into a PC3-NCI prostate mouse tumor model in which it demonstrated a dose-dependent redn. in tumor growth and stasis when dosed orally daily at 200 mg/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8-bp6rwVWNrVg90H21EOLACvtfcHk0ljRQph1UC997A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2gtLnJ&md5=d6aed3020c07ed85e83379c40d53394e</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.09.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.09.112%26sid%3Dliteratum%253Aachs%26aulast%3DBencsik%26aufirst%3DJ.%2BR.%26aulast%3DXiao%26aufirst%3DD.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DKallan%26aufirst%3DN.%2BC.%26aulast%3DMitchell%26aufirst%3DI.%2BS.%26aulast%3DSpencer%26aufirst%3DK.%2BL.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DRisom%26aufirst%3DT.%26aulast%3DWoessner%26aufirst%3DR.%2BD.%26aulast%3DDizon%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DW.-I.%26aulast%3DVigers%26aufirst%3DG.%2BP.%2BA.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DMurray%26aufirst%3DL.%2BJ.%26atitle%3DDiscovery%2520of%2520dihydrothieno-%2520and%2520dihydrofuropyrimidines%2520as%2520potent%2520pan%2520Akt%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D7037%26epage%3D7041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Freeman-Cook, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Autry, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzillo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacci-Tobin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernardo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakubczak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knauth, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luzzio, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marx, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandit, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajamohan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wythes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J.</span><span> </span><span class="NLM_article-title">Design of selective, ATP-competitive inhibitors of Akt</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4615</span><span class="NLM_x">â</span> <span class="NLM_lpage">4622</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1003842" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmt12ku78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4615-4622&author=K.+D.+Freeman-Cookauthor=C.+Autryauthor=G.+Borzilloauthor=D.+Gordonauthor=E.+Barbacci-Tobinauthor=V.+Bernardoauthor=D.+Briereauthor=T.+Clarkauthor=M.+Corbettauthor=J.+Jakubczakauthor=S.+Kakarauthor=E.+Knauthauthor=B.+Lippaauthor=M.+J.+Luzzioauthor=M.+Mansourauthor=G.+Martinelliauthor=M.+Marxauthor=K.+Nelsonauthor=J.+Panditauthor=F.+Rajamohanauthor=S.+Robinsonauthor=C.+Subramanyamauthor=L.+Weiauthor=M.+Wythesauthor=J.+Morris&title=Design+of+selective%2C+ATP-competitive+inhibitors+of+Akt"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Selective, ATP-Competitive Inhibitors of Akt</span></div><div class="casAuthors">Freeman-Cook, Kevin D.; Autry, Christopher; Borzillo, Gary; Gordon, Deborah; Barbacci-Tobin, Elsa; Bernardo, Vincent; Briere, David; Clark, Tracey; Corbett, Matthew; Jakubczak, John; Kakar, Shefali; Knauth, Elizabeth; Lippa, Blaise; Luzzio, Michael J.; Mansour, Mahmoud; Martinelli, Gary; Marx, Matthew; Nelson, Kendra; Pandit, Jayvardhan; Rajamohan, Francis; Robinson, Shaughnessy; Subramanyam, Chakrapani; Wei, Liuqing; Wythes, Martin; Morris, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4615-4622</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This paper describes the design and synthesis of novel, ATP-competitive Akt inhibitors from an elaborated 3-aminopyrrolidine scaffold.  Key findings include the discovery of an initial lead that was modestly selective and medicinal chem. optimization of that lead to provide more selective analogs.  Anal. of the data suggested that highly lipophilic analogs would likely suffer from poor overall properties.  Central to the discussion is the concept of optimization of lipophilic efficiency and the ability to balance overall druglike properties with the careful control of lipophilicity in the lead series.  Discovery of the nonracemic amide series and subsequent modification produced an advanced analog that performed well in advancedaminopyrrolidine substituted pyrrolopyrimidine preclin. assays, including xenograft tumor growth inhibition studies, and this analog was nominated for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqLbzBekJF5LVg90H21EOLACvtfcHk0liLU0z3G9cASg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmt12ku78%253D&md5=e45372a44f93072f7152a0a2600d7be4</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1021%2Fjm1003842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1003842%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman-Cook%26aufirst%3DK.%2BD.%26aulast%3DAutry%26aufirst%3DC.%26aulast%3DBorzillo%26aufirst%3DG.%26aulast%3DGordon%26aufirst%3DD.%26aulast%3DBarbacci-Tobin%26aufirst%3DE.%26aulast%3DBernardo%26aufirst%3DV.%26aulast%3DBriere%26aufirst%3DD.%26aulast%3DClark%26aufirst%3DT.%26aulast%3DCorbett%26aufirst%3DM.%26aulast%3DJakubczak%26aufirst%3DJ.%26aulast%3DKakar%26aufirst%3DS.%26aulast%3DKnauth%26aufirst%3DE.%26aulast%3DLippa%26aufirst%3DB.%26aulast%3DLuzzio%26aufirst%3DM.%2BJ.%26aulast%3DMansour%26aufirst%3DM.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DMarx%26aufirst%3DM.%26aulast%3DNelson%26aufirst%3DK.%26aulast%3DPandit%26aufirst%3DJ.%26aulast%3DRajamohan%26aufirst%3DF.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DWythes%26aufirst%3DM.%26aulast%3DMorris%26aufirst%3DJ.%26atitle%3DDesign%2520of%2520selective%252C%2520ATP-competitive%2520inhibitors%2520of%2520Akt%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4615%26epage%3D4622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Takahara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoneyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, K.</span><span> </span><span class="NLM_article-title">Cardiovascular effects of Y-27632, a selective Rho-associated kinase inhibitor, assessed in the halothane-anesthetized canine model</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">460</span><span class="NLM_x">, </span> <span class="NLM_fpage">51</span><span class="NLM_x">â</span> <span class="NLM_lpage">57</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm301762v&amp;key=10.1016%2FS0014-2999%2802%2902929-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm301762v&amp;key=12535859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivVOltg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=460&publication_year=2003&pages=51-57&author=A.+Takaharaauthor=A.+Sugiyamaauthor=Y.+Satohauthor=M.+Yoneyamaauthor=K.+Hashimoto&title=Cardiovascular+effects+of+Y-27632%2C+a+selective+Rho-associated+kinase+inhibitor%2C+assessed+in+the+halothane-anesthetized+canine+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular effects of Y-27632, a selective Rho-associated kinase inhibitor, assessed in the halothane-anesthetized canine model</span></div><div class="casAuthors">Takahara, Akira; Sugiyama, Atsushi; Satoh, Yoshioki; Yoneyama, Masahiko; Hashimoto, Keitaro</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">460</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-57</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Y-27632, (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl) cyclohexanecarboxamide dihydrochloride monohydrate, is a selective Rho-assocd. kinase inhibitor, which has been suggested to possess multiple clin. applications based on the in vitro observations.  Since information regarding in vivo cardiovascular effects of Y-27632 is still limited, we assessed them using the halothane-anesthetized, closed-chest canine model.  Administration of Y-27632 in a dose of 0.01 mg/kg, i.v. significantly decreased total peripheral vascular resistance together with an increase of cardiac output without affecting other cardiovascular parameters.  Moreover, addnl. administration of Y-27632 in a dose of 0.1 mg/kg, i.v. significantly decreased blood pressure and left ventricular end-diastolic pressure, increased the heart rate and cardiac contractility, enhanced atrioventricular conduction and shortened the repolarization process as well as the effective refractory period.  These results indicate that Y-27632 exerts a potent arterio-venodilator action with cardiostimulatory effects possibly through the sympathetic reflex in the in vivo canine model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlVSFBxYE9HbVg90H21EOLACvtfcHk0liLU0z3G9cASg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivVOltg%253D%253D&md5=15de8377d2dc34af00f331fee8429b35</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2802%2902929-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252802%252902929-1%26sid%3Dliteratum%253Aachs%26aulast%3DTakahara%26aufirst%3DA.%26aulast%3DSugiyama%26aufirst%3DA.%26aulast%3DSatoh%26aufirst%3DY.%26aulast%3DYoneyama%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DK.%26atitle%3DCardiovascular%2520effects%2520of%2520Y-27632%252C%2520a%2520selective%2520Rho-associated%2520kinase%2520inhibitor%252C%2520assessed%2520in%2520the%2520halothane-anesthetized%2520canine%2520model%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2003%26volume%3D460%26spage%3D51%26epage%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Davies, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenwood, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crafter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, D.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maynard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricketts, S.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosulich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chresta, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yates, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pass, M.</span><span> </span><span class="NLM_article-title">Preclinical pharmacology of AZD5363, an inhibitor of AKT: Pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">873</span><span class="NLM_x">â</span> <span class="NLM_lpage">887</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm301762v&amp;key=10.1158%2F1535-7163.MCT-11-0824-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm301762v&amp;key=22294718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BC38Xltl2ntbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=873-887&author=B.+R.+Daviesauthor=H.+Greenwoodauthor=P.+Dudleyauthor=C.+Crafterauthor=D.-H.+Yuauthor=J.+Zhangauthor=J.+Liauthor=B.+Gaoauthor=Q.+Jiauthor=J.+Maynardauthor=S.-A.+Rickettsauthor=D.+Crossauthor=S.+Cosulichauthor=C.+C.+Chrestaauthor=K.+Pageauthor=J.+Yatesauthor=C.+Laneauthor=R.+Watsonauthor=R.+Lukeauthor=D.+Ogilvieauthor=M.+Pass&title=Preclinical+pharmacology+of+AZD5363%2C+an+inhibitor+of+AKT%3A+Pharmacodynamics%2C+antitumor+activity%2C+and+correlation+of+monotherapy+activity+with+genetic+background"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background</span></div><div class="casAuthors">Davies, Barry R.; Greenwood, Hannah; Dudley, Phillippa; Crafter, Claire; Yu, De-Hua; Zhang, Jingchuan; Li, Jing; Gao, Beirong; Ji, Qunsheng; Maynard, Juliana; Ricketts, Sally-Ann; Cross, Darren; Cosulich, Sabina; Chresta, Christine C.; Page, Ken; Yates, James; Lane, Clare; Watson, Rebecca; Luke, Richard; Ogilvie, Donald; Pass, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">873-887</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">AKT is a key node in the most frequently deregulated signaling network in human cancer.  AZD5363, a novel pyrrolopyrimidine-derived compd., inhibited all AKT isoforms with a potency of 10 nmol/L or less and inhibited phosphorylation of AKT substrates in cells with a potency of approx. 0.3 to 0.8 Î¼mol/L.  AZD5363 monotherapy inhibited the proliferation of 41 of 182 solid and hematol. tumor cell lines with a potency of 3 Î¼mol/L or less.  Cell lines derived from breast cancers showed the highest frequency of sensitivity.  There was a significant relationship between the presence of PIK3CA and/or PTEN mutations and sensitivity to AZD5363 and between RAS mutations and resistance.  Oral dosing of AZD5363 to nude mice caused dose- and time-dependent redn. of PRAS40, GSK3Î², and S6 phosphorylation in BT474c xenografts (PRAS40 phosphorylation EC50 â¼ 0.1 Î¼mol/L total plasma exposure), reversible increases in blood glucose concns., and dose-dependent decreases in 2[18F]fluoro-2-deoxy-D-glucose (18F-FDG) uptake in U87-MG xenografts.  Chronic oral dosing of AZD5363 caused dose-dependent growth inhibition of xenografts derived from various tumor types, including HER2+ breast cancer models that are resistant to trastuzumab.  AZD5363 also significantly enhanced the antitumor activity of docetaxel, lapatinib, and trastuzumab in breast cancer xenografts.  It is concluded that AZD5363 is a potent inhibitor of AKT with pharmacodynamic activity in vivo, has potential to treat a range of solid and hematol. tumors as monotherapy or a combinatorial agent, and has potential for personalized medicine based on the genetic status of PIK3CA, PTEN, and RAS.  AZD5363 is currently in phase I clin. trials.  Mol Cancer Ther; 11(4); 873-87.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjG0wV4TyO57Vg90H21EOLACvtfcHk0lgHz-5O9Yzn2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xltl2ntbs%253D&md5=6ddcc67247fd07fd086baa03077983bd</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0824-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0824-T%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DGreenwood%26aufirst%3DH.%26aulast%3DDudley%26aufirst%3DP.%26aulast%3DCrafter%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DD.-H.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DB.%26aulast%3DJi%26aufirst%3DQ.%26aulast%3DMaynard%26aufirst%3DJ.%26aulast%3DRicketts%26aufirst%3DS.-A.%26aulast%3DCross%26aufirst%3DD.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DChresta%26aufirst%3DC.%2BC.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DYates%26aufirst%3DJ.%26aulast%3DLane%26aufirst%3DC.%26aulast%3DWatson%26aufirst%3DR.%26aulast%3DLuke%26aufirst%3DR.%26aulast%3DOgilvie%26aufirst%3DD.%26aulast%3DPass%26aufirst%3DM.%26atitle%3DPreclinical%2520pharmacology%2520of%2520AZD5363%252C%2520an%2520inhibitor%2520of%2520AKT%253A%2520Pharmacodynamics%252C%2520antitumor%2520activity%252C%2520and%2520correlation%2520of%2520monotherapy%2520activity%2520with%2520genetic%2520background%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D873%26epage%3D887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10a','cit10b'],'ref11':['cit11a','cit11b'],'ref12':['cit12a','cit12b','cit12c'],'ref13':['cit13'],'ref14':['cit14']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 73 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Alex K. Mugengana, Nicole A. Vita, Autumn Brown Gandt, Kevin Moran, George Agyapong, Lalit K. Sharma, Elizabeth C. Griffith, Jiuyu Liu, Lei Yang, Ekaterina Gavrish, Kirk E. Hevener, Michael D. LaFleur, <span class="NLM_string-name hlFld-ContribAuthor">Richard E. Lee</span>. </span><span class="cited-content_cbyCitation_article-title">The Discovery and Development of Thienopyrimidines as Inhibitors of Helicobacter pylori That Act through Inhibition of the Respiratory Complex I. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2021,</strong> <em>7 </em>
                                    (5)
                                     , 1044-1058. <a href="https://doi.org/10.1021/acsinfecdis.0c00300" title="DOI URL">https://doi.org/10.1021/acsinfecdis.0c00300</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.0c00300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.0c00300%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DThe%252BDiscovery%252Band%252BDevelopment%252Bof%252BThienopyrimidines%252Bas%252BInhibitors%252Bof%252BHelicobacter%252Bpylori%252BThat%252BAct%252Bthrough%252BInhibition%252Bof%252Bthe%252BRespiratory%252BComplex%252BI%26aulast%3DMugengana%26aufirst%3DAlex%2BK.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D11052020%26date%3D20012021%26volume%3D7%26issue%3D5%26spage%3D1044%26epage%3D1058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Svenja Wiechmann, Benjamin Ruprecht, Theresa Siekmann, Runsheng Zheng, Martin Frejno, Elena Kunold, Thomas Bajaj, Daniel P. Zolg, Stephan A. Sieber, Nils C. Gassen, <span class="NLM_string-name hlFld-ContribAuthor">Bernhard Kuster</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical Phosphoproteomics Sheds New Light on the Targets and Modes of Action of AKT Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2021,</strong> <em>16 </em>
                                    (4)
                                     , 631-641. <a href="https://doi.org/10.1021/acschembio.0c00872" title="DOI URL">https://doi.org/10.1021/acschembio.0c00872</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.0c00872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.0c00872%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DChemical%252BPhosphoproteomics%252BSheds%252BNew%252BLight%252Bon%252Bthe%252BTargets%252Band%252BModes%252Bof%252BAction%252Bof%252BAKT%252BInhibitors%26aulast%3DWiechmann%26aufirst%3DSvenja%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D09112020%26date%3D12032021%26date%3D23032021%26volume%3D16%26issue%3D4%26spage%3D631%26epage%3D641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Amit Mahindra, Omar Janha, Kopano Mapesa, Ana Sanchez-Azqueta, Mahmood M. Alam, Alfred Amambua-Ngwa, Davis C. Nwakanma, Andrew B. Tobin, <span class="NLM_string-name hlFld-ContribAuthor">Andrew G. Jamieson</span>. </span><span class="cited-content_cbyCitation_article-title">Development of Potent PfCLK3 Inhibitors Based on TCMDC-135051 as a New Class of Antimalarials. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (17)
                                     , 9300-9315. <a href="https://doi.org/10.1021/acs.jmedchem.0c00451" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00451</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00451%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252BPotent%252BPfCLK3%252BInhibitors%252BBased%252Bon%252BTCMDC-135051%252Bas%252Ba%252BNew%252BClass%252Bof%252BAntimalarials%26aulast%3DMahindra%26aufirst%3DAmit%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17032020%26date%3D11082020%26date%3D28072020%26volume%3D63%26issue%3D17%26spage%3D9300%26epage%3D9315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaowu Dong, Wenhu Zhan, Mengting Zhao, Jinxin Che, Xiaoyang Dai, Yizhe Wu, Lei Xu, Yubo Zhou, Yanmei Zhao, Tian Tian, Gang Cheng, Zegao Jin, Jia Li, Yanfei Shao, Qiaojun He, Bo Yang, Qinjie Weng, <span class="NLM_string-name hlFld-ContribAuthor">Yongzhou Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (15)
                                     , 7264-7288. <a href="https://doi.org/10.1021/acs.jmedchem.9b00891" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00891</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00891%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B3%25252C4%25252C6-Trisubstituted%252BPiperidine%252BDerivatives%252Bas%252BOrally%252BActive%25252C%252BLow%252BhERG%252BBlocking%252BAkt%252BInhibitors%252Bvia%252BConformational%252BRestriction%252Band%252BStructure-Based%252BDesign%26aulast%3DDong%26aufirst%3DXiaowu%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D03062019%26date%3D24072019%26date%3D12072019%26volume%3D62%26issue%3D15%26spage%3D7264%26epage%3D7288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark A. T.  Blaskovich</span>  . </span><span class="cited-content_cbyCitation_article-title">Unusual Amino Acids in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (24)
                                     , 10807-10836. <a href="https://doi.org/10.1021/acs.jmedchem.6b00319" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00319</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00319%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DUnusual%252BAmino%252BAcids%252Bin%252BMedicinal%252BChemistry%26aulast%3DBlaskovich%26aufirst%3DMark%2BA.%2BT.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D02032016%26date%3D30092016%26date%3D22122016%26date%3D02092016%26volume%3D59%26issue%3D24%26spage%3D10807%26epage%3D10836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">GyÃ¶rgy M.  KeserÅ±</span>, <span class="hlFld-ContribAuthor ">Daniel A.  Erlanson</span>, <span class="hlFld-ContribAuthor ">GyÃ¶rgy G.  Ferenczy</span>, <span class="hlFld-ContribAuthor ">Michael M.  Hann</span>, <span class="hlFld-ContribAuthor ">Christopher W.  Murray</span>, and <span class="hlFld-ContribAuthor ">Stephen D.  Pickett</span>  . </span><span class="cited-content_cbyCitation_article-title">Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (18)
                                     , 8189-8206. <a href="https://doi.org/10.1021/acs.jmedchem.6b00197" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00197</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00197%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252BPrinciples%252Bfor%252BFragment%252BLibraries%25253A%252BMaximizing%252Bthe%252BValue%252Bof%252BLearnings%252Bfrom%252BPharma%252BFragment-Based%252BDrug%252BDiscovery%252B%252528FBDD%252529%252BPrograms%252Bfor%252BUse%252Bin%252BAcademia%26aulast%3DKeser%25C5%25B1%26aufirst%3DGy%25C3%25B6rgy%2BM.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D05022016%26date%3D16052016%26date%3D22092016%26date%3D28042016%26volume%3D59%26issue%3D18%26spage%3D8189%26epage%3D8206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abedawn I.  Khalaf</span>, <span class="hlFld-ContribAuthor ">Judith K.  Huggan</span>, <span class="hlFld-ContribAuthor ">Colin J.  Suckling</span>, <span class="hlFld-ContribAuthor ">Colin L.  Gibson</span>, <span class="hlFld-ContribAuthor ">Kirsten  Stewart</span>, <span class="hlFld-ContribAuthor ">Federica  Giordani</span>, <span class="hlFld-ContribAuthor ">Michael P.  Barrett</span>, <span class="hlFld-ContribAuthor ">Pui Ee  Wong</span>, <span class="hlFld-ContribAuthor ">Keri L.  Barrack</span>, and <span class="hlFld-ContribAuthor ">William N.  Hunter</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure-Based Design and Synthesis of Antiparasitic Pyrrolopyrimidines Targeting Pteridine Reductase 1. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (15)
                                     , 6479-6494. <a href="https://doi.org/10.1021/jm500483b" title="DOI URL">https://doi.org/10.1021/jm500483b</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm500483b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm500483b%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BDesign%252Band%252BSynthesis%252Bof%252BAntiparasitic%252BPyrrolopyrimidines%252BTargeting%252BPteridine%252BReductase%252B1%26aulast%3DKhalaf%26aufirst%3DAbedawn%2BI.%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D27032014%26date%3D29072014%26date%3D14082014%26date%3D09072014%26volume%3D57%26issue%3D15%26spage%3D6479%26epage%3D6494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesco  Ortuso</span>, <span class="hlFld-ContribAuthor ">Rosario  Amato</span>, <span class="hlFld-ContribAuthor ">Anna  Artese</span>, <span class="hlFld-ContribAuthor ">Lucia  Dâantona</span>, <span class="hlFld-ContribAuthor ">GiosuÃ¨  Costa</span>, <span class="hlFld-ContribAuthor ">Cristina  Talarico</span>, <span class="hlFld-ContribAuthor ">Francesco  Gigliotti</span>, <span class="hlFld-ContribAuthor ">Cataldo  Bianco</span>, <span class="hlFld-ContribAuthor ">Francesco  Trapasso</span>, <span class="hlFld-ContribAuthor ">Silvia  Schenone</span>, <span class="hlFld-ContribAuthor ">Francesca  Musumeci</span>, <span class="hlFld-ContribAuthor ">Lorenzo  Botta</span>, <span class="hlFld-ContribAuthor ">Nicola  Perrotti</span>, and <span class="hlFld-ContribAuthor ">Stefano  Alcaro</span>  . </span><span class="cited-content_cbyCitation_article-title">In Silico Identification and Biological Evaluation of Novel Selective Serum/Glucocorticoid-Inducible Kinase 1 Inhibitors Based on the Pyrazolo-Pyrimidine Scaffold. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2014,</strong> <em>54 </em>
                                    (7)
                                     , 1828-1832. <a href="https://doi.org/10.1021/ci500235f" title="DOI URL">https://doi.org/10.1021/ci500235f</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci500235f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci500235f%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DIn%252BSilico%252BIdentification%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252BSelective%252BSerum%25252FGlucocorticoid-Inducible%252BKinase%252B1%252BInhibitors%252BBased%252Bon%252Bthe%252BPyrazolo-Pyrimidine%252BScaffold%26aulast%3DOrtuso%26aufirst%3DFrancesco%26date%3D2014%26date%3D2014%26date%3D05062014%26date%3D13062014%26date%3D28072014%26date%3D04062014%26volume%3D54%26issue%3D7%26spage%3D1828%26epage%3D1832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xue  Yang</span>, <span class="hlFld-ContribAuthor ">Ying  Feng</span>, <span class="hlFld-ContribAuthor ">Yao  Liu</span>, <span class="hlFld-ContribAuthor ">Xieqiong  Ye</span>, <span class="hlFld-ContribAuthor ">Xiaomin  Ji</span>, <span class="hlFld-ContribAuthor ">Le  Sun</span>, <span class="hlFld-ContribAuthor ">Fangyuan  Gao</span>, <span class="hlFld-ContribAuthor ">Qun  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuxin  Li</span>, <span class="hlFld-ContribAuthor ">Bingbing  Zhu</span>, <span class="hlFld-ContribAuthor ">XianBo  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway. </span><span class="cited-content_cbyCitation_journal-name">Phytomedicine</span><span> <strong>2021,</strong> <em>87 </em>, 153575. <a href="https://doi.org/10.1016/j.phymed.2021.153575" title="DOI URL">https://doi.org/10.1016/j.phymed.2021.153575</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phymed.2021.153575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phymed.2021.153575%26sid%3Dliteratum%253Aachs%26jtitle%3DPhytomedicine%26atitle%3DFuzheng%252BJiedu%252BXiaoji%252Bformulation%252Binhibits%252Bhepatocellular%252Bcarcinoma%252Bprogression%252Bin%252Bpatients%252Bby%252Btargeting%252Bthe%252BAKT%25252FCyclinD1%25252Fp21%25252Fp27%252Bpathway%26aulast%3DYang%26aufirst%3DXue%26date%3D2021%26volume%3D87%26spage%3D153575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Iksen</span>, <span class="hlFld-ContribAuthor ">Sutthaorn  Pothongsrisit</span>, <span class="hlFld-ContribAuthor ">Varisa  Pongrakhananon</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (13)
                                     , 4100. <a href="https://doi.org/10.3390/molecules26134100" title="DOI URL">https://doi.org/10.3390/molecules26134100</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26134100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26134100%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DTargeting%252Bthe%252BPI3K%25252FAKT%25252FmTOR%252BSignaling%252BPathway%252Bin%252BLung%252BCancer%25253A%252BAn%252BUpdate%252BRegarding%252BPotential%252BDrugs%252Band%252BNatural%252BProducts%26aulast%3DIksen%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D13%26spage%3D4100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ivan G.  Logvinenko</span>, <span class="hlFld-ContribAuthor ">Ivan S.  Kondratov</span>, <span class="hlFld-ContribAuthor ">Alexey V.  Dobrydnev</span>, <span class="hlFld-ContribAuthor ">Andriy V.  Kozytskiy</span>, <span class="hlFld-ContribAuthor ">Oleksandr O.  Grygorenko</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and reactions of Ï-CF3O-substituted aliphatic sulfonyl chlorides. </span><span class="cited-content_cbyCitation_journal-name">Journal of Fluorine Chemistry</span><span> <strong>2021,</strong> <em>246 </em>, 109799. <a href="https://doi.org/10.1016/j.jfluchem.2021.109799" title="DOI URL">https://doi.org/10.1016/j.jfluchem.2021.109799</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jfluchem.2021.109799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jfluchem.2021.109799%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Fluorine%2520Chemistry%26atitle%3DSynthesis%252Band%252Breactions%252Bof%252B%2525CF%252589-CF3O-substituted%252Baliphatic%252Bsulfonyl%252Bchlorides%26aulast%3DLogvinenko%26aufirst%3DIvan%2BG.%26date%3D2021%26volume%3D246%26spage%3D109799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Akash Anand  Bansod</span>, <span class="hlFld-ContribAuthor ">Gnanam  Ramasamy</span>, <span class="hlFld-ContribAuthor ">Bharathi  Nathan</span>, <span class="hlFld-ContribAuthor ">Rajamani  Kandhasamy</span>, <span class="hlFld-ContribAuthor ">Meenakshisundaram  Palaniappan</span>, <span class="hlFld-ContribAuthor ">Santhanakrishnan  Vichangal Pridiuldi</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the endogenous potential of Hemidesmus indicus against breast cancer using in silico studies and quantification of 2-hydroxy-4-methoxy benzaldehyde through RP-HPLC. </span><span class="cited-content_cbyCitation_journal-name">3 Biotech</span><span> <strong>2021,</strong> <em>11 </em>
                                    (5)
                                     <a href="https://doi.org/10.1007/s13205-021-02768-x" title="DOI URL">https://doi.org/10.1007/s13205-021-02768-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13205-021-02768-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13205-021-02768-x%26sid%3Dliteratum%253Aachs%26jtitle%3D3%2520Biotech%26atitle%3DExploring%252Bthe%252Bendogenous%252Bpotential%252Bof%252BHemidesmus%252Bindicus%252Bagainst%252Bbreast%252Bcancer%252Busing%252Bin%252Bsilico%252Bstudies%252Band%252Bquantification%252Bof%252B2-hydroxy-4-methoxy%252Bbenzaldehyde%252Bthrough%252BRP-HPLC%26aulast%3DBansod%26aufirst%3DAkash%2BAnand%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nalinee  Pradubyat</span>, <span class="hlFld-ContribAuthor ">Athina  Giannoudis</span>, <span class="hlFld-ContribAuthor ">Taha  Elmetwali</span>, <span class="hlFld-ContribAuthor ">Panupong  Mahalapbutr</span>, <span class="hlFld-ContribAuthor ">Carlo  Palmieri</span>, <span class="hlFld-ContribAuthor ">Chalermchai  Mitrpant</span>, <span class="hlFld-ContribAuthor ">Wannarasmi  Ketchart</span>. </span><span class="cited-content_cbyCitation_article-title">1â²-Acetoxychavicol Acetate from Alpinia galanga Represses Proliferation and Invasion, and Induces Apoptosis via HER2-signaling in Endocrine-Resistant Breast Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Planta Medica</span><span> <strong>2021,</strong> <em>339 </em><a href="https://doi.org/10.1055/a-1307-3997" title="DOI URL">https://doi.org/10.1055/a-1307-3997</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/a-1307-3997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fa-1307-3997%26sid%3Dliteratum%253Aachs%26jtitle%3DPlanta%2520Medica%26atitle%3D1%2525E2%252580%2525B2-Acetoxychavicol%252BAcetate%252Bfrom%252BAlpinia%252Bgalanga%252BRepresses%252BProliferation%252Band%252BInvasion%25252C%252Band%252BInduces%252BApoptosis%252Bvia%252BHER2-signaling%252Bin%252BEndocrine-Resistant%252BBreast%252BCancer%252BCells%26aulast%3DPradubyat%26aufirst%3DNalinee%26date%3D2021%26date%3D2021%26volume%3D339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">å½¦å¯  ç</span>. </span><span class="cited-content_cbyCitation_article-title">Research Progress of Small Molecule Inhibitors of Akt KinaseâOverview of ATP Competitive Inhibitor Research. </span><span class="cited-content_cbyCitation_journal-name">Journal of Organic Chemistry Research</span><span> <strong>2021,</strong> <em>09 </em>
                                    (02)
                                     , 13-21. <a href="https://doi.org/10.12677/JOCR.2021.92003" title="DOI URL">https://doi.org/10.12677/JOCR.2021.92003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.12677/JOCR.2021.92003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.12677%2FJOCR.2021.92003%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Organic%2520Chemistry%2520Research%26atitle%3DResearch%252BProgress%252Bof%252BSmall%252BMolecule%252BInhibitors%252Bof%252BAkt%252BKinase%2525E2%252580%252594Overview%252Bof%252BATP%252BCompetitive%252BInhibitor%252BResearch%26aulast%3D%25E7%258E%258B%26aufirst%3D%25E5%25BD%25A6%25E5%2587%25AF%26date%3D2021%26volume%3D09%26issue%3D02%26spage%3D13%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shalini  Bajaj</span>, <span class="hlFld-ContribAuthor ">Maushmi S  Kumar</span>, <span class="hlFld-ContribAuthor ">GJ  Peters</span>, <span class="hlFld-ContribAuthor ">YC  Mayur</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting telomerase for its advent in cancer therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2020,</strong> <em>40 </em>
                                    (5)
                                     , 1871-1919. <a href="https://doi.org/10.1002/med.21674" title="DOI URL">https://doi.org/10.1002/med.21674</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21674%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DTargeting%252Btelomerase%252Bfor%252Bits%252Badvent%252Bin%252Bcancer%252Btherapeutics%26aulast%3DBajaj%26aufirst%3DShalini%26date%3D2020%26date%3D2020%26volume%3D40%26issue%3D5%26spage%3D1871%26epage%3D1919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Quangdon  Tran</span>, <span class="hlFld-ContribAuthor ">Hyunji  Lee</span>, <span class="hlFld-ContribAuthor ">Chaeyeong  Kim</span>, <span class="hlFld-ContribAuthor ">Gyeyeong  Kong</span>, <span class="hlFld-ContribAuthor ">Nayoung  Gong</span>, <span class="hlFld-ContribAuthor ">So Hee  Kwon</span>, <span class="hlFld-ContribAuthor ">Jisoo  Park</span>, <span class="hlFld-ContribAuthor ">Seon-Hwan  Kim</span>, <span class="hlFld-ContribAuthor ">Jongsun  Park</span>. </span><span class="cited-content_cbyCitation_article-title">Revisiting the Warburg Effect: Diet-Based Strategies for Cancer Prevention. </span><span class="cited-content_cbyCitation_journal-name">BioMed Research International</span><span> <strong>2020,</strong> <em>2020 </em>, 1-9. <a href="https://doi.org/10.1155/2020/8105735" title="DOI URL">https://doi.org/10.1155/2020/8105735</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2020/8105735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2020%2F8105735%26sid%3Dliteratum%253Aachs%26jtitle%3DBioMed%2520Research%2520International%26atitle%3DRevisiting%252Bthe%252BWarburg%252BEffect%25253A%252BDiet-Based%252BStrategies%252Bfor%252BCancer%252BPrevention%26aulast%3DTran%26aufirst%3DQuangdon%26date%3D2020%26volume%3D2020%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohammad Kawsar  Sharif Siam</span>, <span class="hlFld-ContribAuthor ">Anusree  Sarker</span>, <span class="hlFld-ContribAuthor ">Mohammad Manzur Sharif  Sayeem</span>. </span><span class="cited-content_cbyCitation_article-title">In silico
              drug design and molecular docking studies targeting Akt1 (RAC-alpha serine/threonine-protein kinase) and Akt2 (RAC-beta serine/threonine-protein kinase) proteins and investigation of CYP (cytochrome P450) inhibitors against MAOB (monoamine oxidase B) for OSCC (oral squamous cell carcinoma) treatment. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2020,</strong> <em>8 </em>, 1-13. <a href="https://doi.org/10.1080/07391102.2020.1802335" title="DOI URL">https://doi.org/10.1080/07391102.2020.1802335</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2020.1802335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2020.1802335%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DIn%252Bsilico%252Bdrug%252Bdesign%252Band%252Bmolecular%252Bdocking%252Bstudies%252Btargeting%252BAkt1%252B%252528RAC-alpha%252Bserine%25252Fthreonine-protein%252Bkinase%252529%252Band%252BAkt2%252B%252528RAC-beta%252Bserine%25252Fthreonine-protein%252Bkinase%252529%252Bproteins%252Band%252Binvestigation%252Bof%252BCYP%252B%252528cytochrome%252BP450%252529%252Binhibitors%252Bagainst%252BMAOB%252B%252528monoamine%252Boxidase%252BB%252529%252Bfor%252BOSCC%252B%252528oral%252Bsquamous%252Bcell%252Bcarcinoma%252529%252Btreatment%26aulast%3DSharif%2BSiam%26aufirst%3DMohammad%2BKawsar%26date%3D2020%26date%3D2020%26volume%3D8%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kai  Chen</span>, <span class="hlFld-ContribAuthor ">Zhongjun  Shang</span>, <span class="hlFld-ContribAuthor ">Ai-lin  Dai</span>, <span class="hlFld-ContribAuthor ">Pei-ling  Dai</span>. </span><span class="cited-content_cbyCitation_article-title">Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene. </span><span class="cited-content_cbyCitation_journal-name">Life Sciences</span><span> <strong>2020,</strong> <em>255 </em>, 117816. <a href="https://doi.org/10.1016/j.lfs.2020.117816" title="DOI URL">https://doi.org/10.1016/j.lfs.2020.117816</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lfs.2020.117816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lfs.2020.117816%26sid%3Dliteratum%253Aachs%26jtitle%3DLife%2520Sciences%26atitle%3DNovel%252BPI3K%25252FAkt%25252FmTOR%252Bpathway%252Binhibitors%252Bplus%252Bradiotherapy%25253A%252BStrategy%252Bfor%252Bnon-small%252Bcell%252Blung%252Bcancer%252Bwith%252Bmutant%252BRAS%252Bgene%26aulast%3DChen%26aufirst%3DKai%26date%3D2020%26volume%3D255%26spage%3D117816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Glorianne  Lazaro</span>, <span class="hlFld-ContribAuthor ">Eleftherios  Kostaras</span>, <span class="hlFld-ContribAuthor ">Igor  Vivanco</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitors in AKTion: ATP-competitive vs allosteric. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Society Transactions</span><span> <strong>2020,</strong> <em>48 </em>
                                    (3)
                                     , 933-943. <a href="https://doi.org/10.1042/BST20190777" title="DOI URL">https://doi.org/10.1042/BST20190777</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/BST20190777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FBST20190777%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Society%2520Transactions%26atitle%3DInhibitors%252Bin%252BAKTion%25253A%252BATP-competitive%252Bvs%252Ballosteric%26aulast%3DLazaro%26aufirst%3DGlorianne%26date%3D2020%26date%3D2020%26volume%3D48%26issue%3D3%26spage%3D933%26epage%3D943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ankur  Vaidya</span>, <span class="hlFld-ContribAuthor ">Shweta  Jain</span>, <span class="hlFld-ContribAuthor ">Sanjeev  Sahu</span>, <span class="hlFld-ContribAuthor ">Pankaj Kumar  Jain</span>, <span class="hlFld-ContribAuthor ">Kamla  Pathak</span>, <span class="hlFld-ContribAuthor ">Devender  Pathak</span>, <span class="hlFld-ContribAuthor ">Raj  Kumar</span>, <span class="hlFld-ContribAuthor ">Sanjay Kumar  Jain</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer Agents Based on Vulnerable Components in a Signalling Pathway. </span><span class="cited-content_cbyCitation_journal-name">Mini-Reviews in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (10)
                                     , 886-907. <a href="https://doi.org/10.2174/1389557520666200212105417" title="DOI URL">https://doi.org/10.2174/1389557520666200212105417</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1389557520666200212105417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1389557520666200212105417%26sid%3Dliteratum%253Aachs%26jtitle%3DMini-Reviews%2520in%2520Medicinal%2520Chemistry%26atitle%3DAnticancer%252BAgents%252BBased%252Bon%252BVulnerable%252BComponents%252Bin%252Ba%252BSignalling%252BPathway%26aulast%3DVaidya%26aufirst%3DAnkur%26date%3D2020%26volume%3D20%26issue%3D10%26spage%3D886%26epage%3D907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vikra Ardiansyah  Zaini</span>, <span class="hlFld-ContribAuthor ">Purwantiningsih  Sugita</span>, <span class="hlFld-ContribAuthor ">Luthfan  Irfana</span>, <span class="hlFld-ContribAuthor ">Suminar Setiati  Achmadi</span>. </span><span class="cited-content_cbyCitation_article-title">In Silico Screening Anticancer of Six Triterpenoids toward miR-494 and TNF-Î± Targets. </span><span class="cited-content_cbyCitation_journal-name">Jurnal Kimia Sains dan Aplikasi</span><span> <strong>2020,</strong> <em>23 </em>
                                    (4)
                                     , 117-123. <a href="https://doi.org/10.14710/jksa.23.4.117-123" title="DOI URL">https://doi.org/10.14710/jksa.23.4.117-123</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.14710/jksa.23.4.117-123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.14710%2Fjksa.23.4.117-123%26sid%3Dliteratum%253Aachs%26jtitle%3DJurnal%2520Kimia%2520Sains%2520dan%2520Aplikasi%26atitle%3DIn%252BSilico%252BScreening%252BAnticancer%252Bof%252BSix%252BTriterpenoids%252Btoward%252BmiR-494%252Band%252BTNF-%2525CE%2525B1%252BTargets%26aulast%3DZaini%26aufirst%3DVikra%2BArdiansyah%26date%3D2020%26date%3D2020%26volume%3D23%26issue%3D4%26spage%3D117%26epage%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kuilong  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Xianan  Sang</span>, <span class="hlFld-ContribAuthor ">Xin  Wu</span>, <span class="hlFld-ContribAuthor ">Qiyuan  Shan</span>, <span class="hlFld-ContribAuthor ">Dongxin  Tang</span>, <span class="hlFld-ContribAuthor ">Xiaofen  Xu</span>, <span class="hlFld-ContribAuthor ">Gang  Cao</span>. </span><span class="cited-content_cbyCitation_article-title">Atractylenolide I inhibits colorectal cancer cell proliferation by affecting metabolism and stemness via AKT/mTOR signaling. </span><span class="cited-content_cbyCitation_journal-name">Phytomedicine</span><span> <strong>2020,</strong> <em>68 </em>, 153191. <a href="https://doi.org/10.1016/j.phymed.2020.153191" title="DOI URL">https://doi.org/10.1016/j.phymed.2020.153191</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phymed.2020.153191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phymed.2020.153191%26sid%3Dliteratum%253Aachs%26jtitle%3DPhytomedicine%26atitle%3DAtractylenolide%252BI%252Binhibits%252Bcolorectal%252Bcancer%252Bcell%252Bproliferation%252Bby%252Baffecting%252Bmetabolism%252Band%252Bstemness%252Bvia%252BAKT%25252FmTOR%252Bsignaling%26aulast%3DWang%26aufirst%3DKuilong%26date%3D2020%26volume%3D68%26spage%3D153191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter  Schmid</span>, <span class="hlFld-ContribAuthor ">Jacinta  Abraham</span>, <span class="hlFld-ContribAuthor ">Stephen  Chan</span>, <span class="hlFld-ContribAuthor ">Duncan  Wheatley</span>, <span class="hlFld-ContribAuthor ">Adrian Murray  Brunt</span>, <span class="hlFld-ContribAuthor ">Gia  Nemsadze</span>, <span class="hlFld-ContribAuthor ">Richard D.  Baird</span>, <span class="hlFld-ContribAuthor ">Yeon Hee  Park</span>, <span class="hlFld-ContribAuthor ">Peter S.  Hall</span>, <span class="hlFld-ContribAuthor ">Timothy  Perren</span>, <span class="hlFld-ContribAuthor ">Robert C.  Stein</span>, <span class="hlFld-ContribAuthor ">LÃ¡szlÃ³  Mangel</span>, <span class="hlFld-ContribAuthor ">Jean-Marc  Ferrero</span>, <span class="hlFld-ContribAuthor ">Melissa  Phillips</span>, <span class="hlFld-ContribAuthor ">John  Conibear</span>, <span class="hlFld-ContribAuthor ">Javier  Cortes</span>, <span class="hlFld-ContribAuthor ">Andrew  Foxley</span>, <span class="hlFld-ContribAuthor ">Elza C.  de Bruin</span>, <span class="hlFld-ContribAuthor ">Robert  McEwen</span>, <span class="hlFld-ContribAuthor ">Daniel  Stetson</span>, <span class="hlFld-ContribAuthor ">Brian  Dougherty</span>, <span class="hlFld-ContribAuthor ">Shah-Jalal  Sarker</span>, <span class="hlFld-ContribAuthor ">Aaron  Prendergast</span>, <span class="hlFld-ContribAuthor ">Max  McLaughlin-Callan</span>, <span class="hlFld-ContribAuthor ">Matthew  Burgess</span>, <span class="hlFld-ContribAuthor ">Cheryl  Lawrence</span>, <span class="hlFld-ContribAuthor ">Hayley  Cartwright</span>, <span class="hlFld-ContribAuthor ">Kelly  Mousa</span>, <span class="hlFld-ContribAuthor ">Nicholas C.  Turner</span>. </span><span class="cited-content_cbyCitation_article-title">Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Oncology</span><span> <strong>2020,</strong> <em>38 </em>
                                    (5)
                                     , 423-433. <a href="https://doi.org/10.1200/JCO.19.00368" title="DOI URL">https://doi.org/10.1200/JCO.19.00368</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1200/JCO.19.00368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1200%2FJCO.19.00368%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Oncology%26atitle%3DCapivasertib%252BPlus%252BPaclitaxel%252BVersus%252BPlacebo%252BPlus%252BPaclitaxel%252BAs%252BFirst-Line%252BTherapy%252Bfor%252BMetastatic%252BTriple-Negative%252BBreast%252BCancer%25253A%252BThe%252BPAKT%252BTrial%26aulast%3DSchmid%26aufirst%3DPeter%26date%3D2020%26volume%3D38%26issue%3D5%26spage%3D423%26epage%3D433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Priya  Mahajan</span>, <span class="hlFld-ContribAuthor ">Bhumika  Wadhwa</span>, <span class="hlFld-ContribAuthor ">Manas Ranjan  Barik</span>, <span class="hlFld-ContribAuthor ">Fayaz  Malik</span>, <span class="hlFld-ContribAuthor ">Amit  Nargotra</span>. </span><span class="cited-content_cbyCitation_article-title">Combining ligand- and structure-based in silico methods for the identification of natural product-based inhibitors of Akt1. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2020,</strong> <em>24 </em>
                                    (1)
                                     , 45-60. <a href="https://doi.org/10.1007/s11030-019-09924-9" title="DOI URL">https://doi.org/10.1007/s11030-019-09924-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-019-09924-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-019-09924-9%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DCombining%252Bligand-%252Band%252Bstructure-based%252Bin%252Bsilico%252Bmethods%252Bfor%252Bthe%252Bidentification%252Bof%252Bnatural%252Bproduct-based%252Binhibitors%252Bof%252BAkt1%26aulast%3DMahajan%26aufirst%3DPriya%26date%3D2020%26date%3D2019%26volume%3D24%26issue%3D1%26spage%3D45%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenda  Di</span>, <span class="hlFld-ContribAuthor ">Robin B.  Gasser</span>, <span class="hlFld-ContribAuthor ">Li  He</span>, <span class="hlFld-ContribAuthor ">Fangfang  Li</span>, <span class="hlFld-ContribAuthor ">Xiaofang  Liu</span>, <span class="hlFld-ContribAuthor ">Caixian  Zhou</span>, <span class="hlFld-ContribAuthor ">Yanqin  Zhou</span>, <span class="hlFld-ContribAuthor ">Rui  Fang</span>, <span class="hlFld-ContribAuthor ">Junlong  Zhao</span>, <span class="hlFld-ContribAuthor ">Min  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">A serine/threonineâspecific protein kinase of
              Haemonchus contortus
              with a role in the development. </span><span class="cited-content_cbyCitation_journal-name">The FASEB Journal</span><span> <strong>2020,</strong> <em>34 </em>
                                    (2)
                                     , 2075-2086. <a href="https://doi.org/10.1096/fj.201900888RR" title="DOI URL">https://doi.org/10.1096/fj.201900888RR</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1096/fj.201900888RR&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1096%2Ffj.201900888RR%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520FASEB%2520Journal%26atitle%3DA%252Bserine%25252Fthreonine%2525E2%252580%252590specific%252Bprotein%252Bkinase%252Bof%252BHaemonchus%252Bcontortus%252Bwith%252Ba%252Brole%252Bin%252Bthe%252Bdevelopment%26aulast%3DDi%26aufirst%3DWenda%26date%3D2020%26date%3D2019%26volume%3D34%26issue%3D2%26spage%3D2075%26epage%3D2086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huiwen  Wang</span>, <span class="hlFld-ContribAuthor ">Zeyu  Guan</span>, <span class="hlFld-ContribAuthor ">Jiadi  Qiu</span>, <span class="hlFld-ContribAuthor ">Ya  Jia</span>, <span class="hlFld-ContribAuthor ">Chen  Zeng</span>, <span class="hlFld-ContribAuthor ">Yunjie  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Novel method to identify group-specific non-catalytic pockets of human kinome for drug design. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2020,</strong> <em>10 </em>
                                    (4)
                                     , 2004-2015. <a href="https://doi.org/10.1039/C9RA07471F" title="DOI URL">https://doi.org/10.1039/C9RA07471F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9RA07471F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9RA07471F%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DNovel%252Bmethod%252Bto%252Bidentify%252Bgroup-specific%252Bnon-catalytic%252Bpockets%252Bof%252Bhuman%252Bkinome%252Bfor%252Bdrug%252Bdesign%26aulast%3DWang%26aufirst%3DHuiwen%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D4%26spage%3D2004%26epage%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aphrothiti J.  Hanrahan</span>, <span class="hlFld-ContribAuthor ">Gopa  Iyer</span>, <span class="hlFld-ContribAuthor ">David B.  Solit</span>. </span><span class="cited-content_cbyCitation_article-title">Intracellular Signaling. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 24-46.e12. <a href="https://doi.org/10.1016/B978-0-323-47674-4.00002-5" title="DOI URL">https://doi.org/10.1016/B978-0-323-47674-4.00002-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-323-47674-4.00002-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-323-47674-4.00002-5%26sid%3Dliteratum%253Aachs%26atitle%3DIntracellular%252BSignaling%26aulast%3DHanrahan%26aufirst%3DAphrothiti%2BJ.%26date%3D2020%26spage%3D24%26epage%3D46.e12%26pub%3DElsevier%26atitle%3DAbeloff%252527s%252BClinical%252BOncology%26date%3D2020%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">VarRuchi  Sharma</span>, <span class="hlFld-ContribAuthor ">Anil K.  Sharma</span>, <span class="hlFld-ContribAuthor ">Vasu  Punj</span>, <span class="hlFld-ContribAuthor ">Panneerselvam  Priya</span>. </span><span class="cited-content_cbyCitation_article-title">Recent nanotechnological interventions targeting PI3K/Akt/mTOR pathway: A focus on breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cancer Biology</span><span> <strong>2019,</strong> <em>59 </em>, 133-146. <a href="https://doi.org/10.1016/j.semcancer.2019.08.005" title="DOI URL">https://doi.org/10.1016/j.semcancer.2019.08.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcancer.2019.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcancer.2019.08.005%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cancer%2520Biology%26atitle%3DRecent%252Bnanotechnological%252Binterventions%252Btargeting%252BPI3K%25252FAkt%25252FmTOR%252Bpathway%25253A%252BA%252Bfocus%252Bon%252Bbreast%252Bcancer%26aulast%3DSharma%26aufirst%3DVarRuchi%26date%3D2019%26volume%3D59%26spage%3D133%26epage%3D146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elkin  Eduardo Sanabria-Chanaga</span>, <span class="hlFld-ContribAuthor ">Irene  Betancourt-Conde</span>, <span class="hlFld-ContribAuthor ">Alicia  HernÃ¡ndez-Campos</span>, <span class="hlFld-ContribAuthor ">Alfredo  TÃ©llez-Valencia</span>, <span class="hlFld-ContribAuthor ">Rafael  Castillo</span>. </span><span class="cited-content_cbyCitation_article-title">In silico
              hit optimization toward AKT inhibition: fragment-based approach, molecular docking and molecular dynamics study. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2019,</strong> <em>37 </em>
                                    (16)
                                     , 4301-4311. <a href="https://doi.org/10.1080/07391102.2018.1546618" title="DOI URL">https://doi.org/10.1080/07391102.2018.1546618</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2018.1546618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2018.1546618%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DIn%252Bsilico%252Bhit%252Boptimization%252Btoward%252BAKT%252Binhibition%25253A%252Bfragment-based%252Bapproach%25252C%252Bmolecular%252Bdocking%252Band%252Bmolecular%252Bdynamics%252Bstudy%26aulast%3DEduardo%2BSanabria-Chanaga%26aufirst%3DElkin%26date%3D2019%26date%3D2019%26volume%3D37%26issue%3D16%26spage%3D4301%26epage%3D4311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maryam  Shariati</span>, <span class="hlFld-ContribAuthor ">Funda  Meric-Bernstam</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting AKT for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2019,</strong> <em>28 </em>
                                    (11)
                                     , 977-988. <a href="https://doi.org/10.1080/13543784.2019.1676726" title="DOI URL">https://doi.org/10.1080/13543784.2019.1676726</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2019.1676726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2019.1676726%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DTargeting%252BAKT%252Bfor%252Bcancer%252Btherapy%26aulast%3DShariati%26aufirst%3DMaryam%26date%3D2019%26date%3D2019%26volume%3D28%26issue%3D11%26spage%3D977%26epage%3D988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenhu  Zhan</span>, <span class="hlFld-ContribAuthor ">Jinxin  Che</span>, <span class="hlFld-ContribAuthor ">Lei  Xu</span>, <span class="hlFld-ContribAuthor ">Yizhe  Wu</span>, <span class="hlFld-ContribAuthor ">Xiaobei  Hu</span>, <span class="hlFld-ContribAuthor ">Yubo  Zhou</span>, <span class="hlFld-ContribAuthor ">Gang  Cheng</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>, <span class="hlFld-ContribAuthor ">Xiaowu  Dong</span>, <span class="hlFld-ContribAuthor ">Jia  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of pyrazole-thiophene derivatives as highly Potent, orally active Akt inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>180 </em>, 72-85. <a href="https://doi.org/10.1016/j.ejmech.2019.07.017" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.07.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.07.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.07.017%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpyrazole-thiophene%252Bderivatives%252Bas%252Bhighly%252BPotent%25252C%252Borally%252Bactive%252BAkt%252Binhibitors%26aulast%3DZhan%26aufirst%3DWenhu%26date%3D2019%26volume%3D180%26spage%3D72%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaiwen  Guo</span>, <span class="hlFld-ContribAuthor ">Wendi  Tang</span>, <span class="hlFld-ContribAuthor ">Huijun  Zhuo</span>, <span class="hlFld-ContribAuthor ">Guisen  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advance of Akt Inhibitors in Clinical Trials. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2019,</strong> <em>4 </em>
                                    (31)
                                     , 9040-9044. <a href="https://doi.org/10.1002/slct.201901293" title="DOI URL">https://doi.org/10.1002/slct.201901293</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201901293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201901293%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DRecent%252BAdvance%252Bof%252BAkt%252BInhibitors%252Bin%252BClinical%252BTrials%26aulast%3DGuo%26aufirst%3DKaiwen%26date%3D2019%26date%3D2019%26volume%3D4%26issue%3D31%26spage%3D9040%26epage%3D9044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Panupong  Mahalapbutr</span>, <span class="hlFld-ContribAuthor ">Piyanuch  Wonganan</span>, <span class="hlFld-ContribAuthor ">Warinthorn  Chavasiri</span>, <span class="hlFld-ContribAuthor ">Thanyada  Rungrotmongkol</span>. </span><span class="cited-content_cbyCitation_article-title">Butoxy Mansonone G Inhibits STAT3 and Akt Signaling Pathways in Non-Small Cell Lung Cancers: Combined Experimental and Theoretical Investigations. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2019,</strong> <em>11 </em>
                                    (4)
                                     , 437. <a href="https://doi.org/10.3390/cancers11040437" title="DOI URL">https://doi.org/10.3390/cancers11040437</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers11040437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers11040437%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DButoxy%252BMansonone%252BG%252BInhibits%252BSTAT3%252Band%252BAkt%252BSignaling%252BPathways%252Bin%252BNon-Small%252BCell%252BLung%252BCancers%25253A%252BCombined%252BExperimental%252Band%252BTheoretical%252BInvestigations%26aulast%3DMahalapbutr%26aufirst%3DPanupong%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D4%26spage%3D437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oleg N  Reva</span>, <span class="hlFld-ContribAuthor ">Sunelle  Rademan</span>, <span class="hlFld-ContribAuthor ">Michelle H  Visagie</span>, <span class="hlFld-ContribAuthor ">Maphuti T  Lebelo</span>, <span class="hlFld-ContribAuthor ">Mokgadi V  Gwangwa</span>, <span class="hlFld-ContribAuthor ">Vitalii V  Klochko</span>, <span class="hlFld-ContribAuthor ">Anna M  Joubert</span>, <span class="hlFld-ContribAuthor ">Namrita  Lall</span>. </span><span class="cited-content_cbyCitation_article-title">Comparison of structures and cytotoxicity of mupirocin and batumin against melanoma and several other cancer cell lines. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2019,</strong> <em>11 </em>
                                    (7)
                                     , 677-691. <a href="https://doi.org/10.4155/fmc-2018-0333" title="DOI URL">https://doi.org/10.4155/fmc-2018-0333</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2018-0333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2018-0333%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DComparison%252Bof%252Bstructures%252Band%252Bcytotoxicity%252Bof%252Bmupirocin%252Band%252Bbatumin%252Bagainst%252Bmelanoma%252Band%252Bseveral%252Bother%252Bcancer%252Bcell%252Blines%26aulast%3DReva%26aufirst%3DOleg%2BN%26date%3D2019%26volume%3D11%26issue%3D7%26spage%3D677%26epage%3D691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruth  Eichner</span>, <span class="hlFld-ContribAuthor ">Vanesa  FernÃ¡ndez-SÃ¡iz</span>, <span class="hlFld-ContribAuthor ">Bianca-Sabrina  Targosz</span>, <span class="hlFld-ContribAuthor ">Florian  Bassermann</span>. </span><span class="cited-content_cbyCitation_article-title">Cross Talk Networks of Mammalian Target of Rapamycin Signaling With the Ubiquitin Proteasome System and Their Clinical Implications in Multiple Myeloma. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 219-297. <a href="https://doi.org/10.1016/bs.ircmb.2018.06.001" title="DOI URL">https://doi.org/10.1016/bs.ircmb.2018.06.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.ircmb.2018.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.ircmb.2018.06.001%26sid%3Dliteratum%253Aachs%26atitle%3DCross%252BTalk%252BNetworks%252Bof%252BMammalian%252BTarget%252Bof%252BRapamycin%252BSignaling%252BWith%252Bthe%252BUbiquitin%252BProteasome%252BSystem%252Band%252BTheir%252BClinical%252BImplications%252Bin%252BMultiple%252BMyeloma%26aulast%3DEichner%26aufirst%3DRuth%26date%3D2019%26spage%3D219%26epage%3D297%26pub%3DElsevier%26date%3D2019%26volume%3D343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eman  Nossier</span>, <span class="hlFld-ContribAuthor ">Somaia  Abd El-Karim</span>, <span class="hlFld-ContribAuthor ">Nagy  Khalifa</span>, <span class="hlFld-ContribAuthor ">Ali  El-Sayed</span>, <span class="hlFld-ContribAuthor ">Emad  Hassan</span>, <span class="hlFld-ContribAuthor ">Salwa  El-Hallouty</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase Inhibitory Activities and Molecular Docking of a Novel Series of Anticancer Pyrazole Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2018,</strong> <em>23 </em>
                                    (12)
                                     , 3074. <a href="https://doi.org/10.3390/molecules23123074" title="DOI URL">https://doi.org/10.3390/molecules23123074</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules23123074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules23123074%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DKinase%252BInhibitory%252BActivities%252Band%252BMolecular%252BDocking%252Bof%252Ba%252BNovel%252BSeries%252Bof%252BAnticancer%252BPyrazole%252BDerivatives%26aulast%3DNossier%26aufirst%3DEman%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D12%26spage%3D3074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria A  Soldatkina</span>, <span class="hlFld-ContribAuthor ">Vitalii V  Klochko</span>, <span class="hlFld-ContribAuthor ">Svitlana D  Zagorodnya</span>, <span class="hlFld-ContribAuthor ">Sunelle  Rademan</span>, <span class="hlFld-ContribAuthor ">Michelle H  Visagie</span>, <span class="hlFld-ContribAuthor ">Maphuti T  Lebelo</span>, <span class="hlFld-ContribAuthor ">Mokgadi V  Gwangwa</span>, <span class="hlFld-ContribAuthor ">Anna M  Joubert</span>, <span class="hlFld-ContribAuthor ">Namrita  Lall</span>, <span class="hlFld-ContribAuthor ">Oleg N  Reva</span>. </span><span class="cited-content_cbyCitation_article-title">Promising anticancer activity of batumin: a natural polyene antibiotic produced by
              Pseudomonas batumici. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2018,</strong> <em>10 </em>
                                    (18)
                                     , 2187-2199. <a href="https://doi.org/10.4155/fmc-2018-0062" title="DOI URL">https://doi.org/10.4155/fmc-2018-0062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2018-0062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2018-0062%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DPromising%252Banticancer%252Bactivity%252Bof%252Bbatumin%25253A%252Ba%252Bnatural%252Bpolyene%252Bantibiotic%252Bproduced%252Bby%252BPseudomonas%252Bbatumici%26aulast%3DSoldatkina%26aufirst%3DMaria%2BA%26date%3D2018%26volume%3D10%26issue%3D18%26spage%3D2187%26epage%3D2199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ricardo L. B.  Costa</span>, <span class="hlFld-ContribAuthor ">Hyo Sook  Han</span>, <span class="hlFld-ContribAuthor ">William J.  Gradishar</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. </span><span class="cited-content_cbyCitation_journal-name">Breast Cancer Research and Treatment</span><span> <strong>2018,</strong> <em>169 </em>
                                    (3)
                                     , 397-406. <a href="https://doi.org/10.1007/s10549-018-4697-y" title="DOI URL">https://doi.org/10.1007/s10549-018-4697-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10549-018-4697-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10549-018-4697-y%26sid%3Dliteratum%253Aachs%26jtitle%3DBreast%2520Cancer%2520Research%2520and%2520Treatment%26atitle%3DTargeting%252Bthe%252BPI3K%25252FAKT%25252FmTOR%252Bpathway%252Bin%252Btriple-negative%252Bbreast%252Bcancer%25253A%252Ba%252Breview%26aulast%3DCosta%26aufirst%3DRicardo%2BL.%2BB.%26date%3D2018%26date%3D2018%26volume%3D169%26issue%3D3%26spage%3D397%26epage%3D406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Emma  Dean</span>, <span class="hlFld-ContribAuthor ">Udai  Banerji</span>, <span class="hlFld-ContribAuthor ">Jan H. M.  Schellens</span>, <span class="hlFld-ContribAuthor ">Matthew G.  Krebs</span>, <span class="hlFld-ContribAuthor ">Begona  Jimenez</span>, <span class="hlFld-ContribAuthor ">Emilie  van Brummelen</span>, <span class="hlFld-ContribAuthor ">Chris  Bailey</span>, <span class="hlFld-ContribAuthor ">Ed  Casson</span>, <span class="hlFld-ContribAuthor ">Diana  Cripps</span>, <span class="hlFld-ContribAuthor ">Marie  Cullberg</span>, <span class="hlFld-ContribAuthor ">Stephen  Evans</span>, <span class="hlFld-ContribAuthor ">Andrew  Foxley</span>, <span class="hlFld-ContribAuthor ">Justin  Lindemann</span>, <span class="hlFld-ContribAuthor ">Paul  Rugman</span>, <span class="hlFld-ContribAuthor ">Nigel  Taylor</span>, <span class="hlFld-ContribAuthor ">Guy  Turner</span>, <span class="hlFld-ContribAuthor ">James  Yates</span>, <span class="hlFld-ContribAuthor ">Peter  Lawrence</span>. </span><span class="cited-content_cbyCitation_article-title">A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK. </span><span class="cited-content_cbyCitation_journal-name">Cancer Chemotherapy and Pharmacology</span><span> <strong>2018,</strong> <em>81 </em>
                                    (5)
                                     , 873-883. <a href="https://doi.org/10.1007/s00280-018-3558-z" title="DOI URL">https://doi.org/10.1007/s00280-018-3558-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00280-018-3558-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00280-018-3558-z%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Chemotherapy%2520and%2520Pharmacology%26atitle%3DA%252BPhase%252B1%25252C%252Bopen-label%25252C%252Bmulticentre%252Bstudy%252Bto%252Bcompare%252Bthe%252Bcapsule%252Band%252Btablet%252Bformulations%252Bof%252BAZD5363%252Band%252Bexplore%252Bthe%252Beffect%252Bof%252Bfood%252Bon%252Bthe%252Bpharmacokinetic%252Bexposure%25252C%252Bsafety%252Band%252Btolerability%252Bof%252BAZD5363%252Bin%252Bpatients%252Bwith%252Badvanced%252Bsolid%252Bmalignancies%25253A%252BOAK%26aulast%3DDean%26aufirst%3DEmma%26date%3D2018%26date%3D2018%26volume%3D81%26issue%3D5%26spage%3D873%26epage%3D883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alvaro  Avivar-Valderas</span>, <span class="hlFld-ContribAuthor ">Robert  McEwen</span>, <span class="hlFld-ContribAuthor ">Amir  Taheri-Ghahfarokhi</span>, <span class="hlFld-ContribAuthor ">Larissa S.  Carnevalli</span>, <span class="hlFld-ContribAuthor ">Elizabeth L.  Hardaker</span>, <span class="hlFld-ContribAuthor ">Marcello  Maresca</span>, <span class="hlFld-ContribAuthor ">Kevin  Hudson</span>, <span class="hlFld-ContribAuthor ">Elizabeth A.  Harrington</span>, <span class="hlFld-ContribAuthor ">Francisco  Cruzalegui</span>. </span><span class="cited-content_cbyCitation_article-title">Functional significance of co-occurring mutations in
              PIK3CA
              and
              MAP3K1
              in breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2018,</strong> <em>9 </em>
                                    (30)
                                     , 21444-21458. <a href="https://doi.org/10.18632/oncotarget.25118" title="DOI URL">https://doi.org/10.18632/oncotarget.25118</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.25118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.25118%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DFunctional%252Bsignificance%252Bof%252Bco-occurring%252Bmutations%252Bin%252BPIK3CA%252Band%252BMAP3K1%252Bin%252Bbreast%252Bcancer%26aulast%3DAvivar-Valderas%26aufirst%3DAlvaro%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D30%26spage%3D21444%26epage%3D21458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  Yang</span>, <span class="hlFld-ContribAuthor ">Hao  Chen</span>, <span class="hlFld-ContribAuthor ">Qiang  Wang</span>, <span class="hlFld-ContribAuthor ">Shihao  Deng</span>, <span class="hlFld-ContribAuthor ">Mi  Huang</span>, <span class="hlFld-ContribAuthor ">Xinhua  Ma</span>, <span class="hlFld-ContribAuthor ">Ping  Song</span>, <span class="hlFld-ContribAuthor ">Jingwen  Du</span>, <span class="hlFld-ContribAuthor ">Yun  Huang</span>, <span class="hlFld-ContribAuthor ">Yanzhang  Wen</span>, <span class="hlFld-ContribAuthor ">Yongshen  Ren</span>, <span class="hlFld-ContribAuthor ">Xinzhou  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitory Effect of Kurarinone on Growth of Human Non-small Cell Lung Cancer: An Experimental Study Both in Vitro and in Vivo Studies. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2018,</strong> <em>9 </em><a href="https://doi.org/10.3389/fphar.2018.00252" title="DOI URL">https://doi.org/10.3389/fphar.2018.00252</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2018.00252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2018.00252%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DInhibitory%252BEffect%252Bof%252BKurarinone%252Bon%252BGrowth%252Bof%252BHuman%252BNon-small%252BCell%252BLung%252BCancer%25253A%252BAn%252BExperimental%252BStudy%252BBoth%252Bin%252BVitro%252Band%252Bin%252BVivo%252BStudies%26aulast%3DYang%26aufirst%3DJie%26date%3D2018%26date%3D2018%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">P.  Muthuraja</span>, <span class="hlFld-ContribAuthor ">M.  Himesh</span>, <span class="hlFld-ContribAuthor ">S.  Prakash</span>, <span class="hlFld-ContribAuthor ">U.  Venkatasubramanian</span>, <span class="hlFld-ContribAuthor ">P.  Manisankar</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of N-(1-(6-acetamido-5-phenylpyrimidin-4-yl) piperidin-3-yl) amide derivatives as potential inhibitors for mitotic kinesin spindle protein. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>148 </em>, 106-115. <a href="https://doi.org/10.1016/j.ejmech.2018.02.010" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.02.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.02.010%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Bof%252BN-%2525281-%2525286-acetamido-5-phenylpyrimidin-4-yl%252529%252Bpiperidin-3-yl%252529%252Bamide%252Bderivatives%252Bas%252Bpotential%252Binhibitors%252Bfor%252Bmitotic%252Bkinesin%252Bspindle%252Bprotein%26aulast%3DMuthuraja%26aufirst%3DP.%26date%3D2018%26volume%3D148%26spage%3D106%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oleksandr O.  Grygorenko</span>, <span class="hlFld-ContribAuthor ">Angelina V.  Biitseva</span>, <span class="hlFld-ContribAuthor ">Serhii  Zhersh</span>. </span><span class="cited-content_cbyCitation_article-title">Amino sulfonic acids, peptidosulfonamides and other related compounds. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2018,</strong> <em>74 </em>
                                    (13)
                                     , 1355-1421. <a href="https://doi.org/10.1016/j.tet.2018.01.033" title="DOI URL">https://doi.org/10.1016/j.tet.2018.01.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2018.01.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2018.01.033%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DAmino%252Bsulfonic%252Bacids%25252C%252Bpeptidosulfonamides%252Band%252Bother%252Brelated%252Bcompounds%26aulast%3DGrygorenko%26aufirst%3DOleksandr%2BO.%26date%3D2018%26volume%3D74%26issue%3D13%26spage%3D1355%26epage%3D1421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meenakshi  Singh</span>, <span class="hlFld-ContribAuthor ">Benjamin  Tam</span>, <span class="hlFld-ContribAuthor ">Barak  Akabayov</span>. </span><span class="cited-content_cbyCitation_article-title">NMR-Fragment Based Virtual Screening: A Brief Overview. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2018,</strong> <em>23 </em>
                                    (2)
                                     , 233. <a href="https://doi.org/10.3390/molecules23020233" title="DOI URL">https://doi.org/10.3390/molecules23020233</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules23020233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules23020233%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DNMR-Fragment%252BBased%252BVirtual%252BScreening%25253A%252BA%252BBrief%252BOverview%26aulast%3DSingh%26aufirst%3DMeenakshi%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D2%26spage%3D233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pedro JosuÃ©  Trejo-Soto</span>, <span class="hlFld-ContribAuthor ">Alicia  HernÃ¡ndez-Campos</span>, <span class="hlFld-ContribAuthor ">Antonio  Romo-Mancillas</span>, <span class="hlFld-ContribAuthor ">JosÃ© L.  Medina-Franco</span>, <span class="hlFld-ContribAuthor ">Rafael  Castillo</span>. </span><span class="cited-content_cbyCitation_article-title">In search of AKT kinase inhibitors as anticancer agents: structure-based design, docking, and molecular dynamics studies of 2,4,6-trisubstituted pyridines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2018,</strong> <em>36 </em>
                                    (2)
                                     , 423-442. <a href="https://doi.org/10.1080/07391102.2017.1285724" title="DOI URL">https://doi.org/10.1080/07391102.2017.1285724</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2017.1285724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2017.1285724%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DIn%252Bsearch%252Bof%252BAKT%252Bkinase%252Binhibitors%252Bas%252Banticancer%252Bagents%25253A%252Bstructure-based%252Bdesign%25252C%252Bdocking%25252C%252Band%252Bmolecular%252Bdynamics%252Bstudies%252Bof%252B2%25252C4%25252C6-trisubstituted%252Bpyridines%26aulast%3DTrejo-Soto%26aufirst%3DPedro%2BJosu%25C3%25A9%26date%3D2018%26date%3D2017%26volume%3D36%26issue%3D2%26spage%3D423%26epage%3D442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daoguang  Zhang</span>, <span class="hlFld-ContribAuthor ">Dongdong  Tong</span>, <span class="hlFld-ContribAuthor ">Dezhi  Yang</span>, <span class="hlFld-ContribAuthor ">Jing  Sun</span>, <span class="hlFld-ContribAuthor ">Fenghe  Zhang</span>, <span class="hlFld-ContribAuthor ">Guisen  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of AKT inhibitors bearing a piperidin-4-yl appendant. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2018,</strong> <em>9 </em>
                                    (8)
                                     , 1340-1350. <a href="https://doi.org/10.1039/C8MD00197A" title="DOI URL">https://doi.org/10.1039/C8MD00197A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8MD00197A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8MD00197A%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252BAKT%252Binhibitors%252Bbearing%252Ba%252Bpiperidin-4-yl%252Bappendant%26aulast%3DZhang%26aufirst%3DDaoguang%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D8%26spage%3D1340%26epage%3D1350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dezhi  Yang</span>, <span class="hlFld-ContribAuthor ">Dongdong  Tong</span>, <span class="hlFld-ContribAuthor ">Qian  Zhang</span>, <span class="hlFld-ContribAuthor ">Yongtao  Wang</span>, <span class="hlFld-ContribAuthor ">Jing  Sun</span>, <span class="hlFld-ContribAuthor ">Fenghe  Zhang</span>, <span class="hlFld-ContribAuthor ">Guisen  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and evaluation of novel Akt1 inhibitors based on an indole scaffold. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2017,</strong> <em>90 </em>
                                    (5)
                                     , 791-803. <a href="https://doi.org/10.1111/cbdd.13000" title="DOI URL">https://doi.org/10.1111/cbdd.13000</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13000%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bevaluation%252Bof%252Bnovel%252BAkt1%252Binhibitors%252Bbased%252Bon%252Ban%252Bindole%252Bscaffold%26aulast%3DYang%26aufirst%3DDezhi%26date%3D2017%26date%3D2017%26volume%3D90%26issue%3D5%26spage%3D791%26epage%3D803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bayard R.  Huck</span>, <span class="hlFld-ContribAuthor ">Igor  Mochalkin</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress towards clinically relevant ATP-competitive Akt inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (13)
                                     , 2838-2848. <a href="https://doi.org/10.1016/j.bmcl.2017.04.090" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.04.090</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.04.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.04.090%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DRecent%252Bprogress%252Btowards%252Bclinically%252Brelevant%252BATP-competitive%252BAkt%252Binhibitors%26aulast%3DHuck%26aufirst%3DBayard%2BR.%26date%3D2017%26volume%3D27%26issue%3D13%26spage%3D2838%26epage%3D2848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter M.  Fischer</span>. </span><span class="cited-content_cbyCitation_article-title">Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2017,</strong> <em>37 </em>
                                    (2)
                                     , 314-367. <a href="https://doi.org/10.1002/med.21409" title="DOI URL">https://doi.org/10.1002/med.21409</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21409%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DApproved%252Band%252BExperimental%252BSmall-Molecule%252BOncology%252BKinase%252BInhibitor%252BDrugs%25253A%252BA%252BMid-2016%252BOverview%26aulast%3DFischer%26aufirst%3DPeter%2BM.%26date%3D2017%26date%3D2016%26volume%3D37%26issue%3D2%26spage%3D314%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesca  Musumeci</span>, <span class="hlFld-ContribAuthor ">Anna Lucia  Fallacara</span>, <span class="hlFld-ContribAuthor ">Chiara  Brullo</span>, <span class="hlFld-ContribAuthor ">Giancarlo  Grossi</span>, <span class="hlFld-ContribAuthor ">Lorenzo  Botta</span>, <span class="hlFld-ContribAuthor ">Pierpaolo  Calandro</span>, <span class="hlFld-ContribAuthor ">Mario  Chiariello</span>, <span class="hlFld-ContribAuthor ">Miroslava  Kissova</span>, <span class="hlFld-ContribAuthor ">Emmanuele  Crespan</span>, <span class="hlFld-ContribAuthor ">Giovanni  Maga</span>, <span class="hlFld-ContribAuthor ">Silvia  Schenone</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of new pyrrolo[2,3- d ]pyrimidines as Src tyrosine kinase inhibitors  inÂ vitro  active against Glioblastoma. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>127 </em>, 369-378. <a href="https://doi.org/10.1016/j.ejmech.2016.12.036" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.12.036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.12.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.12.036%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Bnew%252Bpyrrolo%25255B2%25252C3-%252Bd%252B%25255Dpyrimidines%252Bas%252BSrc%252Btyrosine%252Bkinase%252Binhibitors%252Bin%2525C2%2525A0vitro%252Bactive%252Bagainst%252BGlioblastoma%26aulast%3DMusumeci%26aufirst%3DFrancesca%26date%3D2017%26volume%3D127%26spage%3D369%26epage%3D378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Hoemann</span>, <span class="hlFld-ContribAuthor ">Noel  Wilson</span>, <span class="hlFld-ContribAuthor ">Maria  Argiriadi</span>, <span class="hlFld-ContribAuthor ">David  Banach</span>, <span class="hlFld-ContribAuthor ">Andrew  Burchat</span>, <span class="hlFld-ContribAuthor ">David  Calderwood</span>, <span class="hlFld-ContribAuthor ">Bruce  Clapham</span>, <span class="hlFld-ContribAuthor ">Phil  Cox</span>, <span class="hlFld-ContribAuthor ">David B.  Duignan</span>, <span class="hlFld-ContribAuthor ">Don  Konopacki</span>, <span class="hlFld-ContribAuthor ">Gagandeep  Somal</span>, <span class="hlFld-ContribAuthor ">Anil  Vasudevan</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and optimization of furano[3,2- d ]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (22)
                                     , 5562-5567. <a href="https://doi.org/10.1016/j.bmcl.2016.09.077" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.09.077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.09.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.09.077%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Boptimization%252Bof%252Bfurano%25255B3%25252C2-%252Bd%252B%25255Dpyrimidines%252Bas%252Bselective%252Bspleen%252Btyrosine%252Bkinase%252B%252528Syk%252529%252Binhibitors%26aulast%3DHoemann%26aufirst%3DMichael%26date%3D2016%26volume%3D26%26issue%3D22%26spage%3D5562%26epage%3D5567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bradley C.  Doak</span>, <span class="hlFld-ContribAuthor ">Raymond S.  Norton</span>, <span class="hlFld-ContribAuthor ">Martin J.  Scanlon</span>. </span><span class="cited-content_cbyCitation_article-title">The ways and means of fragment-based drug design. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2016,</strong> <em>167 </em>, 28-37. <a href="https://doi.org/10.1016/j.pharmthera.2016.07.003" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2016.07.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2016.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2016.07.003%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DThe%252Bways%252Band%252Bmeans%252Bof%252Bfragment-based%252Bdrug%252Bdesign%26aulast%3DDoak%26aufirst%3DBradley%2BC.%26date%3D2016%26volume%3D167%26spage%3D28%26epage%3D37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Joy</span>, <span class="hlFld-ContribAuthor ">Manisha  Kapoor</span>, <span class="hlFld-ContribAuthor ">Joseph  Georges</span>, <span class="hlFld-ContribAuthor ">Lacy  Butler</span>, <span class="hlFld-ContribAuthor ">Yongchang  Chang</span>, <span class="hlFld-ContribAuthor ">Chaokun  Li</span>, <span class="hlFld-ContribAuthor ">Acacia  Crouch</span>, <span class="hlFld-ContribAuthor ">Ivan  Smirnov</span>, <span class="hlFld-ContribAuthor ">Mitsitoshi  Nakada</span>, <span class="hlFld-ContribAuthor ">James  Hepler</span>, <span class="hlFld-ContribAuthor ">Max  Marty</span>, <span class="hlFld-ContribAuthor ">Burt G.  Feuerstein</span>. </span><span class="cited-content_cbyCitation_article-title">The role of AKT isoforms in glioblastoma: AKT3 delays tumor progression. </span><span class="cited-content_cbyCitation_journal-name">Journal of Neuro-Oncology</span><span> <strong>2016,</strong> <em>130 </em>
                                    (1)
                                     , 43-52. <a href="https://doi.org/10.1007/s11060-016-2220-z" title="DOI URL">https://doi.org/10.1007/s11060-016-2220-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11060-016-2220-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11060-016-2220-z%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Neuro-Oncology%26atitle%3DThe%252Brole%252Bof%252BAKT%252Bisoforms%252Bin%252Bglioblastoma%25253A%252BAKT3%252Bdelays%252Btumor%252Bprogression%26aulast%3DJoy%26aufirst%3DAnna%26date%3D2016%26date%3D2016%26volume%3D130%26issue%3D1%26spage%3D43%26epage%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel A.  Erlanson</span>, <span class="hlFld-ContribAuthor ">Stephen W.  Fesik</span>, <span class="hlFld-ContribAuthor ">Roderick E.  Hubbard</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Jahnke</span>, <span class="hlFld-ContribAuthor ">Harren  Jhoti</span>. </span><span class="cited-content_cbyCitation_article-title">Twenty years on: the impact of fragments on drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2016,</strong> <em>15 </em>
                                    (9)
                                     , 605-619. <a href="https://doi.org/10.1038/nrd.2016.109" title="DOI URL">https://doi.org/10.1038/nrd.2016.109</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nrd.2016.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnrd.2016.109%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DTwenty%252Byears%252Bon%25253A%252Bthe%252Bimpact%252Bof%252Bfragments%252Bon%252Bdrug%252Bdiscovery%26aulast%3DErlanson%26aufirst%3DDaniel%2BA.%26date%3D2016%26date%3D2016%26volume%3D15%26issue%3D9%26spage%3D605%26epage%3D619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Quangdon  Tran</span>, <span class="hlFld-ContribAuthor ">Hyunji  Lee</span>, <span class="hlFld-ContribAuthor ">Jisoo  Park</span>, <span class="hlFld-ContribAuthor ">Seon-Hwan  Kim</span>, <span class="hlFld-ContribAuthor ">Jongsun  Park</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Cancer Metabolism - Revisiting the Warburg Effects. </span><span class="cited-content_cbyCitation_journal-name">Toxicological Research</span><span> <strong>2016,</strong> <em>32 </em>
                                    (3)
                                     , 177-193. <a href="https://doi.org/10.5487/TR.2016.32.3.177" title="DOI URL">https://doi.org/10.5487/TR.2016.32.3.177</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5487/TR.2016.32.3.177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5487%2FTR.2016.32.3.177%26sid%3Dliteratum%253Aachs%26jtitle%3DToxicological%2520Research%26atitle%3DTargeting%252BCancer%252BMetabolism%252B-%252BRevisiting%252Bthe%252BWarburg%252BEffects%26aulast%3DTran%26aufirst%3DQuangdon%26date%3D2016%26volume%3D32%26issue%3D3%26spage%3D177%26epage%3D193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenhu  Zhan</span>, <span class="hlFld-ContribAuthor ">Lei  Xu</span>, <span class="hlFld-ContribAuthor ">Xiaowu  Dong</span>, <span class="hlFld-ContribAuthor ">Jun  Dong</span>, <span class="hlFld-ContribAuthor ">Xiao  Yi</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Ni  Qiu</span>, <span class="hlFld-ContribAuthor ">Jia  Li</span>, <span class="hlFld-ContribAuthor ">Bo  Yang</span>, <span class="hlFld-ContribAuthor ">Yubo  Zhou</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>117 </em>, 47-58. <a href="https://doi.org/10.1016/j.ejmech.2016.03.074" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.03.074</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.03.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.03.074%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bpyrazol-furan%252Bcarboxamide%252Banalogues%252Bas%252Bnovel%252BAkt%252Bkinase%252Binhibitors%26aulast%3DZhan%26aufirst%3DWenhu%26date%3D2016%26volume%3D117%26spage%3D47%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hong Jun  Kim</span>, <span class="hlFld-ContribAuthor ">Suk-young  Lee</span>, <span class="hlFld-ContribAuthor ">Sang Cheul  Oh</span>. </span><span class="cited-content_cbyCitation_article-title">The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Physiology</span><span> <strong>2016,</strong> <em>7 </em><a href="https://doi.org/10.3389/fphys.2016.00168" title="DOI URL">https://doi.org/10.3389/fphys.2016.00168</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphys.2016.00168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphys.2016.00168%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Physiology%26atitle%3DThe%252BInositide%252BSignaling%252BPathway%252BAs%252Ba%252BTarget%252Bfor%252BTreating%252BGastric%252BCancer%252Band%252BColorectal%252BCancer%26aulast%3DKim%26aufirst%3DHong%2BJun%26date%3D2016%26date%3D2016%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert J.  Cardnell</span>, <span class="hlFld-ContribAuthor ">Ying  Feng</span>, <span class="hlFld-ContribAuthor ">Seema  Mukherjee</span>, <span class="hlFld-ContribAuthor ">Lixia  Diao</span>, <span class="hlFld-ContribAuthor ">Pan  Tong</span>, <span class="hlFld-ContribAuthor ">C. Allison  Stewart</span>, <span class="hlFld-ContribAuthor ">Fatemeh  Masrorpour</span>, <span class="hlFld-ContribAuthor ">YouHong  Fan</span>, <span class="hlFld-ContribAuthor ">Monique  Nilsson</span>, <span class="hlFld-ContribAuthor ">Yuqiao  Shen</span>, <span class="hlFld-ContribAuthor ">John V.  Heymach</span>, <span class="hlFld-ContribAuthor ">Jing  Wang</span>, <span class="hlFld-ContribAuthor ">Lauren A.  Byers</span>, . </span><span class="cited-content_cbyCitation_article-title">Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2016,</strong> <em>11 </em>
                                    (4)
                                     , e0152584. <a href="https://doi.org/10.1371/journal.pone.0152584" title="DOI URL">https://doi.org/10.1371/journal.pone.0152584</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0152584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0152584%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DActivation%252Bof%252Bthe%252BPI3K%25252FmTOR%252BPathway%252Bfollowing%252BPARP%252BInhibition%252Bin%252BSmall%252BCell%252BLung%252BCancer%26aulast%3DCardnell%26aufirst%3DRobert%2BJ.%26date%3D2016%26date%3D2016%26volume%3D11%26issue%3D4%26spage%3De0152584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Antonella  Sistigu</span>, <span class="hlFld-ContribAuthor ">Gwenola  Manic</span>, <span class="hlFld-ContribAuthor ">Florine  Obrist</span>, <span class="hlFld-ContribAuthor ">Ilio  Vitale</span>. </span><span class="cited-content_cbyCitation_article-title">Trial watch â inhibiting PARP enzymes for anticancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Molecular & Cellular Oncology</span><span> <strong>2016,</strong> <em>3 </em>
                                    (2)
                                     , e1053594. <a href="https://doi.org/10.1080/23723556.2015.1053594" title="DOI URL">https://doi.org/10.1080/23723556.2015.1053594</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/23723556.2015.1053594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F23723556.2015.1053594%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520%2526%2520Cellular%2520Oncology%26atitle%3DTrial%252Bwatch%252B%2525E2%252580%252593%252Binhibiting%252BPARP%252Benzymes%252Bfor%252Banticancer%252Btherapy%26aulast%3DSistigu%26aufirst%3DAntonella%26date%3D2016%26date%3D2015%26volume%3D3%26issue%3D2%26spage%3De1053594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">GEORGE MIHAI  NITULESCU</span>, <span class="hlFld-ContribAuthor ">DENISA  MARGINA</span>, <span class="hlFld-ContribAuthor ">PETRAS  JUZENAS</span>, <span class="hlFld-ContribAuthor ">QIAN  PENG</span>, <span class="hlFld-ContribAuthor ">OCTAVIAN TUDOREL  OLARU</span>, <span class="hlFld-ContribAuthor ">EMMANOUIL  SALOUSTROS</span>, <span class="hlFld-ContribAuthor ">CONCETTINA  FENGA</span>, <span class="hlFld-ContribAuthor ">DEMETRIOS A.  SPANDIDOS</span>, <span class="hlFld-ContribAuthor ">MASSIMO  LIBRA</span>, <span class="hlFld-ContribAuthor ">ARISTIDIS M.  TSATSAKIS</span>. </span><span class="cited-content_cbyCitation_article-title">Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review). </span><span class="cited-content_cbyCitation_journal-name">International Journal of Oncology</span><span> <strong>2016,</strong> <em>48 </em>
                                    (3)
                                     , 869-885. <a href="https://doi.org/10.3892/ijo.2015.3306" title="DOI URL">https://doi.org/10.3892/ijo.2015.3306</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/ijo.2015.3306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2Fijo.2015.3306%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Oncology%26atitle%3DAkt%252Binhibitors%252Bin%252Bcancer%252Btreatment%25253A%252BThe%252Blong%252Bjourney%252Bfrom%252Bdrug%252Bdiscovery%252Bto%252Bclinical%252Buse%252B%252528Review%252529%26aulast%3DNITULESCU%26aufirst%3DGEORGE%2BMIHAI%26date%3D2016%26date%3D2015%26volume%3D48%26issue%3D3%26spage%3D869%26epage%3D885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter S.  Kutchukian</span>, <span class="hlFld-ContribAuthor ">Anne Mai  Wassermann</span>, <span class="hlFld-ContribAuthor ">Mika K.  Lindvall</span>, <span class="hlFld-ContribAuthor ">S. Kirk  Wright</span>, <span class="hlFld-ContribAuthor ">Johannes  Ottl</span>, <span class="hlFld-ContribAuthor ">Jaison  Jacob</span>, <span class="hlFld-ContribAuthor ">Clemens  Scheufler</span>, <span class="hlFld-ContribAuthor ">Andreas  Marzinzik</span>, <span class="hlFld-ContribAuthor ">Natasja  Brooijmans</span>, <span class="hlFld-ContribAuthor ">Meir  Glick</span>. </span><span class="cited-content_cbyCitation_article-title">Large Scale Meta-Analysis of Fragment-Based Screening Campaigns. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Screening</span><span> <strong>2015,</strong> <em>20 </em>
                                    (5)
                                     , 588-596. <a href="https://doi.org/10.1177/1087057114565080" title="DOI URL">https://doi.org/10.1177/1087057114565080</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1087057114565080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1087057114565080%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Screening%26atitle%3DLarge%252BScale%252BMeta-Analysis%252Bof%252BFragment-Based%252BScreening%252BCampaigns%26aulast%3DKutchukian%26aufirst%3DPeter%2BS.%26date%3D2015%26date%3D2014%26volume%3D20%26issue%3D5%26spage%3D588%26epage%3D596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryoko  Maesaki</span>, <span class="hlFld-ContribAuthor ">Ryosuke  Satoh</span>, <span class="hlFld-ContribAuthor ">Masato  Taoka</span>, <span class="hlFld-ContribAuthor ">Teppei  Kanaba</span>, <span class="hlFld-ContribAuthor ">Tsunaki  Asano</span>, <span class="hlFld-ContribAuthor ">Chiharu  Fujita</span>, <span class="hlFld-ContribAuthor ">Toshinobu  Fujiwara</span>, <span class="hlFld-ContribAuthor ">Yutaka  Ito</span>, <span class="hlFld-ContribAuthor ">Toshiaki  Isobe</span>, <span class="hlFld-ContribAuthor ">Toshio  Hakoshima</span>, <span class="hlFld-ContribAuthor ">Katsumi  Maenaka</span>, <span class="hlFld-ContribAuthor ">Masaki  Mishima</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient and cost effective production of active-form human PKB using silkworm larvae. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2015,</strong> <em>4 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/srep06016" title="DOI URL">https://doi.org/10.1038/srep06016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/srep06016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fsrep06016%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DEfficient%252Band%252Bcost%252Beffective%252Bproduction%252Bof%252Bactive-form%252Bhuman%252BPKB%252Busing%252Bsilkworm%252Blarvae%26aulast%3DMaesaki%26aufirst%3DRyoko%26date%3D2015%26date%3D2014%26volume%3D4%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaozhuo  Chen</span>, <span class="hlFld-ContribAuthor ">Yanrong  Qian</span>, <span class="hlFld-ContribAuthor ">Shiyong  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">The Warburg effect: Evolving interpretations of an established concept. </span><span class="cited-content_cbyCitation_journal-name">Free Radical Biology and Medicine</span><span> <strong>2015,</strong> <em>79 </em>, 253-263. <a href="https://doi.org/10.1016/j.freeradbiomed.2014.08.027" title="DOI URL">https://doi.org/10.1016/j.freeradbiomed.2014.08.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.freeradbiomed.2014.08.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.freeradbiomed.2014.08.027%26sid%3Dliteratum%253Aachs%26jtitle%3DFree%2520Radical%2520Biology%2520and%2520Medicine%26atitle%3DThe%252BWarburg%252Beffect%25253A%252BEvolving%252Binterpretations%252Bof%252Ban%252Bestablished%252Bconcept%26aulast%3DChen%26aufirst%3DXiaozhuo%26date%3D2015%26volume%3D79%26spage%3D253%26epage%3D263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hanneke  Stegeman</span>, <span class="hlFld-ContribAuthor ">Paul N.  Span</span>, <span class="hlFld-ContribAuthor ">Johannes H.A.M.  Kaanders</span>, <span class="hlFld-ContribAuthor ">Johan  Bussink</span>. </span><span class="cited-content_cbyCitation_article-title">Improving chemoradiation efficacy by PI3-K/AKT inhibition. </span><span class="cited-content_cbyCitation_journal-name">Cancer Treatment Reviews</span><span> <strong>2014,</strong> <em>40 </em>
                                    (10)
                                     , 1182-1191. <a href="https://doi.org/10.1016/j.ctrv.2014.09.005" title="DOI URL">https://doi.org/10.1016/j.ctrv.2014.09.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ctrv.2014.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ctrv.2014.09.005%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Treatment%2520Reviews%26atitle%3DImproving%252Bchemoradiation%252Befficacy%252Bby%252BPI3-K%25252FAKT%252Binhibition%26aulast%3DStegeman%26aufirst%3DHanneke%26date%3D2014%26volume%3D40%26issue%3D10%26spage%3D1182%26epage%3D1191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael A  Walker</span>. </span><span class="cited-content_cbyCitation_article-title">Novel tactics for designing water-soluble molecules in drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2014,</strong> <em>9 </em>
                                    (12)
                                     , 1421-1433. <a href="https://doi.org/10.1517/17460441.2014.960839" title="DOI URL">https://doi.org/10.1517/17460441.2014.960839</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/17460441.2014.960839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F17460441.2014.960839%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DNovel%252Btactics%252Bfor%252Bdesigning%252Bwater-soluble%252Bmolecules%252Bin%252Bdrug%252Bdiscovery%26aulast%3DWalker%26aufirst%3DMichael%2BA%26date%3D2014%26date%3D2014%26volume%3D9%26issue%3D12%26spage%3D1421%26epage%3D1433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liangliang  Liu</span>, <span class="hlFld-ContribAuthor ">Xuesen  Dong</span>, . </span><span class="cited-content_cbyCitation_article-title">Complex Impacts of PI3K/AKT Inhibitors to Androgen Receptor Gene Expression in Prostate Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">PLoS ONE</span><span> <strong>2014,</strong> <em>9 </em>
                                    (10)
                                     , e108780. <a href="https://doi.org/10.1371/journal.pone.0108780" title="DOI URL">https://doi.org/10.1371/journal.pone.0108780</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0108780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0108780%26sid%3Dliteratum%253Aachs%26jtitle%3DPLoS%2520ONE%26atitle%3DComplex%252BImpacts%252Bof%252BPI3K%25252FAKT%252BInhibitors%252Bto%252BAndrogen%252BReceptor%252BGene%252BExpression%252Bin%252BProstate%252BCancer%252BCells%26aulast%3DLiu%26aufirst%3DLiangliang%26date%3D2014%26date%3D2014%26volume%3D9%26issue%3D10%26spage%3De108780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiri  Polivka</span>, <span class="hlFld-ContribAuthor ">Filip  Janku</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2014,</strong> <em>142 </em>
                                    (2)
                                     , 164-175. <a href="https://doi.org/10.1016/j.pharmthera.2013.12.004" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2013.12.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2013.12.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2013.12.004%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DMolecular%252Btargets%252Bfor%252Bcancer%252Btherapy%252Bin%252Bthe%252BPI3K%25252FAKT%25252FmTOR%252Bpathway%26aulast%3DPolivka%26aufirst%3DJiri%26date%3D2014%26volume%3D142%26issue%3D2%26spage%3D164%26epage%3D175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kumaravel  Mohankumar</span>, <span class="hlFld-ContribAuthor ">Sankar  Pajaniradje</span>, <span class="hlFld-ContribAuthor ">Subhashree  Sridharan</span>, <span class="hlFld-ContribAuthor ">Vivek Kumar  Singh</span>, <span class="hlFld-ContribAuthor ">Larance  Ronsard</span>, <span class="hlFld-ContribAuthor ">Akhil C.  Banerjea</span>, <span class="hlFld-ContribAuthor ">Chellakkan Selvanesan  Benson</span>, <span class="hlFld-ContribAuthor ">Mohane Selvaraj  Coumar</span>, <span class="hlFld-ContribAuthor ">Rukkumani  Rajagopalan</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanism of apoptotic induction in human breast cancer cell, MCF-7, by an analog of curcumin in comparison with curcumin â An in vitro and in silico approach. </span><span class="cited-content_cbyCitation_journal-name">Chemico-Biological Interactions</span><span> <strong>2014,</strong> <em>210 </em>, 51-63. <a href="https://doi.org/10.1016/j.cbi.2013.12.006" title="DOI URL">https://doi.org/10.1016/j.cbi.2013.12.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbi.2013.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbi.2013.12.006%26sid%3Dliteratum%253Aachs%26jtitle%3DChemico-Biological%2520Interactions%26atitle%3DMechanism%252Bof%252Bapoptotic%252Binduction%252Bin%252Bhuman%252Bbreast%252Bcancer%252Bcell%25252C%252BMCF-7%25252C%252Bby%252Ban%252Banalog%252Bof%252Bcurcumin%252Bin%252Bcomparison%252Bwith%252Bcurcumin%252B%2525E2%252580%252593%252BAn%252Bin%252Bvitro%252Band%252Bin%252Bsilico%252Bapproach%26aulast%3DMohankumar%26aufirst%3DKumaravel%26date%3D2014%26volume%3D210%26spage%3D51%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenhu  Zhan</span>, <span class="hlFld-ContribAuthor ">Daqiang  Li</span>, <span class="hlFld-ContribAuthor ">Jinxin  Che</span>, <span class="hlFld-ContribAuthor ">Liangren  Zhang</span>, <span class="hlFld-ContribAuthor ">Bo  Yang</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>, <span class="hlFld-ContribAuthor ">Tao  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaowu  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Integrating docking scores, interaction profiles and molecular descriptors to improve the accuracy of molecular docking: Toward the discovery of novel Akt1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>75 </em>, 11-20. <a href="https://doi.org/10.1016/j.ejmech.2014.01.019" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.01.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.01.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.01.019%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIntegrating%252Bdocking%252Bscores%25252C%252Binteraction%252Bprofiles%252Band%252Bmolecular%252Bdescriptors%252Bto%252Bimprove%252Bthe%252Baccuracy%252Bof%252Bmolecular%252Bdocking%25253A%252BToward%252Bthe%252Bdiscovery%252Bof%252Bnovel%252BAkt1%252Binhibitors%26aulast%3DZhan%26aufirst%3DWenhu%26date%3D2014%26volume%3D75%26spage%3D11%26epage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shalise M.  Couvertier</span>, <span class="hlFld-ContribAuthor ">Eranthie  Weerapana</span>. </span><span class="cited-content_cbyCitation_article-title">Cysteine-reactive chemical probes based on a modular 4-aminopiperidine scaffold. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2014,</strong> <em>5 </em>
                                    (3)
                                     , 358-362. <a href="https://doi.org/10.1039/C3MD00289F" title="DOI URL">https://doi.org/10.1039/C3MD00289F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C3MD00289F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC3MD00289F%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DCysteine-reactive%252Bchemical%252Bprobes%252Bbased%252Bon%252Ba%252Bmodular%252B4-aminopiperidine%252Bscaffold%26aulast%3DCouvertier%26aufirst%3DShalise%2BM.%26date%3D2014%26date%3D2014%26volume%3D5%26issue%3D3%26spage%3D358%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tao  Liu</span>, <span class="hlFld-ContribAuthor ">Wenhu  Zhan</span>, <span class="hlFld-ContribAuthor ">Yanming  Wang</span>, <span class="hlFld-ContribAuthor ">Liangren  Zhang</span>, <span class="hlFld-ContribAuthor ">Bo  Yang</span>, <span class="hlFld-ContribAuthor ">Xiaowu  Dong</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>73 </em>, 167-176. <a href="https://doi.org/10.1016/j.ejmech.2013.11.036" title="DOI URL">https://doi.org/10.1016/j.ejmech.2013.11.036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2013.11.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2013.11.036%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-based%252Bdesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bdiphenylmethylamine%252Bderivatives%252Bas%252Bnovel%252BAkt1%252Binhibitors%26aulast%3DLiu%26aufirst%3DTao%26date%3D2014%26volume%3D73%26spage%3D167%26epage%3D176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.  Mortlock</span>, <span class="hlFld-ContribAuthor ">K.  Foote</span>, <span class="hlFld-ContribAuthor ">J.  Kettle</span>, <span class="hlFld-ContribAuthor ">B.  Aquila</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase Inhibitors in Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,<a href="https://doi.org/10.1016/B978-0-12-409547-2.11033-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.11033-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.11033-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.11033-9%26sid%3Dliteratum%253Aachs%26atitle%3DKinase%252BInhibitors%252Bin%252BCancer%26aulast%3DMortlock%26aufirst%3DA.%26date%3D2014%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2014%26volume%3D409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M. Cris  Silva-Santisteban</span>, <span class="hlFld-ContribAuthor ">Isaac M.  Westwood</span>, <span class="hlFld-ContribAuthor ">Kathy  Boxall</span>, <span class="hlFld-ContribAuthor ">Nathan  Brown</span>, <span class="hlFld-ContribAuthor ">Sam  Peacock</span>, <span class="hlFld-ContribAuthor ">Craig  McAndrew</span>, <span class="hlFld-ContribAuthor ">Elaine  Barrie</span>, <span class="hlFld-ContribAuthor ">Meirion  Richards</span>, <span class="hlFld-ContribAuthor ">Amin  Mirza</span>, <span class="hlFld-ContribAuthor ">Antony W.  Oliver</span>, <span class="hlFld-ContribAuthor ">Rosemary  Burke</span>, <span class="hlFld-ContribAuthor ">Swen  Hoelder</span>, <span class="hlFld-ContribAuthor ">Keith  Jones</span>, <span class="hlFld-ContribAuthor ">G. Wynne  Aherne</span>, <span class="hlFld-ContribAuthor ">Julian  Blagg</span>, <span class="hlFld-ContribAuthor ">Ian  Collins</span>, <span class="hlFld-ContribAuthor ">Michelle D.  Garrett</span>, <span class="hlFld-ContribAuthor ">Rob L. M.  van Montfort</span>, . </span><span class="cited-content_cbyCitation_article-title">Fragment-Based Screening Maps Inhibitor Interactions in the ATP-Binding Site of Checkpoint Kinase 2. </span><span class="cited-content_cbyCitation_journal-name">PLoS ONE</span><span> <strong>2013,</strong> <em>8 </em>
                                    (6)
                                     , e65689. <a href="https://doi.org/10.1371/journal.pone.0065689" title="DOI URL">https://doi.org/10.1371/journal.pone.0065689</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0065689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0065689%26sid%3Dliteratum%253Aachs%26jtitle%3DPLoS%2520ONE%26atitle%3DFragment-Based%252BScreening%252BMaps%252BInhibitor%252BInteractions%252Bin%252Bthe%252BATP-Binding%252BSite%252Bof%252BCheckpoint%252BKinase%252B2%26aulast%3DSilva-Santisteban%26aufirst%3DM.%2BCris%26date%3D2013%26date%3D2013%26volume%3D8%26issue%3D6%26spage%3De65689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301762v&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Allosteric inhibitor of inactive Akt, MK-2206 (<b>1</b>), and an example of an inhibitor of active Akt, GDC-0068 (<b>2</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301762v&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Inhibitors of Akt arising from collaboration with Astex Therapeutics Ltd. and the Institute of Cancer Research.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301762v&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis of Akt Inhibitors <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301762v&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) NaHCO<sub>3</sub>, CH<sub>3</sub>CN/H<sub>2</sub>O, reflux 24 h; (ii) <i>N</i>-(3-dimethylaminopropyl)-3-ethylcarbodiimide, HBT, DMF, 16 h; (iii) 4 M HCl in dioxane, RT, 16 h.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0008.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Representative Substituted Benzylamines Used in the Elaboration of Akt Inhibitors <b>45</b>, <b>61</b>, and <b>63</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301762v&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) BH<sub>3</sub>.THF, RT, 5 h; (ii) di-<i>tert</i>-butyl dicarbonate, DCM, RT, 2 h; (iii) MsCl, Et<sub>3</sub>N, DCM, RT, 2 h; (iv) Me<sub>2</sub>NH, TBAI, THF, 150 Â°C, 0.5 h; (v) 4 M HCl, dioxane, DCM, methanol, RT, 4 h; (vi) NaH, MeI, THF, RT, 4 h.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0009.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Representative Substituted Benzylamines Used in the Elaboration of Akt Inhibitors <b>55</b>, <b>56</b>, <b>58</b>, and <b>59</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301762v&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) NaBH<sub>4</sub>, I<sub>2</sub>, THF, reflux, 12 h, and then di-<i>tert</i>-butyl dicarbonate, Et<sub>3</sub>N, RT, 2 h; (ii) MsCl, DIPEA, DCM, RT, 2â18 h; (iii) KSAc, DMF, 50 Â°C, 1 h; (iv) NCS, 2 M HCl, CH<sub>3</sub>CN, 10 Â°C, 0.3 h; (v) NH<sub>3</sub>, CH<sub>3</sub>CN, RT, 16 h; (vi) TFA, RT, 0.3 h; (vii) NaN<sub>3</sub>, DMF, 80 Â°C, 1 h, and then H<sub>2</sub>, 10% Pd/C, ethanol, RT, 1 h; (viii) Ac<sub>2</sub>O, DIPEA, THF, RT, 2 h; (ix) MsCl, DIPEA, THF, RT, 2 h; (x) NaCN, DMF, 80 Â°C, 3 h; (xi) LiAlH<sub>4</sub>, THF, RT, 2 h.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Ligand binding mode of compound <b>64</b> in Akt1 determined by X-ray crystallography at 1.49 Ã resolution. The 2<i>F</i><sub>o</sub> â <i>F</i><sub>c</sub> electron density map is displayed in orange and contoured at 1Ï around the inhibitor. Nearby water molecules are represented as red spheres. (b) Molecular surface representation of the Akt1 binding pocket, looking toward the kinase hinge region. (c) Hydrogen-bond network formed by <b>64</b> and Akt1 residues within 3 Ã of the inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301762v&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Pharmacodynamic activity of <b>64</b> in a BT474c xenograft model in nude mice. Concentration response was established by dosing groups at either 100 or 300 mg/kg and assaying for compound and effect at 1, 2, 4, 8, 16, and 24 h time points. Each point represents the mean of four animals.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301762v&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/medium/jm-2012-01762v_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Activity of <b>64</b> in a BT474c tumor-bearing nude mouse disease model. Each error bar represents one standard error from the mean.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301762v/production/images/large/jm-2012-01762v_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301762v&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i89">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35777" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35777" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 14 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J. J.</span><span> </span><span class="NLM_article-title">Targeting the phosphoinositide 3-kinase pathway in cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">627</span><span class="NLM_x">â</span> <span class="NLM_lpage">644</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm301762v&amp;key=10.1038%2Fnrd2926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm301762v&amp;key=19644473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=627-644&author=P.+Liuauthor=H.+Chengauthor=T.+M.+Robertsauthor=J.+J.+Zhao&title=Targeting+the+phosphoinositide+3-kinase+pathway+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the phosphoinositide 3-kinase pathway in cancer</span></div><div class="casAuthors">Liu, Pixu; Cheng, Hailing; Roberts, Thomas M.; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">627-644</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K) pathway is a key signal transduction system that links oncogenes and multiple receptor classes to many essential cellular functions, and is perhaps the most commonly activated signalling pathway in human cancer.  This pathway therefore presents both an opportunity and a challenge for cancer therapy.  Even as inhibitors that target PI3K isoforms and other major nodes in the pathway, including AKT and mammalian target of rapamycin (mTOR), reach clin. trials, major issues remain.  Here, we highlight recent progress that has been made in our understanding of the PI3K pathway and discuss the potential of and challenges for the development of therapeutic agents that target this pathway in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUk9T-ZoNDtLVg90H21EOLACvtfcHk0liY8ODh9ZE10A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D&md5=fdc94abd15178a9dbe7c56dafbfb7787</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd2926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2926%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DTargeting%2520the%2520phosphoinositide%25203-kinase%2520pathway%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D627%26epage%3D644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Manning, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span> </span><span class="NLM_article-title">Navigating downstream of AKT</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">1261</span><span class="NLM_x">â</span> <span class="NLM_lpage">1274</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2007&pages=1261-1274&author=B.+D.+Manningauthor=L.+C.+Cantley&title=Navigating+downstream+of+AKT"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DB.%2BD.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DNavigating%2520downstream%2520of%2520AKT%26jtitle%3DCell%26date%3D2007%26volume%3D129%26spage%3D1261%26epage%3D1274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Bozulic, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemmings, B. A.</span><span> </span><span class="NLM_article-title">PIKKing on PKB: Regulation of PKB activity by phosphorylation</span> <span class="citation_source-journal">Curr. Opin. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">256</span><span class="NLM_x">â</span> <span class="NLM_lpage">261</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm301762v&amp;key=10.1016%2Fj.ceb.2009.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm301762v&amp;key=19303758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVClu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=256-261&author=L.+Bozulicauthor=B.+A.+Hemmings&title=PIKKing+on+PKB%3A+Regulation+of+PKB+activity+by+phosphorylation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">PIKKing on PKB: regulation of PKB activity by phosphorylation</span></div><div class="casAuthors">Bozulic, Lana; Hemmings, Brian A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">256-261</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Protein kinase B (PKB)/Akt kinase is a key regulator of a wide range of cellular processes including growth, proliferation and survival.  PKB is clearly a crucial signaling mol. and extensive research efforts aim to understand its regulation and action.  Recent studies of the regulation of PKB activity by hydrophobic motif phosphorylation have yielded several exciting findings about members of the phosphatidylinositol 3-kinase (PI3K)-like family of kinases (PIKKs) acting as PKB regulators.  Mammalian target of rapamycin complex 2 (mTORC2) and DNA-dependent protein kinase (DNA-PK) can both phosphorylate Ser-473 and activate PKB.  This review concerns PKB regulation by mTORC2 and DNA-PK in a stimulus-dependent and context-dependent manner and the possible implications of this for PKB activity, substrate specificity, and therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgDTdYbqJWtLVg90H21EOLACvtfcHk0li1La9uem-oyg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVClu7Y%253D&md5=0b7a3e6ea561f8479701a01133b5d30c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2009.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2009.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DBozulic%26aufirst%3DL.%26aulast%3DHemmings%26aufirst%3DB.%2BA.%26atitle%3DPIKKing%2520on%2520PKB%253A%2520Regulation%2520of%2520PKB%2520activity%2520by%2520phosphorylation%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2009%26volume%3D21%26spage%3D256%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Sarbassov, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guertin, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatini, D. M.</span><span> </span><span class="NLM_article-title">Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">307</span><span class="NLM_x">, </span> <span class="NLM_fpage">1098</span><span class="NLM_x">â</span> <span class="NLM_lpage">1101</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm301762v&amp;key=10.1126%2Fscience.1106148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm301762v&amp;key=15718470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=1098-1101&author=D.+D.+Sarbassovauthor=D.+A.+Guertinauthor=S.+M.+Aliauthor=D.+M.+Sabatini&title=Phosphorylation+and+regulation+of+Akt%2FPKB+by+the+rictor-mTOR+complex"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex</span></div><div class="casAuthors">Sarbassov, Dos D.; Guertin, David A.; Ali, Siraj M.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5712</span>),
    <span class="NLM_cas:pages">1098-1101</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Deregulation of Akt/protein kinase B (PKB) is implicated in the pathogenesis of cancer and diabetes.  Akt/PKB activation requires the phosphorylation of Thr308 in the activation loop by the phosphoinositide-dependent kinase 1 (PDK1) and Ser473 within the carboxyl-terminal hydrophobic motif by an unknown kinase.  We show that in Drosophila and human cells the target of rapamycin (TOR) kinase and its assocd. protein rictor are necessary for Ser473 phosphorylation and that a redn. in rictor or mammalian TOR (mTOR) expression inhibited an Akt/PKB effector.  The rictor-mTOR complex directly phosphorylated Akt/PKB on Ser473 in vitro and facilitated Thr308 phosphorylation by PDK1.  Rictor-mTOR may serve as a drug target in tumors that have lost the expression of PTEN, a tumor suppressor that opposes Akt/PKB activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfO1KyVE3glrVg90H21EOLACvtfcHk0li1La9uem-oyg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D&md5=de758fd8128561e34301e67a42ae13a6</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.1106148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1106148%26sid%3Dliteratum%253Aachs%26aulast%3DSarbassov%26aufirst%3DD.%2BD.%26aulast%3DGuertin%26aufirst%3DD.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DPhosphorylation%2520and%2520regulation%2520of%2520Akt%252FPKB%2520by%2520the%2520rictor-mTOR%2520complex%26jtitle%3DScience%26date%3D2005%26volume%3D307%26spage%3D1098%26epage%3D1101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Pearce, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komander, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alessi, D. R.</span><span> </span><span class="NLM_article-title">The nuts and bolts of ABC protein kinases</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">â</span> <span class="NLM_lpage">22</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm301762v&amp;key=10.1038%2Fnrm2822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm301762v&amp;key=20027184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFymt7bI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=9-22&author=L.+R.+Pearceauthor=D.+Komanderauthor=D.+R.+Alessi&title=The+nuts+and+bolts+of+ABC+protein+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The nuts and bolts of AGC protein kinases</span></div><div class="casAuthors">Pearce, Laura R.; Komander, David; Alessi, Dario R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-22</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The AGC kinase subfamily of protein kinases contains 60 members, including protein kinase A (PKA), protein kinase G (PKG), and protein kinase C (PKC).  The family comprises some intensely examd. protein kinases (such as Akt, S6K, RSK, MSK, PDK1 and GRK) as well as many less well-studied enzymes (such as SGK, NDR, LATS, CRIK, SGK494, PRKX, PRKY, and MAST).  Research has shed new light onto the architecture and regulatory mechanisms of these kinases.  In addn., AGC kinases mediate diverse and important cellular functions, and their mutation and/or dysregulation contributes to the pathogenesis of many human diseases, including cancer and diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDlqo5AR3FN7Vg90H21EOLACvtfcHk0liOgBLaL9vDkQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFymt7bI&md5=9752bf2068b10ab67b97e257f1f127d5</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrm2822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2822%26sid%3Dliteratum%253Aachs%26aulast%3DPearce%26aufirst%3DL.%2BR.%26aulast%3DKomander%26aufirst%3DD.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26atitle%3DThe%2520nuts%2520and%2520bolts%2520of%2520ABC%2520protein%2520kinases%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2010%26volume%3D11%26spage%3D9%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Mattmann, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoops, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span> </span><span class="NLM_article-title">Inhibition of Akt with small molecules and biologics: Historical perspective and current status of the patent landscape</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1309</span><span class="NLM_x">â</span> <span class="NLM_lpage">1338</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm301762v&amp;key=10.1517%2F13543776.2011.587959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm301762v&amp;key=21635152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVWnurfM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1309-1338&issue=9&author=M.+E.+Mattmannauthor=S.+L.+Stoopsauthor=C.+W.+Lindsley&title=Inhibition+of+Akt+with+small+molecules+and+biologics%3A+Historical+perspective+and+current+status+of+the+patent+landscape"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape</span></div><div class="casAuthors">Mattmann, Margrith E.; Stoops, Sydney L.; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1309-1338</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Akt plays a pivotal role in cell survival and proliferation through a no. of downstream effectors; unregulated activation of the PI3K/PTEN/Akt pathway is a prominent feature of many human cancers.  Akt is considered an attractive target for cancer therapy by the inhibition of Akt alone or in combination with std. cancer chemotherapeutics.  Both preclin. animal studies and clin. trials in humans have validated Akt as an important target of cancer drug discovery.Area covered: A historical perspective of Akt inhibitors, including PI analogs, ATP-competitive and allosteric Akt inhibitors, along with other inhibitory mechanisms are reviewed in this paper with a focus on issued patents, patent applications and a summary of clin. trial updates since the last review in 2007.Expert opinion: A vast diversity of inhibitors of Akt, both small mol. and biol., have been developed in the past 5 years, with over a dozen in various phases of clin. development, and several displaying efficacy in humans.  While it is not yet clear which mechanism of Akt inhibition will be optimal in humans, or which Akt isoforms to inhibit, or whether a small mol. or biol. agent will be best, data to all of these points will be available in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoByLgyoYrIULVg90H21EOLACvtfcHk0liOgBLaL9vDkQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVWnurfM&md5=292eeb3e83a0a8aaa3fea0cb8df7d83d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1517%2F13543776.2011.587959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2011.587959%26sid%3Dliteratum%253Aachs%26aulast%3DMattmann%26aufirst%3DM.%2BE.%26aulast%3DStoops%26aufirst%3DS.%2BL.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DInhibition%2520of%2520Akt%2520with%2520small%2520molecules%2520and%2520biologics%253A%2520Historical%2520perspective%2520and%2520current%2520status%2520of%2520the%2520patent%2520landscape%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2011%26volume%3D21%26issue%3D9%26spage%3D1309%26epage%3D1338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Hirai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sootome, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakatsuru, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taguchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuijioka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majumder, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, B.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotani, H.</span><span> </span><span class="NLM_article-title">MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1956</span><span class="NLM_x">â</span> <span class="NLM_lpage">1967</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm301762v&amp;key=10.1158%2F1535-7163.MCT-09-1012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm301762v&amp;key=20571069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFertbnL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1956-1967&issue=7&author=H.+Hiraiauthor=H.+Sootomeauthor=Y.+Nakatsuruauthor=K.+Miyamaauthor=S.+Taguchiauthor=K.+Tsuijiokaauthor=Y.+Uenoauthor=H.+Hatchauthor=P.+K.+Majumderauthor=B.-S.+Panauthor=H.+Kotani&title=MK-2206%2C+an+allosteric+Akt+inhibitor%2C+enhances+antitumor+efficacy+by+standard+chemotherapeutic+agents+or+molecular+targeted+drugs+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo</span></div><div class="casAuthors">Hirai, Hiroshi; Sootome, Hiroshi; Nakatsuru, Yoko; Miyama, Katsuyoshi; Taguchi, Shunsuke; Tsujioka, Kyoko; Ueno, Yoko; Hatch, Harold; Majumder, Pradip K.; Pan, Bo-Sheng; Kotani, Hidehito</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1956-1967</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The serine/threonine kinase Akt lies at a crit. signaling node downstream of phosphatidylinositol-3-kinase and is important in promoting cell survival and inhibiting apoptosis.  An Akt inhibitor may be particularly useful for cancers in which increased Akt signaling is assocd. with reduced sensitivity to cytotoxic agents or receptor tyrosine kinase inhibitors.  We evaluated the effect of a novel allosteric Akt inhibitor, MK-2206, in combination with several anticancer agents.  In vitro, MK-2206 synergistically inhibited cell proliferation of human cancer cell lines in combination with mol. targeted agents such as erlotinib (an epidermal growth factor receptor inhibitor) or lapatinib (a dual epidermal growth factor receptor/human epidermal growth factor receptor 2 inhibitor).  Complementary inhibition of erlotinib-insensitive Akt phosphorylation by MK-2206 was one mechanism of synergism, and a synergistic effect was found even in erlotinib-insensitive cell lines.  MK-2206 also showed synergistic responses in combination with cytotoxic agents such as topoisomerase inhibitors (doxorubicin, camptothecin), antimetabolites (gemcitabine, 5-fluorouracil), anti-microtubule agents (docetaxel), and DNA cross-linkers (carboplatin) in lung NCI-H460 or ovarian A2780 tumor cells.  The synergy with docetaxel depended on the treatment sequence; a schedule of MK-2206 dosed before docetaxel was not effective.  MK-2206 suppressed the Akt phosphorylation that is induced by carboplatin and gemcitabine.  In vivo, MK-2206 in combination with these agents exerted significantly more potent tumor inhibitory activities than each agent in the monotherapy setting.  These findings suggest that Akt inhibition may augment the efficacy of existing cancer therapeutics; thus, MK-2206 is a promising agent to treat cancer patients who receive these cytotoxic and/or mol. targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPgnWgk1SeALVg90H21EOLACvtfcHk0lhPUeDLJmMCzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFertbnL&md5=f2d97ab64963cc82d97b35697e49b172</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-1012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-1012%26sid%3Dliteratum%253Aachs%26aulast%3DHirai%26aufirst%3DH.%26aulast%3DSootome%26aufirst%3DH.%26aulast%3DNakatsuru%26aufirst%3DY.%26aulast%3DMiyama%26aufirst%3DK.%26aulast%3DTaguchi%26aufirst%3DS.%26aulast%3DTsuijioka%26aufirst%3DK.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DHatch%26aufirst%3DH.%26aulast%3DMajumder%26aufirst%3DP.%2BK.%26aulast%3DPan%26aufirst%3DB.-S.%26aulast%3DKotani%26aufirst%3DH.%26atitle%3DMK-2206%252C%2520an%2520allosteric%2520Akt%2520inhibitor%252C%2520enhances%2520antitumor%2520efficacy%2520by%2520standard%2520chemotherapeutic%2520agents%2520or%2520molecular%2520targeted%2520drugs%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26issue%3D7%26spage%3D1956%26epage%3D1967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Blake, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bencsik, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlachter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banka, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woessner, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G. P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safina, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oeh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liederer, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N. J.</span><span> </span><span class="NLM_article-title">Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8110</span><span class="NLM_x">â</span> <span class="NLM_lpage">8127</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301024w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yrtr7K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8110-8127&author=J.+F.+Blakeauthor=R.+Xuauthor=J.+R.+Bencsikauthor=D.+Xiaoauthor=N.+C.+Kallanauthor=S.+Schlachterauthor=I.+S.+Mitchellauthor=K.+L.+Spencerauthor=A.+L.+Bankaauthor=E.+M.+Wallaceauthor=S.+L.+Gloorauthor=M.+Martinsonauthor=R.+D.+Woessnerauthor=G.+P.+A.+Vigersauthor=B.+J.+Brandhuberauthor=J.+Liangauthor=B.+S.+Safinaauthor=J.+Liauthor=B.+Zhangauthor=C.+Chabotauthor=S.+Doauthor=L.+Leeauthor=J.+Oehauthor=D.+Sampathauthor=B.+B.+Leeauthor=K.+Linauthor=B.+M.+Liedererauthor=N.+J.+Skelton&title=Discovery+and+preclinical+pharmacology+of+a+selective+ATP-competitive+Akt+inhibitor+%28GDC-0068%29+for+the+treatment+of+human+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors</span></div><div class="casAuthors">Blake, James F.; Xu, Rui; Bencsik, Josef R.; Xiao, Dengming; Kallan, Nicholas C.; Schlachter, Stephen; Mitchell, Ian S.; Spencer, Keith L.; Banka, Anna L.; Wallace, Eli M.; Gloor, Susan L.; Martinson, Matthew; Woessner, Richard D.; Vigers, Guy P. A.; Brandhuber, Barbara J.; Liang, Jun; Safina, Brian S.; Li, Jun; Zhang, Birong; Chabot, Christine; Do, Steven; Lee, Leslie; Oeh, Jason; Sampath, Deepak; Lee, Brian B.; Lin, Kui; Liederer, Bianca M.; Skelton, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8110-8127</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery and optimization of a series of 6,7-dihydro-5H-cyclopenta[d]pyrimidine compds. that are ATP-competitive, selective inhibitors of protein kinase B/Akt is reported.  The initial design and optimization was guided by the use of X-ray structures of inhibitors in complex with Akt1 and the closely related protein kinase A.  The resulting compds. demonstrate potent inhibition of all three Akt isoforms in biochem. assays and poor inhibition of other members of the cAMP-dependent protein kinase/protein kinase G/protein kinase C extended family and block the phosphorylation of multiple downstream targets of Akt in human cancer cell lines.  Biol. studies with one such compd., 28 (GDC-0068), demonstrate good oral exposure resulting in dose-dependent pharmacodynamic effects on downstream biomarkers and a robust antitumor response in xenograft models in which the phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin pathway is activated. 28 is currently being evaluated in human clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowH24ZkuGlNLVg90H21EOLACvtfcHk0lhPUeDLJmMCzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yrtr7K&md5=1fa690cda22a2548eb2795305e1c7253</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm301024w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301024w%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DBencsik%26aufirst%3DJ.%2BR.%26aulast%3DXiao%26aufirst%3DD.%26aulast%3DKallan%26aufirst%3DN.%2BC.%26aulast%3DSchlachter%26aufirst%3DS.%26aulast%3DMitchell%26aufirst%3DI.%2BS.%26aulast%3DSpencer%26aufirst%3DK.%2BL.%26aulast%3DBanka%26aufirst%3DA.%2BL.%26aulast%3DWallace%26aufirst%3DE.%2BM.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DWoessner%26aufirst%3DR.%2BD.%26aulast%3DVigers%26aufirst%3DG.%2BP.%2BA.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DSafina%26aufirst%3DB.%2BS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DChabot%26aufirst%3DC.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DB.%2BB.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520and%2520preclinical%2520pharmacology%2520of%2520a%2520selective%2520ATP-competitive%2520Akt%2520inhibitor%2520%2528GDC-0068%2529%2520for%2520the%2520treatment%2520of%2520human%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8110%26epage%3D8127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Pal, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reckamp, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figlin, R. A.</span><span> </span><span class="NLM_article-title">Akt inhibitors in clinical development for the treatment of cancer</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1355</span><span class="NLM_x">â</span> <span class="NLM_lpage">1366</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=1355-1366&issue=11&author=S.+K.+Palauthor=K.+Reckampauthor=H.+Yuauthor=R.+A.+Figlin&title=Akt+inhibitors+in+clinical+development+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPal%26aufirst%3DS.%2BK.%26aulast%3DReckamp%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DFiglin%26aufirst%3DR.%2BA.%26atitle%3DAkt%2520inhibitors%2520in%2520clinical%2520development%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2010%26volume%3D19%26issue%3D11%26spage%3D1355%26epage%3D1366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McHardy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldwell, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlands, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruddle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Haven Brandon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seavers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Discovery of 4-amino-1-(7<i>H</i>-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2239</span><span class="NLM_x">â</span> <span class="NLM_lpage">2249</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901788j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2239-2249&author=T.+McHardyauthor=J.+J.+Caldwellauthor=K.-M.+Cheungauthor=L.+J.+Hunterauthor=K.+Taylorauthor=M.+Rowlandsauthor=R.+Ruddleauthor=A.+Henleyauthor=A.+de+Haven+Brandonauthor=M.+Valentiauthor=T.+G.+Daviesauthor=L.+Fazalauthor=L.+Seaversauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=G.+W.+Aherneauthor=M.+D.+Garrettauthor=I.+Collins&title=Discovery+of+4-amino-1-%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29piperidine-4-carboxamides+as+selective%2C+orally+active+inhibitors+of+protein+kinase+B+%28Akt%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1021%2Fjm901788j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901788j%26sid%3Dliteratum%253Aachs%26aulast%3DMcHardy%26aufirst%3DT.%26aulast%3DCaldwell%26aufirst%3DJ.%2BJ.%26aulast%3DCheung%26aufirst%3DK.-M.%26aulast%3DHunter%26aufirst%3DL.%2BJ.%26aulast%3DTaylor%26aufirst%3DK.%26aulast%3DRowlands%26aufirst%3DM.%26aulast%3DRuddle%26aufirst%3DR.%26aulast%3DHenley%26aufirst%3DA.%26aulast%3Dde%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DT.%2BG.%26aulast%3DFazal%26aufirst%3DL.%26aulast%3DSeavers%26aufirst%3DL.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DDiscovery%2520of%25204-amino-1-%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529piperidine-4-carboxamides%2520as%2520selective%252C%2520orally%2520active%2520inhibitors%2520of%2520protein%2520kinase%2520B%2520%2528Akt%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2239%26epage%3D2249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Caldwell, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donald, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHardy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlands, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruddle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdonk, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Identification of 4-(4-aminopiperidin-1-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2147</span><span class="NLM_x">â</span> <span class="NLM_lpage">2157</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701437d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2147-2157&author=J.+J.+Caldwellauthor=T.+G.+Daviesauthor=A.+Donaldauthor=T.+McHardyauthor=M.+G.+Rowlandsauthor=G.+W.+Aherneauthor=L.+K.+Hunterauthor=K.+Taylorauthor=R.+Ruddleauthor=F.+I.+Raynaudauthor=M.+Verdonkauthor=P.+Workmanauthor=M.+D.+Garrettauthor=I.+Collins&title=Identification+of+4-%284-aminopiperidin-1-yl%29-7H-pyrrolo%5B2%2C3-d%5Dpyrimidines+as+selective+inhibitors+of+protein+kinase+B+through+fragment+elaboration"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1021%2Fjm701437d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701437d%26sid%3Dliteratum%253Aachs%26aulast%3DCaldwell%26aufirst%3DJ.%2BJ.%26aulast%3DDavies%26aufirst%3DT.%2BG.%26aulast%3DDonald%26aufirst%3DA.%26aulast%3DMcHardy%26aufirst%3DT.%26aulast%3DRowlands%26aufirst%3DM.%2BG.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DHunter%26aufirst%3DL.%2BK.%26aulast%3DTaylor%26aufirst%3DK.%26aulast%3DRuddle%26aufirst%3DR.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DVerdonk%26aufirst%3DM.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DIdentification%2520of%25204-%25284-aminopiperidin-1-yl%2529-7H-pyrrolo%255B2%252C3-d%255Dpyrimidines%2520as%2520selective%2520inhibitors%2520of%2520protein%2520kinase%2520B%2520through%2520fragment%2520elaboration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2147%26epage%3D2157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Saxty, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodhead, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdonk, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyatt, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downham, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, R. A.</span><span> </span><span class="NLM_article-title">Identification of inhibitors of protein kinase B using fragment-based lead discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2293</span><span class="NLM_x">â</span> <span class="NLM_lpage">2296</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm070091b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksVKjur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2293-2296&author=G.+Saxtyauthor=S.+J.+Woodheadauthor=V.+Berdiniauthor=T.+G.+Daviesauthor=M.+L.+Verdonkauthor=P.+G.+Wyattauthor=R.+G.+Boyleauthor=D.+Barfordauthor=R.+Downhamauthor=M.+D.+Garrettauthor=R.+A.+Carr&title=Identification+of+inhibitors+of+protein+kinase+B+using+fragment-based+lead+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Inhibitors of Protein Kinase B Using Fragment-Based Lead Discovery</span></div><div class="casAuthors">Saxty, Gordon; Woodhead, Steven J.; Berdini, Valerio; Davies, Thomas G.; Verdonk, Marcel L.; Wyatt, Paul G.; Boyle, Robert G.; Barford, David; Downham, Robert; Garrett, Michelle D.; Carr, Robin A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2293-2296</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Using fragment-based screening techniques, 5-methyl-4-phenyl-1H-pyrazole (IC50 80 Î¼M) was identified as a novel, low mol. wt. inhibitor of protein kinase B (PKB).  Herein we describe the rapid elaboration of highly potent and ligand efficient analogs using a fragment growing approach.  Iterative structure-based design was supported by protein-ligand structure detns. using a PKA-PKB "chimera" and a final protein-ligand structure of a lead compd. in PKBÎ² itself.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlCYaIT8Xn87Vg90H21EOLACvtfcHk0ligewgmL0Nh_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksVKjur8%253D&md5=2a09e4bbaca1493be8e215927e7e72e1</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1021%2Fjm070091b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070091b%26sid%3Dliteratum%253Aachs%26aulast%3DSaxty%26aufirst%3DG.%26aulast%3DWoodhead%26aufirst%3DS.%2BJ.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DDavies%26aufirst%3DT.%2BG.%26aulast%3DVerdonk%26aufirst%3DM.%2BL.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DBoyle%26aufirst%3DR.%2BG.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DDownham%26aufirst%3DR.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DCarr%26aufirst%3DR.%2BA.%26atitle%3DIdentification%2520of%2520inhibitors%2520of%2520protein%2520kinase%2520B%2520using%2520fragment-based%2520lead%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2293%26epage%3D2296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Donald, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHardy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlands, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, L. J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2289</span><span class="NLM_x">â</span> <span class="NLM_lpage">2292</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0700924" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2289-2292&author=A.+Donaldauthor=T.+McHardyauthor=M.+G.+Rowlandsauthor=L.+J.+K.+Hunterauthor=T.+G.+Daviesauthor=V.+Berdiniauthor=R.+G.+Boyleauthor=G.+W.+Aherneauthor=M.+D.+Garrettauthor=I.+Collins&title=Rapid+evolution+of+6-phenylpurine+inhibitors+of+protein+kinase+B+through+structure-based+design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1021%2Fjm0700924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0700924%26sid%3Dliteratum%253Aachs%26aulast%3DDonald%26aufirst%3DA.%26aulast%3DMcHardy%26aufirst%3DT.%26aulast%3DRowlands%26aufirst%3DM.%2BG.%26aulast%3DHunter%26aufirst%3DL.%2BJ.%2BK.%26aulast%3DDavies%26aufirst%3DT.%2BG.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBoyle%26aufirst%3DR.%2BG.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DRapid%2520evolution%2520of%25206-phenylpurine%2520inhibitors%2520of%2520protein%2520kinase%2520B%2520through%2520structure-based%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2289%26epage%3D2292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ashton, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Jean, D. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poon, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lofgren, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fotsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hungate, R.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel amide AKT1 inhibitors with selectivity over CDK2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">5191</span><span class="NLM_x">â</span> <span class="NLM_lpage">5196</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=5191-5196&author=K.+S.+Ashtonauthor=D.+J.+St.+Jeanauthor=S.+F.+Poonauthor=M.+R.+Leeauthor=J.+G.+Allenauthor=S.+Zhangauthor=J.+A.+Lofgrenauthor=X.+Zhangauthor=C.+Fotschauthor=R.+Hungate&title=Design+and+synthesis+of+novel+amide+AKT1+inhibitors+with+selectivity+over+CDK2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAshton%26aufirst%3DK.%2BS.%26aulast%3DSt.%2BJean%26aufirst%3DD.%2BJ.%26aulast%3DPoon%26aufirst%3DS.%2BF.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DAllen%26aufirst%3DJ.%2BG.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLofgren%26aufirst%3DJ.%2BA.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DHungate%26aufirst%3DR.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520amide%2520AKT1%2520inhibitors%2520with%2520selectivity%2520over%2520CDK2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D5191%26epage%3D5196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bencsik, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woessner, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dizon, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G. P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L. J.</span><span> </span><span class="NLM_article-title">Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">7037</span><span class="NLM_x">â</span> <span class="NLM_lpage">7041</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Fjm301762v&amp;key=10.1016%2Fj.bmcl.2010.09.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Fjm301762v&amp;key=20971641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2gtLnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7037-7041&author=J.+R.+Bencsikauthor=D.+Xiaoauthor=J.+F.+Blakeauthor=N.+C.+Kallanauthor=I.+S.+Mitchellauthor=K.+L.+Spencerauthor=R.+Xuauthor=S.+L.+Gloorauthor=M.+Martinsonauthor=T.+Risomauthor=R.+D.+Woessnerauthor=F.+Dizonauthor=W.-I.+Wuauthor=G.+P.+A.+Vigersauthor=B.+J.+Brandhuberauthor=N.+J.+Skeltonauthor=W.+W.+Priorauthor=L.+J.+Murray&title=Discovery+of+dihydrothieno-+and+dihydrofuropyrimidines+as+potent+pan+Akt+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors</span></div><div class="casAuthors">Bencsik, Josef R.; Xiao, Dengming; Blake, James F.; Kallan, Nicholas C.; Mitchell, Ian S.; Spencer, Keith L.; Xu, Rui; Gloor, Susan L.; Martinson, Matthew; Risom, Tyler; Woessner, Richard D.; Dizon, Faith; Wu, Wen-I.; Vigers, Guy P. A.; Brandhuber, Barbara J.; Skelton, Nicholas J.; Prior, Wei Wei; Murray, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7037-7041</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis of a novel series of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors is reported.  Inhibitors displaying increased PKA and general kinase selectivity with improved tolerability compared to the progenitor pyrrolopyrimidine were developed using previous SAR and anal. of the amino acid sequences in the binding site.  Dihydrothieno compd. I was advanced into a PC3-NCI prostate mouse tumor model in which it demonstrated a dose-dependent redn. in tumor growth and stasis when dosed orally daily at 200 mg/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8-bp6rwVWNrVg90H21EOLACvtfcHk0ljwuCGjddoBtA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2gtLnJ&md5=d6aed3020c07ed85e83379c40d53394e</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.09.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.09.112%26sid%3Dliteratum%253Aachs%26aulast%3DBencsik%26aufirst%3DJ.%2BR.%26aulast%3DXiao%26aufirst%3DD.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DKallan%26aufirst%3DN.%2BC.%26aulast%3DMitchell%26aufirst%3DI.%2BS.%26aulast%3DSpencer%26aufirst%3DK.%2BL.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DRisom%26aufirst%3DT.%26aulast%3DWoessner%26aufirst%3DR.%2BD.%26aulast%3DDizon%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DW.-I.%26aulast%3DVigers%26aufirst%3DG.%2BP.%2BA.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DMurray%26aufirst%3DL.%2BJ.%26atitle%3DDiscovery%2520of%2520dihydrothieno-%2520and%2520dihydrofuropyrimidines%2520as%2520potent%2520pan%2520Akt%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D7037%26epage%3D7041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Freeman-Cook, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Autry, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzillo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacci-Tobin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernardo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakubczak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knauth, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luzzio, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marx, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandit, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajamohan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wythes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J.</span><span> </span><span class="NLM_article-title">Design of selective, ATP-competitive inhibitors of Akt</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4615</span><span class="NLM_x">â</span> <span class="NLM_lpage">4622</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1003842" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmt12ku78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4615-4622&author=K.+D.+Freeman-Cookauthor=C.+Autryauthor=G.+Borzilloauthor=D.+Gordonauthor=E.+Barbacci-Tobinauthor=V.+Bernardoauthor=D.+Briereauthor=T.+Clarkauthor=M.+Corbettauthor=J.+Jakubczakauthor=S.+Kakarauthor=E.+Knauthauthor=B.+Lippaauthor=M.+J.+Luzzioauthor=M.+Mansourauthor=G.+Martinelliauthor=M.+Marxauthor=K.+Nelsonauthor=J.+Panditauthor=F.+Rajamohanauthor=S.+Robinsonauthor=C.+Subramanyamauthor=L.+Weiauthor=M.+Wythesauthor=J.+Morris&title=Design+of+selective%2C+ATP-competitive+inhibitors+of+Akt"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Selective, ATP-Competitive Inhibitors of Akt</span></div><div class="casAuthors">Freeman-Cook, Kevin D.; Autry, Christopher; Borzillo, Gary; Gordon, Deborah; Barbacci-Tobin, Elsa; Bernardo, Vincent; Briere, David; Clark, Tracey; Corbett, Matthew; Jakubczak, John; Kakar, Shefali; Knauth, Elizabeth; Lippa, Blaise; Luzzio, Michael J.; Mansour, Mahmoud; Martinelli, Gary; Marx, Matthew; Nelson, Kendra; Pandit, Jayvardhan; Rajamohan, Francis; Robinson, Shaughnessy; Subramanyam, Chakrapani; Wei, Liuqing; Wythes, Martin; Morris, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4615-4622</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This paper describes the design and synthesis of novel, ATP-competitive Akt inhibitors from an elaborated 3-aminopyrrolidine scaffold.  Key findings include the discovery of an initial lead that was modestly selective and medicinal chem. optimization of that lead to provide more selective analogs.  Anal. of the data suggested that highly lipophilic analogs would likely suffer from poor overall properties.  Central to the discussion is the concept of optimization of lipophilic efficiency and the ability to balance overall druglike properties with the careful control of lipophilicity in the lead series.  Discovery of the nonracemic amide series and subsequent modification produced an advanced analog that performed well in advancedaminopyrrolidine substituted pyrrolopyrimidine preclin. assays, including xenograft tumor growth inhibition studies, and this analog was nominated for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqLbzBekJF5LVg90H21EOLACvtfcHk0ljwuCGjddoBtA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmt12ku78%253D&md5=e45372a44f93072f7152a0a2600d7be4</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1021%2Fjm1003842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1003842%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman-Cook%26aufirst%3DK.%2BD.%26aulast%3DAutry%26aufirst%3DC.%26aulast%3DBorzillo%26aufirst%3DG.%26aulast%3DGordon%26aufirst%3DD.%26aulast%3DBarbacci-Tobin%26aufirst%3DE.%26aulast%3DBernardo%26aufirst%3DV.%26aulast%3DBriere%26aufirst%3DD.%26aulast%3DClark%26aufirst%3DT.%26aulast%3DCorbett%26aufirst%3DM.%26aulast%3DJakubczak%26aufirst%3DJ.%26aulast%3DKakar%26aufirst%3DS.%26aulast%3DKnauth%26aufirst%3DE.%26aulast%3DLippa%26aufirst%3DB.%26aulast%3DLuzzio%26aufirst%3DM.%2BJ.%26aulast%3DMansour%26aufirst%3DM.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DMarx%26aufirst%3DM.%26aulast%3DNelson%26aufirst%3DK.%26aulast%3DPandit%26aufirst%3DJ.%26aulast%3DRajamohan%26aufirst%3DF.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DWythes%26aufirst%3DM.%26aulast%3DMorris%26aufirst%3DJ.%26atitle%3DDesign%2520of%2520selective%252C%2520ATP-competitive%2520inhibitors%2520of%2520Akt%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4615%26epage%3D4622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Takahara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoneyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, K.</span><span> </span><span class="NLM_article-title">Cardiovascular effects of Y-27632, a selective Rho-associated kinase inhibitor, assessed in the halothane-anesthetized canine model</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">460</span><span class="NLM_x">, </span> <span class="NLM_fpage">51</span><span class="NLM_x">â</span> <span class="NLM_lpage">57</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm301762v&amp;key=10.1016%2FS0014-2999%2802%2902929-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm301762v&amp;key=12535859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivVOltg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=460&publication_year=2003&pages=51-57&author=A.+Takaharaauthor=A.+Sugiyamaauthor=Y.+Satohauthor=M.+Yoneyamaauthor=K.+Hashimoto&title=Cardiovascular+effects+of+Y-27632%2C+a+selective+Rho-associated+kinase+inhibitor%2C+assessed+in+the+halothane-anesthetized+canine+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular effects of Y-27632, a selective Rho-associated kinase inhibitor, assessed in the halothane-anesthetized canine model</span></div><div class="casAuthors">Takahara, Akira; Sugiyama, Atsushi; Satoh, Yoshioki; Yoneyama, Masahiko; Hashimoto, Keitaro</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">460</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-57</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Y-27632, (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl) cyclohexanecarboxamide dihydrochloride monohydrate, is a selective Rho-assocd. kinase inhibitor, which has been suggested to possess multiple clin. applications based on the in vitro observations.  Since information regarding in vivo cardiovascular effects of Y-27632 is still limited, we assessed them using the halothane-anesthetized, closed-chest canine model.  Administration of Y-27632 in a dose of 0.01 mg/kg, i.v. significantly decreased total peripheral vascular resistance together with an increase of cardiac output without affecting other cardiovascular parameters.  Moreover, addnl. administration of Y-27632 in a dose of 0.1 mg/kg, i.v. significantly decreased blood pressure and left ventricular end-diastolic pressure, increased the heart rate and cardiac contractility, enhanced atrioventricular conduction and shortened the repolarization process as well as the effective refractory period.  These results indicate that Y-27632 exerts a potent arterio-venodilator action with cardiostimulatory effects possibly through the sympathetic reflex in the in vivo canine model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlVSFBxYE9HbVg90H21EOLACvtfcHk0liJ-VXVjCFQpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivVOltg%253D%253D&md5=15de8377d2dc34af00f331fee8429b35</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2802%2902929-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252802%252902929-1%26sid%3Dliteratum%253Aachs%26aulast%3DTakahara%26aufirst%3DA.%26aulast%3DSugiyama%26aufirst%3DA.%26aulast%3DSatoh%26aufirst%3DY.%26aulast%3DYoneyama%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DK.%26atitle%3DCardiovascular%2520effects%2520of%2520Y-27632%252C%2520a%2520selective%2520Rho-associated%2520kinase%2520inhibitor%252C%2520assessed%2520in%2520the%2520halothane-anesthetized%2520canine%2520model%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2003%26volume%3D460%26spage%3D51%26epage%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Davies, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenwood, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crafter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, D.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maynard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricketts, S.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosulich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chresta, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yates, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pass, M.</span><span> </span><span class="NLM_article-title">Preclinical pharmacology of AZD5363, an inhibitor of AKT: Pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">873</span><span class="NLM_x">â</span> <span class="NLM_lpage">887</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm301762v&amp;key=10.1158%2F1535-7163.MCT-11-0824-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm301762v&amp;key=22294718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm301762v&amp;key=1%3ACAS%3A528%3ADC%252BC38Xltl2ntbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=873-887&author=B.+R.+Daviesauthor=H.+Greenwoodauthor=P.+Dudleyauthor=C.+Crafterauthor=D.-H.+Yuauthor=J.+Zhangauthor=J.+Liauthor=B.+Gaoauthor=Q.+Jiauthor=J.+Maynardauthor=S.-A.+Rickettsauthor=D.+Crossauthor=S.+Cosulichauthor=C.+C.+Chrestaauthor=K.+Pageauthor=J.+Yatesauthor=C.+Laneauthor=R.+Watsonauthor=R.+Lukeauthor=D.+Ogilvieauthor=M.+Pass&title=Preclinical+pharmacology+of+AZD5363%2C+an+inhibitor+of+AKT%3A+Pharmacodynamics%2C+antitumor+activity%2C+and+correlation+of+monotherapy+activity+with+genetic+background"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background</span></div><div class="casAuthors">Davies, Barry R.; Greenwood, Hannah; Dudley, Phillippa; Crafter, Claire; Yu, De-Hua; Zhang, Jingchuan; Li, Jing; Gao, Beirong; Ji, Qunsheng; Maynard, Juliana; Ricketts, Sally-Ann; Cross, Darren; Cosulich, Sabina; Chresta, Christine C.; Page, Ken; Yates, James; Lane, Clare; Watson, Rebecca; Luke, Richard; Ogilvie, Donald; Pass, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">873-887</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">AKT is a key node in the most frequently deregulated signaling network in human cancer.  AZD5363, a novel pyrrolopyrimidine-derived compd., inhibited all AKT isoforms with a potency of 10 nmol/L or less and inhibited phosphorylation of AKT substrates in cells with a potency of approx. 0.3 to 0.8 Î¼mol/L.  AZD5363 monotherapy inhibited the proliferation of 41 of 182 solid and hematol. tumor cell lines with a potency of 3 Î¼mol/L or less.  Cell lines derived from breast cancers showed the highest frequency of sensitivity.  There was a significant relationship between the presence of PIK3CA and/or PTEN mutations and sensitivity to AZD5363 and between RAS mutations and resistance.  Oral dosing of AZD5363 to nude mice caused dose- and time-dependent redn. of PRAS40, GSK3Î², and S6 phosphorylation in BT474c xenografts (PRAS40 phosphorylation EC50 â¼ 0.1 Î¼mol/L total plasma exposure), reversible increases in blood glucose concns., and dose-dependent decreases in 2[18F]fluoro-2-deoxy-D-glucose (18F-FDG) uptake in U87-MG xenografts.  Chronic oral dosing of AZD5363 caused dose-dependent growth inhibition of xenografts derived from various tumor types, including HER2+ breast cancer models that are resistant to trastuzumab.  AZD5363 also significantly enhanced the antitumor activity of docetaxel, lapatinib, and trastuzumab in breast cancer xenografts.  It is concluded that AZD5363 is a potent inhibitor of AKT with pharmacodynamic activity in vivo, has potential to treat a range of solid and hematol. tumors as monotherapy or a combinatorial agent, and has potential for personalized medicine based on the genetic status of PIK3CA, PTEN, and RAS.  AZD5363 is currently in phase I clin. trials.  Mol Cancer Ther; 11(4); 873-87.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjG0wV4TyO57Vg90H21EOLACvtfcHk0liJ-VXVjCFQpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xltl2ntbs%253D&md5=6ddcc67247fd07fd086baa03077983bd</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0824-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0824-T%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DGreenwood%26aufirst%3DH.%26aulast%3DDudley%26aufirst%3DP.%26aulast%3DCrafter%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DD.-H.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DB.%26aulast%3DJi%26aufirst%3DQ.%26aulast%3DMaynard%26aufirst%3DJ.%26aulast%3DRicketts%26aufirst%3DS.-A.%26aulast%3DCross%26aufirst%3DD.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DChresta%26aufirst%3DC.%2BC.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DYates%26aufirst%3DJ.%26aulast%3DLane%26aufirst%3DC.%26aulast%3DWatson%26aufirst%3DR.%26aulast%3DLuke%26aufirst%3DR.%26aulast%3DOgilvie%26aufirst%3DD.%26aulast%3DPass%26aufirst%3DM.%26atitle%3DPreclinical%2520pharmacology%2520of%2520AZD5363%252C%2520an%2520inhibitor%2520of%2520AKT%253A%2520Pharmacodynamics%252C%2520antitumor%2520activity%252C%2520and%2520correlation%2520of%2520monotherapy%2520activity%2520with%2520genetic%2520background%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D873%26epage%3D887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2X39" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2X39','PDB','2X39'); return false;">PDB: 2X39</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GV1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GV1','PDB','4GV1'); return false;">PDB: 4GV1</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i84"><a href="/doi/suppl/10.1021/jm301762v">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_70761"></div></div></div></div></div><hr /></hr><p class="last">Additional text with details of the full synthesis and spectroscopic characterization of all additional compounds and intermediate, together with all protocols for in vitro and in vivo experiments, and one table listing crystallographic information. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm301762v/suppl_file/jm301762v_si_001.pdf">jm301762v_si_001.pdf (244.03 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm301762v&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-5%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Fjm301762v" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm301762v" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799a3dd195e1252","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
